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Abstract
Abstract
The influenza A virus genome codes for up to 12 proteins. Segment
2 encodes three proteins, the polymerase subunit PB1, a small protein
PB1-F2 and an N-terminally truncated version of PB1 called N40. Different
functions have been reported for PB1-F2 such as induction of apoptosis,
regulation of the viral polymerase activity, enhancement of secondary
bacterial infections and modulation of the innate immune system. So far,
no function has been ascribed to N40.
To study PB1-F2 in more detail, its coding sequence was deleted from
its original position and inserted downstream of the PB1 (segment 2),
NA (segment 6) or M (segment 7) open reading frames (ORF) employing
different strategies, including the use of an overlapping Stop-Start cassette,
a duplicated promoter sequence and the self-cleaving 2A peptide derived
from foot-and-mouth disease virus. Viruses with bicistronic segments
were rescued and tested for their ability to express PB1-F2. Whereas
no expression of PB1-F2 was detected from bicistronic segments 2 and
7, expression of PB1-F2 from segment 6 was observed in high levels.
However, the phenotype of all these viruses was similar to that of viruses
lacking PB1-F2 which made mutational analysis of PB1-F2 not worthwhile.
Previously, the function of PB1-F2 was mainly studied using a virus deficient
in PB1-F2 production but showing increased N40 expression. In the present
study, recombinant WSN viruses lacking either PB1-F2 or N40, or both
proteins were engineered and the effects of these mutations on the viral
life cycle were examined. Viruses deficient for PB1-F2 that overexpressed
N40 showed the most attenuated phenotype, whereas the loss of PB1-F2
alone did not obviously affect virus replication. Reduced viral polymerase
activity was observed for viruses lacking N40, however attenuation in vivo
was only seen in combination with the loss of PB1-F2. Neither the loss of
PB1-F2 nor N40 alone had a great impact, but changes in the expression
level of both proteins were disadvantageous for the virus. Increased levels
of N40 shifted the polymerase activity towards replication, suggesting a new
function for N40.
Thus, it was shown that the segment 2 gene products and their expression
level influence viral replication and pathogenicity, and a careful design
of mutant recombinant viruses is vital for determining the experimental
outcome.
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Chapter 1
INTRODUCTION
Aims of Chapter 1
This chapter provides an introduction on influenza A viruses (IAV), including
some general aspects such as virus structure, genome organisation and
viral life cycle. More specifically, it contains information about PB1-F2,
however, this particular part only covers the knowledge until 2007, when this
project was started. This is because the recent findings on PB1-F2 and the
discovery of a 12th protein expressed by influenza A viruses changed the
project in certain ways. Therefore, recent findings on IAV segment 2 made
after 2007 can be found in the individual results Chapters and in Chapter
7 (Conclusions). Furthermore, an overview of reverse genetics is given, as
this provides the foundation of the presented work.
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1.1 General information on influenza A viruses
1.1.1 Orthomyxoviridae: Classification and taxonomy
The name Orthomyxoviridae originates from the Greek words orthos,
meaning ”standard” or ”straight”, and myxa meaning ”mucus”. The spherical
to pleomorphic shaped virions possess a helical nucleocapsid, which is
enveloped by a host cell membrane-derived lipid layer. The International
Committee on Taxonomy of Viruses (ICTVdB, 2009) lists 5 genera of
vertebrate viruses in the family Orthomyxoviridae: three genera of influenza
viruses (Influenza virus A, B and C), Thogotovirus (Leahy et al., 1997;
Pringle, 1996) and Isavirus (Krossøy et al., 1999). A number of other viruses
was suggested to be part of the Orthomyxoviridae family (Silva et al., 2005;
Presti et al., 2009). All members have a linear negative single-stranded RNA
genome composed of six to eight segments (Table 1.1). Replication takes
place in the nucleus of infected cells.
Genus Species Segments
Influenzavirus A Influenza A virus 8
Influenzavirus B Influenza B virus 8
Influenzavirus C Influenza C virus 7
Thogotovirus Thogoto virus 6
Dhori virus 7
Isavirus Infectious Salmon Anemia virus 8
Table 1.1: Orthomyxoviridae: Summary of the characterised genera and their
species and numbers of genome segments. The type species of each genus is
shown in bold.
The classification of influenza viruses into three types (A, B and C) is
made on antigenic features of the matrix protein M1 and the nucleoprotein
(Knipe et al., 2001). Influenza A viruses are further divided into subtypes
due to the antigenic characteristics of the two surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA). So far, 16 HA and nine NA
subtypes are known (Fouchier et al., 2005; Laver et al., 1984). Influenza
viruses are able to exchange segments (reassortment) following dual
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infection of the same cell, which can lead to the development of new
subtypes. Influenza A viruses can infect a broad range of host species,
however, aquatic birds are the natural reservoir. Influenza B viruses are
only found in humans and seals (Osterhaus et al., 2000). Although no
different subtypes for influenza B viruses exist, they are also capable
for reassortment in nature to form different strains (McCullers et al.,
1999). Influenza C viruses possess only 7 RNA segments due to the
nature of the glycoprotein hemagglutinin-esterase (HEF), which combines
three functions: receptor-binding (hemagglutination), receptor-destroying
(esterase) and fusion (Herrler et al., 1988). Antigenic and sequence
differences are not sufficient to separate this genus into subtypes. The
Thogotovirus genus contains two species: Thogoto virus and Dhori virus.
They are insect-borne viruses that infect both insects and vertebrates. The
genome of Thogoto viruses consist of 6 segments whereas Dhori viruses
contain 7 segments. No protein analogs for neuraminidase or non-structural
protein (NS) have been found (Macken et al., 2001). Infectious salmon
anemia virus is the only known species in the genus Isavirus. The virus
infects Atlantic salmon (Salmo salar ) and has therefore a great negative
financial impact in aqua culture (Scheel et al., 2007).
1.1.2 Structure of influenza A viruses
Influenza A virus is one of the major human pathogens with the capability
to cause epidemics and pandemics. According to the World Health
Organisation (WHO) it is believed that influenza A viruses infect about
5-15% of the world’s population every year and 300,000 - 500,000 people
worldwide die as a consequence of the infection (Kamps, 2006). Due to
a high mutation rate of the low fidelity viral polymerase and the ability
to reassort, antigenically novel influenza A viruses can emerge. If they
encounter an immunologically naı¨ve population the morbidity and mortality
rate can be much higher (Digard et al., 2009).
The spherical to filamentous virus particles have an average diameter of
100 nm, but can be up to 20-30 µm in length (Roberts and Compans, 1998;
Simpson-Holley et al., 2002). Each virus comprises 8 segments of negative
sense RNA (Figure 1.1). The viruses are enclosed by a lipid envelope that
derives from the host cell. Embedded within this envelope are the two viral
glycoproteins, hemagglutinin and neuraminidase, and the matrix protein 2
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Figure 1.1: Schematic
diagram of an influenza
virus particle: In the
center of the virion are
the eight negative sense
RNA segments. Each
segment is covered by a
number of copies of the
nucleoprotein and one copy
of each polymerase subunit.
These so-called RNPs are
surrounded by a layer of
matrix protein 1 and a lipid
envelope that derives from
the host cell. Within this
lipid envelope the two viral
glycoproteins, hemagglutinin
and neuraminidase, are
incorporated as well as the
matrix protein 2. Picture
taken from Horimoto and
Kawaoka (2005).
(Zebedee et al., 1985; Lamb et al., 1985; Cox et al., 2005). M2 is an ion
channel protein and is required for acidification of the virus particle during
cell entry (Pinto et al., 1992). Below the lipid envelope is a layer of the
matrix protein 1 (Ruigrok et al., 1989). In the center of the virion are the
so-called ribonucleoproteins (RNPs), each consisting of one RNA segment.
The RNA is covered by a number of nucleoprotein molecules. Also attached
to each segment is a polymerase complex, which is composed of the
three polymerase subunits PB2, PB1 and PA. RNPs represent the minimal
infectious unit, since it is necessary for negative sense RNA viruses to
provide their own RNA-dependent RNA polymerase (RdRp) for replication
and transcription (Huang et al., 1990; Honda et al., 2002). When looking
at serially sectioned virus particles using transmission electron microscopy,
the eight segments appear in an organised structure. Seven segments are
in a circular array surrounding one segment in the center (Noda et al., 2006).
It is not known if the middle one is a specific segment or if this varies. The
ends of each RNA segment are complementary and highly conserved and
are proposed to interact to form a panhandle or a ”corkscrew” structure (Hsu
et al., 1987; Flick et al., 1996).
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1.1.3 Influenza A virus genome and gene products
Depending on the strain, up to 12 proteins are expressed from the influenza
A virus genome (Figure 1.2) (Wise et al., 2009). Hence, some of the
segments encode more than one protein (Table 1.2). Whereas segment
1 and 3 to 6 are monocistronic, segments 2, 7 and 8 encode two or three
proteins each.
Segment Protein Abbreviation
1 Polymerase basic protein 2 PB2
2 Polymerase basic protein 1 PB1
PB1-Frame 2 PB1-F2
N40 N40
3 Polymerase acidic protein PA
4 Hemagglutinin HA
5 Nucleoprotein NP
6 Neuraminidase NA
7 Matrix protein 1 M1
Matrix protein 2 M2
8 Non-structural protein 1 NS1
Nuclear export protein NEP
Table 1.2: Influenza A virus (A/WSN/33): Segments and encoded proteins of
each segment.
Segment 1 encodes one of the basic polymerase protein, PB2. PB2 is,
like the two other polymerase subunits PB1 and PA, an essential part of
the viral RNA-dependent RNA polymerase complex. During viral infection
short 5’ cap structures are cleaved from cellular pre-mRNAs and are used
for initiation of viral transcription (Plotch et al., 1981). This process is known
as ’cap-snatching’. One of the involved polymerase proteins is the PB2
subunit. It was shown to possess cap recognition and binding activity (Blaas
et al., 1982). PB2 also plays a role in host range restriction. One confirmed
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contributing amino acid is at position 627 (Subbarao et al., 1993b). In order
to ”jump” from an avian host to a human host, changes of amino acid
627 from glutamic acid to lysine often occur, as seen in the recent H5N1
outbreaks in Hong Kong (Hatta et al., 2001) or with a Dutch patient infected
with H7N7 (Fouchier et al., 2004).
The basic polymerase protein 1 (PB1), encoded by segment 2, is the
core subunit of the polymerase complex. It binds to PB2 and PA to form
an active heterotrimer. It is responsible for initiation and elongation during
transcription and replication (Braam et al., 1983). PB1 recognises and
binds, therefore, to the promoter region of the viral RNA (Gonza´lez and
Ortı´n, 1999). By a process called leaky ribosomal scanning up to two
other proteins are expressed from segment 2 mRNA. The 87 - 90 aa short
pro-apoptotic protein PB1-F2 is translated from an alternative +1 ORF from
most influenza A virus strains (Chen et al., 2001), and an N-terminally
truncated form of the PB1 protein, called N40, is observed in infected cells
(Wise et al., 2009). Segment 2 will be described in more detail in Section
1.2, as well as in Chapters 3 and 6.
PB2
Segment 1
Segment 2
Segment 3
Segment 4
Segment 5
Segment 6
Segment 7
Segment 8
PB1
PA
HA
NP
NA
M1
M2
NS1
NEP
PB1-F2
N40
Figure 1.2: Schematic map of the influenza A virus genome: The linear
segmented negative sense RNA genome encodes up to 12 proteins.
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PA is the acidic polymerase subunit encoded by the third largest viral
segment. In 2009 the endonuclease activity for the ”cap-snatching” process
was mapped to the N-terminus of the PA subunit (Dias et al., 2009; Yuan
et al., 2009).
One of the viral glycoproteins, hemagglutinin, is encoded by segment 4.
HA is one of the most abundant viral proteins and it is distributed evenly
on the viral surface as a homotrimer (Wiley et al., 1977). The protein
facilitates binding to the cell surface by interacting with sialic acid-containing
receptors. Cleavage of the HA0 precursor into two subunits, HA1 and
HA2, by cellular proteases is required for infectivity (Garten and Klenk,
1983). After binding to the host cell membrane and internalisation of the
particle by endocytosis, the cleaved hemagglutinin mediates membrane
fusion between the endosomal membrane and the virus membrane in order
to release the vRNPs into the cytoplasm (Skehel and Wiley, 2000).
The nucleoprotein, encoded on segment 5, is the most abundant protein
of the ribonucleocapsid. The RNA-binding groove is composed of a
number of highly conserved basic residues that are spread over the primary
sequence of NP but cluster between the head and the body domain of the
folded protein (Ye et al., 2006). The RNA is believed to wrap around NP
which acts as a scaffold. Several signals on the nucleoprotein regulate the
import and export of vRNPs into the nucleus (O’Neill et al., 1995; Neumann
et al., 1997). Whereas the protein localises to the nucleus early in infection,
localisation is mainly cytoplasmic late in infection. This process is regulated
by phosphorylation of NP (Neumann et al., 1997; Bullido et al., 2000).
The second viral glycoprotein is neuraminidase, which is encoded on
segment 6. Beside HA, NA is the major antigen of the influenza A virus.
The protein forms a homotetramer on the virus surface and is responsible
for the release of progeny virus particles from the cell by its sialidase activity.
Segment 7 encodes the two matrix proteins 1 and 2. M1 is the most
abundant protein in the virus particle that, amongst other factors, determines
the morphology of the virion (Roberts et al., 1998b; Bourmakina and
Garcı´a-Sastre, 2005). M1 was also shown to be important for the nuclear
export of vRNPs (Whittaker et al., 1996). It functions as a bridge between
vRNPs and the lipid envelope by interacting with both (Gregoriades, 1980;
Sakaguchi et al., 2003). The small ion channel protein M2 is translated
from a spliced mRNA transcribed from the same segment. It forms a
homotetramer and localises to the lipid envelope (Holsinger and Lamb,
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1991; Lamb et al., 1985). M2 is activated by low pH in the late endosome
and permits protons to enter the virus particle, which leads to a process
known as uncoating (Pinto et al., 1992; Sugrue et al., 1990).
The smallest viral segment is, like segment 7, bicistronic. The
non-structural protein NS1 is the major virulence factor. Although it is small,
it is a multifunctional protein, but it mainly functions as an interferon (IFN)
antagonist (Garcı´a-Sastre et al., 1998; Hale et al., 2008). It inhibits the
export and splicing of host-cell mRNAs, which leads to host cell protein
shut-off (Alonso-Caplen et al., 1992; Chen and Krug, 2000; Krug et al.,
2003). NS1 maintains all these functions by a large number of interactions
with host cell proteins. The second protein expressed from segment 8 is
called NEP and is translated from spliced mRNA. It contains a nuclear
export signal (NES) and deletion of the protein causes retention of RNPs
in the nucleus. Therefore, it was suggested that NEP functions as a nuclear
export protein for RNPs by binding to them via the matrix protein M1 (O’Neill
et al., 1998; Shimizu et al., 2011). Further, it was proposed that NEP is
involved in transcription and replication because it was shown to alter the
levels of viral RNA species synthesised in a ribonucleoprotein reconstitution
assay (Robb et al., 2009).
1.1.4 Influenza A virus life cycle
Human influenza viruses establish disease primarily in the upper
respiratory tract in epithelial cells. The specificity of HA to bind
to host cell receptors differs amongst influenza A viruses. Human
viruses prefer N-acetylneuraminic acid linked to galactose by α2,6-linkage
(NeuAcα2,6Gal) which is present on bronchial epithelial cells in the upper
respiratory tract (Shinya et al., 2006). Avian influenza viruses in contrast
preferentially bind to sialic acids containing NeuAcα2,3Gal linkages present
in the intestine of birds and in the lower respiratory tract of humans (Rogers
et al., 1983; Rogers and Paulson, 1983; van Riel et al., 2006). After binding
to the host cell membrane by the hemagglutinin the virus is taken up by the
cell via endocytosis (Matlin et al., 1981). By lowering the endosomal pH,
the host cell attempts to denature the viral particles. However, instead of
destroying the virus, this lower pH helps the virus to translocate the vRNPs
from the endosome into the cytoplasm. A conformational change in the
hemagglutinin protein leads to the fusion of the viral and the endosomal
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membrane (Skehel et al., 1982). Acidification of the virus particle mediated
by the M2 ion channel results in the release of the vRNPs into the cytoplams
(Pinto et al., 1992; Wharton et al., 1994).
Replication and transcription of the influenza A viral genome takes place in
the nucleus of infected cells (Herz et al., 1981). Because of this, some of the
newly expressed viral proteins, such as the viral RdRp, have to be located
to the nucleus to fulfil their tasks. The three subunits form a heterotrimer
to function as a polymerase (Detjen et al., 1987). PB1 is believed to be
the central subunit, interacting with PB2 and PA, however more recently an
interaction of PB2 and PA was also confirmed (Toyoda et al., 1996; Gonza´lez
et al., 1996; Hemerka et al., 2009). After translation of viral proteins in
the cytoplasm, the three subunits have to be transported into the nucleus.
Different models have tried to explain the mechanism of translocating the
subunits into the nucleus (Deng et al., 2005, 2006a; Naito et al., 2007).
The most recent ones suggest dimerisation of the PB1 and PA subunits in
the cytoplasm and transport of the heterodimer into the nucleus, whereas
PB2 localises to the nucleus as a monomer. Formation of the trimer takes
place in the nucleus (Huet et al., 2010). A possible involvement of heat
shock protein 90 (Hsp90) and RanBP5 in transport and trimerisation were
reported (Deng et al., 2006a; Naito et al., 2007).
Viral membrane proteins, HA, NA and M2, are synthesised at
membrane-bound ribosomes and translocated into the lumen of the
ER, where post-translational modification, such as glycosylation and
palmitoylation, and oligomerisation takes place. Viral membrane proteins
are subsequently transported via the Golgi apparatus to the apical plasma
membrane (Doms et al., 1993; Holsinger et al., 1995). The progeny vRNPs
are transported to the same site of the cell membrane, where finally virus
assembly and budding takes place (Figure 1.3) (Cox et al., 2005). vRNP
transport was not well understood for a long time. Recent findings suggest
the involvement of the protein Rab11 (Bruce et al., 2010; Eisfeld et al.,
2011; Amorim et al., 2011). After replication of the individual segments
in the nucleus, vRNAs are assembled into vRNPs and, by interaction
with M1 and the nuclear export protein NEP, they are transported into
the cytoplasm. They accumulate near the microtubule-organizing centre
(MTOC) and via interaction with Rab11 they are transported to the apical
membrane along the microtubule network (Eisfeld et al., 2011; Amorim
et al., 2011). The process of assembly of the individual components may be
9
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Figure 1.3: Influenza A virus replication cycle: Viruses attach to sialic acid
containing receptors on the host cell surface. After endocytosis of virus particles,
the viral genome is released into the cytoplasm and vRNPs are transported to the
nucleus, where transcription and replication occur. Viral mRNAs are translocated
to the cytoplasm for translation of viral proteins. Early in infection, the produced
proteins are mainly involved in replication and are therefore transported back to
the nucleus. Structural proteins required for virus particles and newly synthesised
vRNPs are translocated to the cell membrane, where virus assembly and budding
takes place. The non-structural proteins PB1-F2 and NS1 are made early in
infection. PB1-F2 interacts with mitochondria and NS1 is involved in interfering
with the host cell immune response. Picture taken from Neumann et al. (2009).
triggered by protein-protein interactions as well as RNA-RNA interactions of
the segments. Although it is an evolutionary advantage to have a segmented
genome, the virus has to make sure that each segment is incorporated
once (at least) into a virus particle. How this is maintained is not fully
understood, however findings suggest a specific mechanism (Fujii et al.,
2003; Hutchinson et al., 2010). Assembly of the segments in combination
with interactions between the cytoplasmic tails of HA, NA and M2 with the
vRNPs via M1 is thought to induce the process known as budding, which
includes the formation, growth and release of the progeny virion (Nayak
et al., 2009; Hutchinson et al., 2010).
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1.1.5 Viral transcription and replication
The minimal complex for viral replication is the vRNP, which consists of
the negative sense RNA, one copy of the polymerase complex and a
number of nucleoprotein molecules. The vRNPs are the starting point for
viral transcription and replication. Whereas the initiation of transcription
depends on a primer, synthesis of cRNA and vRNA are primer-independent
processes (Figure 1.4).
Cap-snatching is required for initiating viral mRNA synthesis. The viral
RdRp binds to cellular RNA polymerase II (RNAPII), more specifically
to the C-terminal domain in its Ser5-phosphorylated stage (Engelhardt
et al., 2005). RNAPII is the polymerase responsible for the synthesis of
cellular mRNA. Its CTD gets differentially phosphorylated throughout the
transcription process, and binding of the viral RdRp to the form that is
engaged in the initiation of cellular transcription was thought be bring the
viral RdRp in close proximity to newly made 5’ capped mRNAs (Engelhardt
et al., 2005). The polymerase subunit PB2 was shown to recognise and
bind to the 5’ cap and cleavage is performed by the PA subunit (Blaas et al.,
1982; Braam et al., 1983; Dias et al., 2009; Yuan et al., 2009). Although it
was first reported that no base-pairing is needed between the primer and the
3’ end of the vRNA, recent reports suggest a preference of complementary
sequences both in vitro and in vivo (Krug et al., 1980; Geerts-Dimitriadou
et al., 2011a,b). The non-translated regions of each segment are partially
complementary and form a stable complex (Figure 1.5). Two models have
been proposed: the panhandle and the ”corkscrew” model (Hsu et al., 1987;
Flick et al., 1996). The interaction of the 3’ and 5’ end of the viral RNA
are thought to be important for transcription and replication (Fodor et al.,
1994; Flick and Hobom, 1999a; Azzeh et al., 2001). After binding of the viral
polymerase complex to the promoter region and cap snatching, the PB1
subunit starts transcription at the penultimate cytosine in the vRNA (Caton
and Robertson, 1980; Beaton and Krug, 1981). PB1 contains conserved
motifs that are characteristic for RNA-dependent RNA polymerases (Argos,
1988; Biswas and Nayak, 1994).
After elongation of viral mRNA by PB1, a poly(A) tail is attached in a process
that is different to cellular polyadenylation (Fodor et al., 2001). Synthesis of
mRNA is halted when the polymerase reaches the 5-7 uridine stretch near
the 5’ end of the vRNA (Robertson et al., 1981). The polymerase complex
is believed to be stably bound to the 5’ end of the vRNA and the loop of
11
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Figure 1.4: Schematic overview of influenza A virus transcription and
replication: The viral RNA genome is the starting point for mRNA synthesis and
cRNA synthesis. cRNA is used as a template for vRNA synthesis. mRNA synthesis
is primed by a short capped primer that derives from host mRNA. The product
is about 15-22 nucleotides shorter than the vRNA template and polyadenylated.
cRNA and vRNA are synthesised without the use of a primer. The products are
covered with nucleoprotein molecules to form RNPs.
remaining template that still needs to be transcribed gets shorter throughout
the process (Figure 1.5). Eventually, the complex provides a physical barrier
that results in stuttering of the polymerase at the uridine stretch (Luo et al.,
1991; Li and Palese, 1994; Tiley et al., 1994; Fodor et al., 1994; Poon et al.,
1999).
When the uridine stretch was mutated into an adenine stretch, the viral
mRNA contained a poly(U) tail, supporting the model of a stuttering RdRp
(Poon et al., 1999). Also, tight binding of the RdRp to the 5’ end is crucial for
polyadenylation (Tiley et al., 1994; Fodor et al., 1994; Pritlove et al., 1998).
12
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Figure 1.5: Proposed model for influenza A virus transcription initiation,
elongation and polyadenylation: The viral polymerase complex binds the 5’
and 3’ termini of each segment and starts transcription in a primer-dependent
manner. The viral RdRp is bound to the 5’ end throughout the transcription process.
When the polymerase complex reaches the Uridine stretch, it stutters due to steric
hindrance, which leads to the polyadenylation of the viral mRNA (Tiley et al., 1994;
Fodor et al., 1994; Poon et al., 1999). Picture taken from Fodor et al. (2001).
Replication of the viral genome is divided into two steps. Before new
genomes can be made, an intermediate of positive sense full-length RNA
is produced. This antigenome is complementary to the vRNA and is
therefore called cRNA (Figure 1.4). In contrast to mRNA synthesis, the
process of cRNA and vRNA synthesis is primer-independent (Shapiro and
13
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Krug, 1988). Initiation of cRNA and vRNA are reported to differ between
each other (Figure 1.6). Two models have been proposed for the initiation
of cRNA synthesis. Deng et al. hypothesised that the synthesis of a
pppApG dinucleotide starts at the terminal 3’ end of the vRNA promoter
and proceeds directly into elongation (Figure 1.6(A)) (Deng et al., 2006b).
A newer model by Zhang et al. suggests that the de novo synthesis of
cRNA starts internally at the second nucleotide and an external nucleotide
(preferably a purine) is added by a cellular ribonucleotidyl transferase
(Zhang et al., 2010b). A model for the de novo synthesis of vRNA is shown
in Figure 1.6(B). Initiation starts internally at nucleotide 4 and 5 leading to
the synthesis of a dinucleotide pppApG (Deng et al., 2006b). The RdRp
is thought to pause at the following uridine residues, which causes the
polymerase to realign at the 3’ end of the cRNA template (Zhang et al.,
2010b). The dinucleotide serves as a primer to initiate full length vRNA
synthesis.
Synthesis of both mRNA and cRNA starts from a vRNA template.
Different models have been proposed to explain the switch from transcription
to replication, however this remains an open question. NP was shown to
interact with the viral RdRp and with the RNA to form c/vRNPs (Kobayashi
et al., 1994; Biswas et al., 1998). Temperature sensitive mutants with
lesions in NP were shown to be defective in replication and/or transcription
(Mena et al., 1999) and the depletion of NP abolished c/vRNA synthesis
(Beaton and Krug, 1986). The mechanism of this is not well understood.
A model proposed by Vreede et al. suggested that no regulation towards
transcription or replication exists per se, but newly synthesised cRNA
gets degraded within the cell unless it is covered and protected by NP
molecules (Vreede et al., 2004; Vreede and Brownlee, 2007). A study
titrating increasing amounts of NP to cells infected with influenza A viruses
however did not support this model (Mullin et al., 2004). Levels of mRNA
and vRNA were not different regardless the transfected amount of plasmids
to express NP. Alternatively, NP could alter the structure of the promoter
region to favour transcription or replication, or it could influence the replicase
or transcriptase function of the viral polymerase by binding to it (Fodor et al.,
1994; Newcomb et al., 2009).
Additional factors have been described that are involved in this process of
switching from transcription to replication. High levels of capped cellular
mRNAs were shown to support transcription, whereas high levels of viral
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(A) (B)
Figure 1.6: Proposed model for initiation of cRNA and vRNA synthesis: (A)
Synthesis of cRNA was proposed to start at the very end of the 3’ end of vRNA
templates by ATP. The addition of a second nucleotide triggers elongation of the
cRNA synthesis (Deng et al., 2006b). (B) Synthesis of vRNA initiates also with ATP
to produce a pppApG dinucleotide. However, this happens at positions 4 and 5
and the dinucleotide translocates back to the 3’ end to realign and inititate vRNA
synthesis from this short dinucleotide primer (”internal initiation and realignment
model”) (Deng et al., 2006b; Zhang et al., 2010b). Picture taken from Digard et al.
(2009).
RdRp and 5’ end vRNA promote viral replication (Olson et al., 2010). The
latter report is in line with a recent finding by Perez et al., suggesting that
small viral RNAs corresponding to the 5’ end of each vRNA switch the
viral RdRp towards a replicase (Perez et al., 2010). However, the exact
mechanism has yet to be determined. It cannot be ruled out that additional
viral factors influence the switch, such as NEP (Robb et al., 2009) and
that the process of regulating viral transcription and replication depends on
multiple effectors.
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1.1.6 Viral pathogenicity and the involvement of host cell
proteins
Several factors have to act together so that viruses can infect a host and
induce disease. These include effects the virus has on the host cell, e.g.
during viral replication, and aspects the host contributes itself, e.g. via the
immune response. The degree of pathogenicity is thereby determined by
this interplay. Are specific receptors available on the host cell and is the
virus able to bind to them? Is the virus able to hijack the transcription and
translation machinery within the host cell? How effective is the immune
system to counteract the viral infection and what mechanisms does the virus
have to escape or modulate these host defence systems?
These aspects have a great influence on the success of the viral infection
and are key issues for the development of viral pandemics. Aquatic birds
are the natural hosts of influenza A viruses. Frequently viruses cross the
species barrier from an avian host to humans or other mammals. In order
to be able to replicate in a mammalian host, the virus needs to adapt to it.
Different factors have been described that are important for this to happen.
One way to cross the species barrier is by direct introduction of an avian
strain into the human population followed by accumulation of mutations that
change the virus’ specificity. The 1918 pandemic is believed to have been
directly transmitted from birds to humans (Taubenberger and Morens, 2006).
Several viral proteins were shown to be involved in the process of adaptation
and virulence, such as HA, polymerase subunits, NS1 and PB1-F2 (Kobasa
et al., 2004; Watanabe et al., 2009; McAuley et al., 2007). Since 1997,
continued interspecies transmissions of H5N1 viruses have been reported
(Smith et al., 2006). A second possibility to cross the species barrier is
by reassortment between an avian and a human strain. Because of the
segmented nature of the viral genome, this can happen when one cell gets
infected by two virus strains. In this context, swine are believed to be good
”mixing vessels”, because they have both receptors recognised by human
and avian viruses (Ma et al., 2008). Such an event most likely did happen
with the last pandemic virus from 2009 (Smith et al., 2009). However a new
virus is introduced into the human population, further adaptations within the
viral proteins are needed for efficient replication and transmission. Two main
reasons for this are:
(1) Replication of the viral genome depends largely on the interaction of viral
proteins with cellular proteins.
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(2) Host cell immune responses are induced by viral infection which the virus
has to counteracted in order to replicate efficiently.
Figure 1.7: Interaction map of cellular and viral proteins involved in viral
replication and transcription: A large number of cellular proteins were identified
as interaction partners for viral proteins. Proteins shown in this map are involved
in viral replication and transcription. The cellular factors can be categorised in
groups involved in nuclear transport, nucleoporins, metabolic enzymes, translation,
splicing factors, chromatin, molecular chaperones, cell proliferation, cytoskeleton
and transcription and translation. Picture taken from Nagata et al. (2008).
Figure 1.7 shows some of the identified cellular proteins that interact
with viral proteins, specifically those who are involved in viral replication and
transcription. With the use of new techniques such as RNAi screenings,
even more interactions have been identified (Hao et al., 2008; Karlas et al.,
2010; Stertz and Shaw, 2011). Some of the shown proteins are involved
in the nuclear transport of vRNPs and viral proteins, such as CRM1 and
RanBP5 (Elton et al., 2001; Deng et al., 2006a). Other interactions help
transcribing and processing viral mRNAs. The viral RdRp was found to
bind to the C-terminal domain of cellular RNA polymerase II which has
been proposed to support cap snatching (Engelhardt and Fodor, 2006).
NS1 was found to interact with several cellular factors involved in splicing,
such as NS1-binding protein (NS1-BP), the 30kDa subunit of the cleavage
and polyadenylation factor (CPSF) and the poly(A)-binding protein PAB-II
(Wolff et al., 1998; Nemeroff et al., 1998; Chen et al., 1999). Besides being
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important for viral transcription, these interactions contribute to host cell
protein shut off.
Apart from exploiting cellular proteins to transcribe and replicate the viral
genome, the virus utilises cellular proteins to induce or inhibit apoptosis
and to interfere with the host cell immune system. Apoptosis and its
regulation will be explained in more detail in Section 1.1.7. The innate
immune response is the ”first line of defence” and very important for fighting
a viral infection. Cellular receptors recognise specific pathogen-associated
molecular patterns (PAMPs) such as 5’ triphosphorylated RNA, which does
not exist naturally in a cell (Pichlmair et al., 2006). The cellular receptor
RIG-I gets activated upon RNA binding. The CARD domain of RIG-I
interacts with the CARD domain of the mitochondrial membrane protein
MAVS (also known as VISA, IPS-1 and CARDIF) and triggers a signalling
cascade that leads to the activation of several transcription factors such as
IRF-3 and NFκB. These transcription factors are translocated to the nucleus
and form an ”enhanceosome” complex on the IFN-β promoter (Figure 1.8)
(Seth et al., 2005; Xu et al., 2005; Kawai et al., 2005; Meylan et al., 2005).
IFN-β is subsequently secreted from the cell and functions in an
autocrine or paracrine manner by binding to the IFN-α/β-receptor on the
cell surface. This triggers a JAK/STAT signalling cascade leading to the
expression of IFN-stimulated genes, which create an antiviral state within
the cell that limits viral replication. Influenza A viruses have evolved a
number of strategies to prevent this in order to replicate efficiently. The
small non-structural protein NS1 was shown to be the main IFN-antagonist.
It inhibits RIG-I signalling, most likely by preventing the ubiquitination of
the CARD domain of RIG-I by inhibiting the ubiquitin-ligase TRIM25 (Gack
et al., 2009). Influenza viruses also act downstream of the IFN-α/β-receptor,
e.g. by enhancing the expression of suppressor of cytokine signaling-3
(SOCS-3) proteins (Pauli et al., 2008). SOCS-3 proteins were shown to
negatively regulate the JAK/STAT pathway by inhibition of the JAK kinase
activity (Starr et al., 1997; Song and Shuai, 1998). Additionally host-cell
protein shut-off by NS1 and the polymerase complex as described above
also adds to counteraction of the innate immune response.
The interplay between a virus and its host determines the clinical outcome
of the infection. By expressing cytokines and IFNs the host intends to
inhibit viral replication, however this response may be detrimental for the
host under certain circumstances. Especially high pathogenic avian H5N1
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MAVS
Figure 1.8: Schematic of IFN-β induction by viral RNA: Influenza A viruses
induce IFN-β via RIG-I. The CARD domains of RIG-I and MAVS interact which
leads to the activation of IRF-3 and NFκB. Translocation of these transcription
factors to the nucleus initiates IFN-β expression. Picture adapted from Shaw
(2009).
viruses were shown to induce the innate immune response in an excessive
way that it becomes disadvantageous for the host (de Jong et al., 2006;
Alberts et al., 2010).
Collectively it can be said that the host-virus-relation must be a well
balanced one. The virus must be able to control the host for successful
replication. It needs to find the right balance to infect, replicate and escape
from the host cell to infect a new cell or host before the host either induces
an effective immune response or the infection ends fatally before replication
is completed. Interactions with host proteins are therefore indispensable
and viruses in a new host need to adapt to get the right balance.
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1.1.7 Apoptosis and its regulation by viral proteins
Apoptosis, also known as programmed cell death, is an extremely powerful
way to remove cells without causing an inflammatory response. Apoptosis
is one of the oldest first-line defences against viral infections and viruses
have generated many ways during evolution to modulate the process.
Apoptosis can be differentiated from necrosis by specific cellular and
nuclear morphological changes (Kerr et al., 1972). Cells shrink, DNA is
fragmented, apoptotic cells lose contact to their neighbouring cells, and the
cell is finally broken up into small vesicles. These vesicles are removed
by macrophages or neighbouring cells via phagocytosis and no immune
response is induced. Apoptosis can be activated through a number of
stimuli, external or internal, resulting in extrinsic or intrinsic induction both
leading to the activation of several caspases (Figure 1.9). Mitochondria are
thought to be the central element in the intrinsic pathways. Mitochondrial
transmembrane potential is disrupted upon stimuli, which leads to the
release of cytochrome C into the cytoplasm (Liu et al., 1996). The
permeability transition can be mediated by a pore protein complex in the
mitochondrial membrane. This permeability transition pore complex (PTPC)
is a large complex with three major components, VDAC, ANT and cyclophilin
D. ANT (adenine nucleotide translocator) is the most abundant protein
in the inner mitochondrial membrane, whereas VDAC (voltage dependent
anion channel) is the most abundant protein in the outer membrane. Upon
activation, they are thought to form a non-selective pore, following a sudden
increase in the inner mitochondrial permeability and an up-regulated entry
of water with the result of osmotic swelling (Shoshan-Barmatz et al., 2010;
Keinan et al., 2010). Several proteins in the cytoplasm and the mitochondrial
membrane regulate the mitochondrial membrane potential and therefore
apoptosis. These proteins belong to the so-called Bcl-2 family. Members
of this family are pro- or anti-apoptotic. Pro-survival members such as Bcl-2
and Bcl-XL stabilise the mitochondrial membrane e.g. by sequestering
pro-apoptotic members (Cheng et al., 2001). Pro-apoptotic members of
the Bcl-2 family (e.g. Bax, Bak) can change the permeability of the
outer mitochondrial membrane either by integrating into the mitochondrial
membrane and forming pores or via induction of mitochondrial permeability
transition at the inner mitochondrial membrane by interacting with members
of the PTPC. The idea that apoptosis is induced only by host cells to
defend itself and limit viral replication was found to be imperfect as evidence
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Figure 1.9: Apoptosis induction pathways: Three routes can lead to the
induction of caspases that results in apoptosis. (1) The extrinsic pathway is
activated by binding of FasL or TNF-α to a death receptor on the cell surface. This
triggers a recruitment of adaptor proteins and Caspase-8 to the receptor, which
leads to the activation of casapse-8. Active caspase-8 proteolytically processes
and activates a number of other caspases leading to cell death. (2) The intrinsic
pathway involves the activation of BH-3 only proteins of the Bcl-2 family. These
pro-apoptotic family members are negative regulated by anti-apoptotic members
of the same family. Upon activation, cleavage of BID into truncated BID (tBID)
promotes cytochrome C release from mitochondria either by interacting with the
PTPC or by integration of Bax/Bak into the mitochondrial membrane. Cytochrome
C release activates the formation of an apoptosome in the cytoplasm (APAF-1 and
Caspase-9). Crosstalk between pathway (1) and (2) is possible via Caspase-8.
(3) The granzyme pathway is activated by delivery of granzyme into the cytoplasm
through a cell surface perforin channel. Picture taken from Taylor et al. (2008).
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increased for viral-induced apoptosis. Several viruses have found ways
to modulate the induction of apoptosis. Inhibition of apoptosis can help
viruses to prolong their replication time within the cell or to evade the
immune system. Many viruses also stimulate apoptosis which may help
the virus to spread or to dysregulate the host immune system by specifically
inducing apoptosis in immune cells. However, this process needs to be
tightly regulated in order not to kill the host cell too quickly. Often apoptosis
seems to be beneficial for the pathogenicity of the virus. A large number
of viruses encode proteins that modulate mitochondrial apoptosis, some of
which are listed in Figure 1.10. These proteins target components of the
PTPC or members of the Bcl-2 family, such as Bax, Bak or Bcl-2. They may
also be able to directly integrate in the mitochondrial membrane to induce
mitochondrial membrane permeabilisation (MMP).
Figure 1.10: Viral peptides involved in modulating mitochondrial apoptosis:
Viral proteins may be pro- or antiapoptotic modulating the mitochondrial membrane
permeabilisation (MMP). This can be by acting on the permeability transition pore
complex (PTPC) or via interacting with members of the Bcl-2 family. Virus names
are listed in abbreviations. Picture taken from Galluzzi et al. (2008).
Hepatitis B virus protein X (HBx) was found to interact with VDAC3 to
induce apoptosis, similar to HIV-1 protein Vpr, which additionally interacts
with ANT. HTLV-1 encodes a small protein called p13(II), which also targets
mitochondria and causes swelling and fragmentation of the mitochondria
(D’agostino et al., 2005). All three proteins were shown to have an
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amphipathic α-helix that is necessary for the integration in the mitochondrial
membrane (Takada et al., 1999; Shirakata and Koike, 2003; Jacotot et al.,
2000, 2001; D’Agostino et al., 2002). The HIV- protease was found to
proteolytically activate caspase-8, which triggers apoptosis (Nie et al.,
2002). Other viral proteins target members of the Bcl-2 family to induce
or suppress apoptosis. Beside its interaction with VDAC and ANT, HIV-1
Vpr was also found to induce mitochondrial membrane permeabilisation in
a Bax-dependent manner (Andersen et al., 2006). Especially anti-apoptotic
viral proteins have sequence or conformational similarities to pro-survival
members of the Bcl-2 family. This includes the adenovirus protein E1B-19K
that acts similar to the cellular Bcl-2 protein and sequesters Bax and Bak
(Han et al., 1996, 1998; Cuconati et al., 2002).
It is not surprising that influenza A viruses also regulate apoptosis.
Induction can be either by extrinsic or intrinsic mechanisms (Lowy, 2003).
Several influenza virus proteins were shown to induce cell death. Earlier
studies had already revealed that induction of apoptosis relies on the
replication of the virus as UV or chemically inactivated viruses did not induce
apoptosis (Takizawa et al., 1993; Hinshaw et al., 1994). In infected cells,
levels of the biological active form of TGF-β increase. This cytokine usually
exists in an inactive form in all cells. The viral neuraminidase was shown
to activate TGF-β, which induces apoptosis (Schultz-Cherry and Hinshaw,
1996). Expression of M1 from plasmids induces apoptosis, possibly by
interacting with caspase-8 (Morris et al., 2002; Zhirnov et al., 2002b).
Another inducer is NS1, although its role is rather controversial. Expression
of NS1 was shown to induce apoptosis in different cell lines (Schultz-Cherry
et al., 2001; Lam et al., 2008). On the other hand, recombinant viruses
lacking NS1 were shown to be greater inducers of apoptosis, suggesting
that NS1 could be anti-apoptotic. However, this may be due to its role
in antagonising IFN expression (Zhirnov et al., 2002a). Beside this, an
IFN-independent anti-apoptotic function was reported for NS1. NS1 was
shown to bind to and activate PI3K by binding to the p85β subunit (Hale
et al., 2006). PI3K is involved in a number of cellular processes such
as cell proliferation and survival and the activation of PI3K by NS1 was
thought to prevent apoptosis (Ehrhardt et al., 2007). More recent data
using recombinant viruses that fail to induce the PI3K pathway, however,
show that the activation does not affect apoptosis (Jackson et al., 2010).
The second non-structural protein, PB1-F2, was shown to be pro-apoptotic,
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which is described in Section 1.2.2. Overall, the induction of apoptosis by
influenza A viruses is thought to be supportive for viral replication. Wurzer et
al. showed that the activation of caspases-3 is essential for viral replication
in that knockdown of caspase-3 led to retention of vRNPs in the nucleus
(Wurzer et al., 2003). A recent study suggested a positive role of Bax in
the virus replication cycle, and thereby support the findings of Wurzer et al.
(McLean et al., 2009): although cells lacking Bax still underwent apoptosis,
the downregulation of Bax resulted in retention of NP in the nucleus and
decreased virus titres.
1.2 PB1-F2 and its reported functions within
infected cells
When the gene products of influenza A viruses were first characterised,
ten proteins expressed from eight negative strand RNA segments were
described (Palese and Schulman, 1976; Ritchey et al., 1976; Palese et al.,
1977; Inglis et al., 1979; Lamb et al., 1981). Then, about 20 years later, an
additional protein was found to be expressed from segment 2 by a process
called leaky ribosomal scanning. The 87-90 aa long protein was discovered
during a search for unknown CD8+ T cell epitopes and was named PB1-F2
(Chen et al., 2001).
The mechanism for leaky ribosomal scanning is not an invention of
influenza A viruses. It is a strategy that is also used by other viruses such as
bunyaviruses, paramyxoviruses and vesicular stomatitis virus (Elliott, 1989;
Bellini et al., 1985; Luk et al., 1986; Herman, 1986). Beside overlapping
ORFs, viruses have evolved several other strategies to increase their coding
capacity, e.g. splicing events (e.g. influenza A virus segment 7 and 8),
ambisense sequences (e.g. Uukuniemi virus S segment, Rift Valley fever
virus S segment), overlapping Stop-Start sequences (influenza B viruses),
RNA editing (e.g. measles virus, human parainfluenza virus type 3) and the
use of self-cleaving peptide (e.g. picornavirus 2A) (Inglis et al., 1979; Lamb
et al., 1981; Simons et al., 1990; Giorgi et al., 1991; Horvath et al., 1990;
Cattaneo et al., 1989; Galinski et al., 1992; Lloyd et al., 1986).
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1.2.1 General information about PB1-F2
In 2001, the existence of a small protein (∼10.5 kDa) translated from an
internal +1 ORF from segment 2 was reported by Chen et al. (Chen et al.,
2001). Because the protein is translated from a second ORF, it was named
PB1-frame 2 (short PB1-F2). In contrast to PB1-F2, the start codon of PB1
is in a suboptimal Kozak consensus sequence (Kozak, 1986; Chen et al.,
2001). Therefore, it was suggested that ribosomes which miss the first AUG
continue to scan for another AUG along the mRNA until they reach one in a
stronger consensus sequence further downstream (Chen et al., 2001). This
process is called leaky ribosomal scanning. Sequence analysis revealed
that almost all avian influenza virus strains contain a full length PB1-F2 but
human H1N1 viruses isolated after 1947 and classical swine H1N1 virus
isolates express a truncated version of 57 aa or 11 aa, respectively (Zell
et al., 2007). The pandemic H1N1 virus from 2009 only expresses 11 aa
of the PB1-F2 ORF as it contains three stop codons at position 12, 58 and
88 (Trifonov and Rabadan, 2009). PB1-F2 is not incorporated into virions,
it only is present in infected cells, and the protein is expressed early in
infection. About 2 hours post infection it can be detected by Western blot
analysis with maximum expression at 5 hpi. The protein has a half-life of only
30 min and degradation is mediated by the proteasome (Chen et al., 2001).
The intracellular localisation differs between infected cells. Independent
of the cell type, it was observed that PB1-F2 localises in about half of
cells to the mitochondrial membrane, whereas in other cells it stays in the
nucleus and in the cytoplasm (Chen et al., 2001; Zamarin et al., 2005). The
protein was shown to induce apoptosis via mitochondria in a cell-dependent
manner. In contrast to epithelial cells, immune cells seem to be affected
by PB1-F2 expression (Chen et al., 2001). This feature of PB1-F2 will be
discussed in more detail below.
1.2.2 PB1-F2 and its pro-apoptotic function
About 55% of cells infected with A/PR/8/34 show a mitochondrial localisation
of PB1-F2 (Chen et al., 2001). The mitochondrial targeting signal (MTS) is
located between amino acids 65 and 87 and forms a charged amphipathic
α-helix (Gibbs et al., 2003). Another prediction for the MTS is between
amino acids 46 and 75 (Yamada et al., 2004). The observed differences are
most likely the result of various methodologies employed by the two groups.
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The sequence identified by Yamada et al. is consistent with the finding that
viruses isolated from European swine had a truncated PB1-F2 of 79 aa
that still localises to mitochondria (Zell et al., 2007). The MTS is similar to
the sequence of a protein called p13(II) from HTLV-1. PB1-F2 was shown
to interact with two mitochondrial membrane proteins, ANT3 (adenine
nucleotide translocase) in the inner mitochondrial membrane and VDAC1
(voltage-dependent anion channel) in the outer mitochondrial membrane
(Zamarin et al., 2005). It was suggested that this interaction is involved
in the induction of apoptosis since both mitochondrial proteins are part of
the permeability transition pore, which has been shown to play a role in
programmed cell death (Belzacq et al., 2002; Zaid et al., 2005). Whether
PB1-F2 alone is able to induce apoptosis, or if viral infection is needed, is
not clear. Whereas Yamada et al. (Yamada et al., 2004) did not find efficient
induction of cell death by just transfecting cells with a PB1-F2 expressing
plasmid, other groups report it is an intrinsic feature of the protein and no
other viral proteins are required (Chen et al., 2001; Gibbs et al., 2003).
It might depend on the amount of PB1-F2 produced in transfected cells
and on the cell type. PB1-F2 was shown to oligomerise and it was found
to form variably sized pores in phospholipid bilayers (Chanturiya et al.,
2004; Henklein et al., 2005). Oligomerisation was mapped to the α-helix
in the C-terminus of the protein (Bruns et al., 2007). To what extent the
interaction of PB1-F2 with ANT3 and VDAC1 is responsible for the induction
of apoptosis is not known. Several hypothesis have been proposed.
PB1-F2 could mediate a bridge between the two mitochondrial proteins and
therefore cause mitochondrial membrane permeabilisation and cytochrome
C release. Another possibility is the formation of multimeric PB1-F2
complexes which themselves could form pores and lead to cytochrome C
release (Zamarin et al., 2005). Additionally, expression of PB1-F2 was
shown to sensitise cells to the effect of TNF-α and DNA damage, stimuli
that are known to trigger apoptosis (Zamarin et al., 2005). It is not
well understood why cell death is only induced in immune cells, whereas
epithelial cells are not affected, although PB1-F2 localises to mitochondria
in all cell types. A different expression level of the isoforms of ANT1 and
VDAC3 was suggested, but no clear evidence for this hypothesis exists
(Zamarin et al., 2006). More cellular factors might be involved in this
process. Possible candidates would be the pro-apoptotic proteins Bax and
Bak. Bax was shown to interact with the PTPC, which is important for the
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induction of apoptosis by the permeability transition pore (Marzo et al., 1998;
Shimizu et al., 1999; Giorgi et al., 2002). The HIV-1 protein Vpr was shown
to bind ANT and VDAC and induces apoptosis, which was shown to be a
Bax-dependent process (Jacotot et al., 2000; Andersen et al., 2006).
1.2.3 Involvement of PB1-F2 in influenza A virus
pathogenicity
The involvement of PB1-F2 in viral pathogenicity is not clearly understood
nor defined yet. Inducing apoptosis in immune cells, e.g. in alveolar
macrophages, could impair the host immune system, decrease viral
clearance from lungs and therefore increase virulence (Chen et al., 2001;
Zamarin et al., 2006). Beside this, PB1-F2 was also shown to help
development of secondary bacterial infections caused by Streptococcus
pneumoniae, possibly by lowering the host defence system (McAuley et al.,
2007). Secondary bacterial infections are the most common but also the
most severe complications of influenza A virus infections (McCullers and
Rehg, 2002). The C-terminus of PB1-F2 appeared to be responsible for this
effect, as mice were unaffected when only the N-terminal peptide was given
(McAuley et al., 2007). Despite the fact that some strains do not seem to be
affected by deletion of PB1-F2 in tissue culture (e g. A/PR/8/34), introducing
PB1-F2 from the highly pathogenic strain A/Brevig Mission/1/1918 into a
A/PR/8/34 background had a clear effect on plaque size, in vitro growth
and pathogenicity in mice, suggesting that the protein can influence some
functions (Zamarin et al., 2006; McAuley et al., 2007). With regards to
this, one amino acid in the ORF of PB1-F2 was identified to be different
compared to less pathogentic influenza A viruses, residue 66. Most
strains encode an asparagine at position 66 with the exception of A/Brevig
Mission/1918 and the highly pathogenic avian strains from the 1997 H5N1
group. These viruses code for serine at position 66. Exchanging just amino
acid 66 (N66S) led to an increase in viral lung titres in infected mice, raised
the level of cytokines and finally led to higher mortality (Conenello and
Palese, 2007). To what extent PB1-F2 contributes to viral pathogenesis
remains unclear. PB1-F2 of some strains might lead to an increased
pathogenicity in a specific genetic background, but other viral strains might
not profit from PB1-F2 expression.
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1.3 Reverse genetics of negative-strand RNA
viruses
1.3.1 Synthesis of non-segmented and segmented RNA
viruses
In molecular virology, reverse genetics describes the generation of infectious
viruses from cloned cDNA. This methodology allows the direct manipulation
of the viral genome to study the relationship between virus structure,
morphology and components and the pathogenicity of a virus. Beside this,
reverse genetics is a powerful tool for generating vaccines.
The first RNA virus generated from cloned DNA was the bacteriophage
Qβ (Taniguchi et al., 1978). Transfection of cloned DNA into E. coli
resulted in the formation of infectious phages. In 1981, Racaniello et al.
transfected mammalian cells with a plasmid containing a cDNA copy of
the poliovirus genome which also led to the production of infectious virus
particle (Racaniello and Baltimore, 1981). Reverse genetics systems of
many other positive-strand RNA viruses, such as Sindbis virus and Semliki
forest virus, followed (Rice et al., 1987; Liljestro¨m et al., 1991). Genomes of
positive-strand RNA viruses transfected into cells serve as mRNA and newly
expressed viral proteins can replicate the viral genome, however transfection
of cDNA was shown to be also effective (Racaniello and Baltimore, 1981).
Rescue of negative-strand RNA viruses turned out to be more difficult and
complex, because neither the genome nor the antigenome can serve as
mRNA and the minimal infectious unit is an RNP. This means viruses have
to deliver their own replication machinery including the RNA-dependent
RNA polymerase. The need of the polymerase and the nucleoprotein was
determined in minireplicon systems for influenza viruses, but also other
negative-strand RNA viruses such as VSV and bunyavirus (Honda et al.,
1988; Szewczyk et al., 1988; Pattnaik and Wertz, 1991; Dunn et al., 1995).
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(A) (B)
(C)(D)
Figure 1.11: Strategies to generate negative strand RNA viruses from cDNA:
(A) Individual replacement of segments of the influenza virus genome either by in
vitro reconstitution or in vivo assembly of RNP followed by infection with a helper
virus. (B) Rescues of non-segmented negative-strand RNA viruses was done by
transfecting plasmids with the viral antigenome under a T7 promoter along with
plasmids encoding the viral proteins to support RNP formation. T7 polymerase
was supplied by infection with a recombinant Vaccinia viruses expressing the T7
RNAP (VV-T7) or by transfected cell lines stably expressing T7 RNAP. (C) The first
rescue of a segmented negative-strand RNA virus was reported for Bunyamwera
viruses. Transfection of plasmids encoding the three RNA segments (antigenomic
sense) together with plasmids expressing the viral proteins using a T7 promoter.
T7 RNAP was supplied by infection with VV-T7 or by transfected cell lines stably
expressing T7 RNAP. (D) One method to rescue influenza A viruses is using the
12-plasmid rescue system. Eight segments coding for each RNA segment under
control of the RNA polymerase I promoter along with four plasmids encoding the
polymerase subunits and the nucleoprotein (under control of the pol II promoter)
were transfected into a target cell. Picture adapted from Pekosz et al. (1999).
The first steps towards modifying the genome of a negative-strand RNA
virus were done by Luytjes et al. (1989). cDNA in negative orientation of
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chloramphenicol acetyltransferase (CAT) gene was cloned under the control
of a T7 promoter and in vitro-synthesised virus-like RNA was transfected
into cells along with purified polymerase proteins and nucleoprotein.
Superinfection with a helper virus resulted in the generation of viruses
carrying the CAT gene (Luytjes et al., 1989). Using the approach of Luytjes
et al., the introduction of site-directed mutations into the influenza virus
genome followed (Enami et al., 1990). In 1993, a T7-independent system
was developed utilising cellular RNA polymerase I (pol I) removing the need
to infect with recombinant vaccinia viruses or generating stably transfected
cell lines (Zobel et al., 1993). The products of cellular RNA polymerase I
do not have 5’ or 3’ modifications, which results in the synthesis of precise
viral RNA segments. The hemagglutinin coding sequence or the CAT gene
were cloned between a mouse polymerase I promoter sequence and mouse
termination elements which resulted in the generation of vRNAs in vitro
and in vivo. Primer extension analysis confirmed the precise 5’ and 3’
end (Zobel et al., 1993; Neumann et al., 1994). Pleschka et al. used
a similar system to reconstitute viral RNPs intracellular. They transfected
cells with four plasmids expressing the three polymerase subunits and the
nucleoprotein under polymerase II promoter along with a plasmid coding for
an RNA-like transcript under the control of the human polymerase I promoter
and hepatitis delta virus genomic ribozyme (Pleschka et al., 1996). This new
approach was an alternative to in vitro reconstitution assays which removed
the need of purifying viral proteins (Figure 1.11 (A)). Intracellular generation
of RNPs followed by infection with a helper virus resulted in the production
of recombinant viruses (Pleschka et al., 1996). However, all the systems
described above were based on helper viruses and therefore required
strong selection methods to separate the recombinant and the helper virus.
Selection was achieved by using temperature-sensitive helper viruses,
change of host range due to the inserted mutation, trypsin-independent
growth or the use of specific antibodies (Li et al., 1995; Yasuda et al., 1994;
Subbarao et al., 1993a; Pleschka et al., 1996; Enami and Palese, 1991).
The first negative-strand RNA virus rescue entirely from cloned cDNA was
done by Schnell et al. in 1994, who rescued rabies virus (Schnell et al.,
1994). The antigenome of this non-segmented virus was cloned under
the control of a T7 promoter and transfected into cells along with plasmids
expressing the proteins N, L and P. Infection with a recombinant vaccinia
virus expressing the T7 polymerase resulted in the formation of infectious
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rabies viruses. The key to a successful approach was the use of the
antigenome rather than the genome. It is believed that the genome which is
in a negative orientation could hybridise with the mRNA of the co-transfected
N, L and P expressing plasmids, which would strongly interfere with virus
replication (Figure 1.11 (B)). A further development of the system was the
use of stably transfected cell lines that constitutively express T7 polymerase
(Radecke et al., 1995). In the following years, several other non-segmented
negative-strand RNA viruses were rescued, such as Measles virus, Sendai
virus, Ebola virus and many others (Radecke et al., 1995; Garcin et al.,
1995; Volchkov et al., 2001; Neumann et al., 2002).
Two years after the rescue of rabies viruses, the successful rescue
of a segmented negative-strand RNA virus was reported. Bridgen and
Elliott described the rescue of the three-segmented Bunyamwera virus from
cloned DNA and showed that it is possible to generate more than one
vRNA artificially (Bridgen and Elliott, 1996). The viral genome was cloned
into plasmids flanked by the T7 polymerase promoter and hepatitis delta
virus ribozyme. Cells were transfected with these plasmids together with
plasmids expressing all viral proteins. Infection with recombinant vaccinia
virus provided the T7 polymerase (Figure 1.11 (C)).
The rescue of influenza viruses proved to be more difficult due to the
complexity of the genome and the proteins necessary for vRNP formation.
In 1999, two groups reported the generation of influenza A viruses entirely
from cDNA (Neumann et al., 1999; Fodor et al., 1999). Neumann et al.
cloned the cDNA of each viral segment between a human RNA polymerase
I promoter and a mouse RNA polymerase I terminator (Figure 1.12(A)).
These eight plasmids were transfected into 293T cells along with four
plasmids expressing the viral polymerase subunits and the nucleoprotein
(Neumann et al., 1999), which led to the generation of infectious influenza
A viruses (Figure 1.11(D)). The approach of Fodor et al. was similar,
using a hepatitis delta virus ribozyme instead of a mouse Pol I terminator
sequence (Figure 1.12(B)) (Fodor et al., 1999). In the following years,
several attempts were made to improve the system, mainly by reducing the
numbers of plasmids required. Hoffmann et al. developed two 8-plasmid
rescue systems, a bidirectional and a unidirectional approach (Figure 1.12
(C and D)). The viral cDNA was cloned between a polymerase I promoter
and terminator and this Pol I cassette was flanked by a polymerase II
promoter and polyadenylation signal, which allowed the synthesis of viral
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RNA and mRNA from one plasmid (Hoffmann et al., 2000a; Hoffmann and
Webster, 2000; Hoffmann et al., 2000b).
Pol I PH Pol I THPoly(A)BGH Pol II PCMV
viral cDNA
viral cDNAPol I PH Pol I THPol II PCMV Poly(A)SV40
(A) Neumann et al.: 12-plasmid rescue system (B) Fodor et al.: 12-plasmid rescue system
(C) Hoffmann et al.: Bidirectional rescue system (D) Hoffmann et al.: Unidirectional rescue system
viral cDNAPol I PH Pol I TM
viral cDNA PB2 / PB1 / PA / NPPol II PCMV Poly(A)BGH
viral cDNAPol I PH Δ
viral cDNA PB2 / PB1 / PA / NP Poly(A)SV40Pol II PMLP
(E) De Wit et al.: T7-based rescue system
viral cDNA Δ T7 TT7 P
viral cDNA PB2 / PB1 / PA / NPPol II PHMG Poly(A)SV40
Figure 1.12: Reverse genetics systems for influenza A viruses: (A) 12-plasmid
rescue system developed by Neumann et al. (1999). Eight plasmids expressing
viral RNA are co-transfected with four plasmids expressing viral proteins PB2,
PB1, PA and NP. (B) 12-plasmid rescue system developed by Fodor et al.
(1999). Eight plasmids expressing viral RNA are co-transfected with four plasmids
expressing viral proteins PB2, PB1, PA and NP. (C) Bidirectional 8-plasmid rescue
system developed by Hoffmann et al. (2000a,b). Viral cDNA is inserted between
the polymerase I promoter and terminator sequence flanked by polymerase II
promoter and polyadenylation signal in a bidirectional orientation. (D) Unidirectional
8-plasmid rescue system developed by Hoffmann and Webster (2000). Viral
cDNA is inserted between the polymerase I promoter and terminator sequence
flanked by polymerase II promoter and polyadenylation signal in a unidirectional
orientation. (E) T7 based rescue system developed by de Wit et al. (2007).
Eight plasmids expressing the viral RNA under the control of a T7 promoter and
terminator are transfected along with four plasmids expressing viral polymerase
proteins and nucleoprotein. Pol I PH=Human polymerase I promoter; Pol I
TM=mouse polymerase I terminator; Pol II PMLP=Adenovirus type 2 major late
promoter; Pol II PCMV=Polymerase II promoter derived from cytomegalovirus;
Poly(A)SV40=simian virus 40 polyadenylation signal; Poly(A)BGH=bovine growth
hormone polyadenylation signal; ∆=hepatitis delta virus ribozyme sequences; T7
P=T7 polymerase promoter; T7 T=T7 polyermase terminator; Pol II PHMG=mouse
hydroxymethylglutaryl coenzyme A reductase promoter.
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The position of the two promoters relative to the cDNA determined if the
system was bidirectional or unidirectional, and if viral RNA produced was
vRNA or cRNA, respectively. Although infectious virus could be recovered
with both systems, the unidirectional system was less efficient and much
lower viral titres were obtained (Hoffmann and Webster, 2000). Recently,
even more compact procedures were developed for vaccine production.
Cells suitable for vaccine production are not suitable for transfections with
high numbers of plasmids in parallel. Neumann et al. generated a system
with cDNA of either all segments cloned into one plasmid or six segments
on one plasmid and the cDNA for NA and HA on a second. The plasmids
were transfected with two additional plasmids that provide the polymerase
subunits (combined on one plasmid) and the nucleoprotein. This reduced
the number of plasmids to be transfected from 8 or 12 to only 3 or 4 plasmids
(Neumann et al., 2005).
The use of RNA polymerase I promoters in influenza A virus rescues
has some advantages compared to the T7-based system. Influenza A
viruses replicate in the nucleus and only the RNA polymerase I is located in
this compartment, whereas the T7 polymerase localises to the cytoplasm.
However, the cellular polymerase I promoter shows host specificity, and
the human polymerase I promoter is not functional in cells of avian or
canine origin. Such rescue systems are therefore limited to specific cell
types. A T7 based system was generated to rescue influenza A viruses in
a variety of cells including human, canine and avian cells (Figure 1.12(E)).
The system was improved by adding a nuclear localisation sequence to the
T7 polymerase to support efficient transcription of influenza A virus cDNA
(de Wit et al., 2007).
Beside rescue systems for the Bunyamwera virus and influenza A viruses,
several other segmented negative-strand and ambisense RNA viruses have
been rescued from cloned cDNA in the last decade, amongst them influenza
B and C viruses, Thogoto virus, Rift Valley fever virus and recently the
arenaviruses Lassa virus, lymphocytic choriomeningitis virus (LCMV) and
Junin virus (JUNV) (Hoffmann et al., 2002; Crescenzo-Chaigne and van der
Werf, 2007; Wagner et al., 2001; Ikegami et al., 2006; Albarin˜o et al., 2011;
Sa´nchez and de la Torre, 2006; Emonet et al., 2011).
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1.3.2 Expression of foreign epitopes and proteins
The concept of integrating foreign epitopes or even complete genes into
viral genomes seems appealing. It offers a wide range of opportunities
to study the virus in more detail regarding genome size, packaging of
segments or replication of the genome. It would also offer a straightforward
way for drug screening. Additionally, the insertion of foreign sequences
would allow the engineering of vaccines that immunise against multiple
pathogens. Although the integration of foreign sequences often is not stable
and insertion of large genes does not always support viral replication, some
approaches have shown promise. Several non-segmented viruses e.g. VSV
and Rabies virus carrying HIV-I epitopes have been tested for vaccine use
(Schnell et al., 2000; Rose et al., 2001). VSV has also been used to express
influenza A virus HA and NA, which protected mice from challenge with
a lethal dose of influenza virus (Kretzschmar et al., 1997; Roberts et al.,
1998a). However, the problem using VSV is the strong induction of an
immune response against the VSV G protein, which prevents reinfection
and also re-boosting of the vaccination (Rose et al., 2000).
Influenza A viruses have been also used to insert epitopes and genes
into the viral genome. Chimeric hemagglutinins were engineered and
studied as well as the integration of HIV-I epitopes into one of the influenza
virus glycoproteins (Li et al., 1992, 1993; Muster et al., 1994, 1995).
Garcia-Sastre et al. studied the use of an internal ribosomal entry site
(IRES) to insert polypeptides containing amino acid sequences from the
gp41 protein of HIV-1 into segment 6 of influenza A viruses (Garcı´a-Sastre
et al., 1994). The generation of influenza A viruses carrying bicistronic
segments would also allow the insertion of full-length proteins. Segment
6 and 8 were mainly used for such attempts. In 1994, Percy et al.
made a bicistronic segment 6 expressing the bacterial chloramphenicol
acetyltransferase (CAT). A short self-cleaving 2A peptide from a FMDV was
used to ”cleave” the two proteins during translation (Percy et al., 1994).
The downside of this approach was the presence of additional amino acid
residues on the upstream protein corresponding to the 2A peptide, which
may interfere with the protein structure or function. However, a recombinant
virus with GFP inserted upstream or downstream of NA via 2A may be a
useful tool for drug screening (Li et al., 2010).
The proof that the viral promoter is not only functional when at the exterior
of a viral segment opened up a path to use a duplicated promoter internally
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between two ORFs (Flick and Hobom, 1999b; Machado et al., 2003, 2006).
Three different proteins (GFP, VP0c and CAT) were successfully introduced
and expressed from an ORF downstream of NA via duplicated 3’UTR
(Chapter 5; Figure 5.10).
Segment 8 was used for the insertion of GFP or IL-2 using two different
method, first the overlapping Stop-Start cassette from an influenza B virus
and second an artificial caspase-cleavage site (Kittel et al., 2004, 2005).
The different strategies to express foreign genes in influenza A viruses are
introduced in more detail in Chapter 5.
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1.4 Aims
Because of the nature of segment 2 expressing PB1-F2 from an internal
overlapping ORF, the possibilities to study this protein are rather limited.
Introduction of point mutations have to be chosen carefully in order not to
alter the amino acid sequence of the overlapping polymerase subunit.
Several goals were defined at the beginning of the project to investigate
the role of PB1-F2 on viral replication, apoptosis and virulence. To
make PB1-F2 more accessible for genetic modifications, it was planned to
separate the overlapping PB1-F2 ORF from the PB1 ORF:
• Deletion of PB1-F2 by inserting three point mutations (Chapter 3)
• Inserting PB1-F2 as an independent ORF into segment 2 using three
different methods (Chapter 5):
- Insertion of PB1-F2 via an overlapping Stop-Start cassette
- Insertion of PB1-F2 using a duplicated promoter
- Insertion of PB1-F2 using a short self-cleaving 2A peptide (FMDV)
• Insertion of PB1-F2 as an independent ORF into segment 6 and 7
using a duplicated promoter (Chapter 5)
After engineering the plasmids, viruses were rescued, the effectiveness of
the constructs for PB1-F2 expression has been tested and recombinant
viruses were characterised using different experiments. Investigations of the
phenotypic characterisation included comparisons of plaque sizes, growth
characteristics, the ability to induce apoptosis and in vivo replication using
a mouse model.
With the discovery of N40 and the resulting consequences that deletion of
PB1-F2 by mutation of its start codon had on the level of N40, aims of this
project were adjusted:
• Deletion of PB1-F2 by inserting two point mutations (Chapter 3)
• Engineering of N40 and PB1-F2/N40 mutant viruses (Chapter 6)
• in vitro and in vivo characterisation of the recombinant viruses
(Chapter 3 and 6)
The influence of PB1-F2 on viral polymerase activity and the ability to
degrade cellular polymerase II was tested. After the discovery that
the polymerase subunits PB2 and PA participate in the cellular RNAPII
degradation, amino acids that are potentially involved were identified,
mutated and recombinant viruses were tested for their effect (Chapter 4).
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2.1 Cell lines and tissue culture
2.1.1 Cell lines used in this study
Cells that were used in this study are summarised in Table 2.1.
Name Description
293FT Highly transfectable clone derived from human
embryonal kidney cells
A549 Adenocarcinomic human alveolar basal epithelial
cell line
MDCK Madin-Darby Canine Kidney epithelial cell line
RAW/W Mouse leukaemic monocyte macrophage cell line
Macrophage 1 and 2 Fresh human macrophages type 1 and 2
Table 2.1: Cell lines used in this study.
MDCK cells were used for virus propagation, purification, titration,
immunoblotting, measuring virus growth and in protein labelling
experiments. A549 cells were also used for measuring virus growth
and immunoblotting and several other assays to characterise the different
influenza A virus mutants such as primer extension assays. 293FT
cells were used for influenza A virus rescues as well as transfection for
luciferase assays. RAW/W cells were used in a cell viability assay. Human
macrophages were used in a macrophage assay.
2.1.2 Cell maintenance
Cell monolayers were maintained in 75 cm2 (medium) or 175 cm2 (large)
culture flasks (Greiner) in DMEM (Dulbecco’s modified Eagle medium;
Invitrogen) and incubated at 37°C and 5% CO2. DMEM was supplemented
with 10% fetal bovine serum (FBS). Cell monolayers were passaged
regularly using Trypsin/EDTA. Therefore cells were washed with PBS before
adding 3 ml (medium flask) or 5 ml (large flask) of Trypsin/EDTA. Cells
were incubated for up to 20 min to detach and Trypsin/EDTA solution was
removed from the cells by centrifugation (1000xg, 5min). Pelleted cells were
resuspended in fresh DMEM supplemented with FBS and 1/8 of the cells
was transferred into a new flask.
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2.1.3 Macrophage subset differentiation protocol
The mononuclear cell fraction of freshly drawn blood was used to isolate
CD14+ cells by magnetic cell sorting. Cells were centrifuged at 300xg for 10
min and the supernatant was removed completely. Pellet was resuspended
in 16 µl MACS buffer (PBS / 2% FCS / 2mM EDTA) per 107 total cells and
4 µl anti-CD14 microbeads (Miltenyi Biotec) were added and gently mixed.
After 20 min incubation at 4°C cells were washed with 5 ml MACS buffer
and centrifuged at 300xg for 6 min. Cells were resuspended in 500 µl
cold MACS buffer and applied onto a MACS LS column (Miltenyi Biotec),
which had been rinsed with MACS buffer. Unlabelled cells (flow-through)
were collected by washing the column three times with MACS buffer. After
removal of the column from the magnet, they were placed in a 15 ml falcon
tube. 5 ml MACS buffer were added onto the column and cells were flushed
out using a plunger. CD14+ cells were washed, counted and resuspended
in culture medium IMDM (R&D Systems).
CD14+ cells were cultured in 24-well plates in IMDM containing
penicillin/streptomycin (PPA Laboratories, 50U/ml) and 10%
heat-inactivated FCS. To generate the macrophage subset 1 or 2, cells
were cultured in the presence of either GM-CSF (Peprotech) or M-CSF
(R&D Systems) as seen in Table 2.2.
Macrophage subset Differentiation media
Macrophage 1 IMDM supplemented with FCS and GM-CSF at
final concentration of 50 U/ml
Macrophage 2 IMDM supplemented with FCS and M-CSF at final
concentration of 25 ng/ml
Table 2.2: Macrophage subset and the required media.
At day 2 and day 4, fresh media containing the appropriate cytokine
(GM-CSF or M-CSF) was added to the cells. Cells were ready for further
experiments at day 6, when they were infected with influenza A virus
(A/Udorn/72).
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2.2 Virus infections
2.2.1 Viruses used in this study
Recombinant viruses used in this study are listed in Tables 2.3 to 2.6.
Name Description
rUdo WT recombinant wild-type IAV (A/Udorn/1972)
rWSN WT recombinant wild-type IAV (A/WSN/33)
Table 2.3: Recombinant wild type viruses (A/Udorn/72 and A/WSN/33) used
in this study. Plasmids to generate the viruses were provided by D. Jackson
(University of St Andrews, UK)
Name Description
rUdo ∆AUG recombinant Udorn virus deficient in its PB1-F2
expression; point mutations in segment 2 at position
120, 153 and 291
rWSN ∆AUG recombinant WSN virus deficient in its PB1-F2
expression; point mutations in segment 2 at position
120, 153 and 291; described previously by Zamarin
et al. (2006)
rWSN F2-11 recombinant WSN virus deficient in its PB1-F2
expression; point mutations at position 153 and 291;
the N-terminal 11 aa of PB1-F2 are expressed
rWSN ∆N40 recombinant WSN virus deficient in its N40
expression; point mutations in segment 2 at position
142; PB1 residue 40 Met → Leu; described
previously by Wise et al. (2009)
rWSN ∆F2/∆N40 recombinant WSN virus deficient in PB1-F2 and N40;
point mutations in segment 2 at position 144 and 291;
PB1 residue 40 Met→ Ile; two stop codons to delete
PB1-F2 at aa 9 and 58
Table 2.4: Recombinant WSN and Udorn viruses carrying mutations in
segment 2: The different viruses are deficient in the expression of PB1-F2, N40 or
deficient in both ORF.
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Name Description
rWSN ∆AUG-StSt-F2 recombinant WSN virus carrying three point
mutations to delete PB1-F2; expression of
PB1-F2 from an individual ORF from segment 2
via an overlapping Stop-Start codon
rWSN ∆AUG-2A-F2 recombinant WSN virus carrying three point
mutations to delete PB1-F2; expression of
PB1-F2 from an individual ORF from segment 2
using the self-cleaving 2A peptide (FMDV)
rWSN ∆AUG/NA-F2 recombinant WSN virus carrying three point
mutations to delete PB1-F2; expression of
PB1-F2 from an individual ORF from segment 6
using a duplicated promoter
rWSN F2-11/NA-F2 recombinant WSN virus carrying two point
mutations to delete PB1-F2; expression of
PB1-F2 from an individual ORF from segment 6
using a duplicated promoter
Table 2.5: Recombinant influenza A viruses (A/WSN/33) carrying an individual
PB1-F2 ORF in segment 2 or segment 6.
Name Description
rWSN PB2504 recombinant WSN virus deficient; point mutation in
segment 1; PB2 residue 504 Val→ Ile
rWSN PA550 recombinant WSN virus deficient; point mutation in
segment 3; PA residue 550 Leu→ Ile
rWSN PB2504 /PA550 recombinant WSN virus deficient; point mutations
in segment 1 and 3; PB2 residue 504 Val→ Ile and
PA residue 550 Leu→ Ile
Table 2.6: Recombinant WSN viruses carrying mutations in segment 1 and 3.
2.2.2 Virus rescues
Influenza A virus rescues were done using the 12-plasmid rescue system
described by Neumann et al. (1999). Eight plasmids expressing the viral
RNA segments (pHH-PB2, pHH-PB1, pHH-PA, pHH-HA, pHH-NP, pHH-NA,
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pHH-M, pHH-NS: 0.5 µg each) together with four plasmids expressing viral
proteins for the three polymerase subunits (pcDNA-PB2 1 µg; pcDNAPB1
1 µg; pcDNA-PA 0.2 µg) and the nucleoprotein (pcDNA-NP 1 µg) were
transfected into 293FT cells using FuGENE 6 transfection reagent (Roche).
Plasmids were mixed with 3 µl FuGENE/1 µg DNA and 130 µl DMEM
containing 3% FBS.
After an incubation time of 20 min this mixture was added dropwise to
the confluent 293FT cell monolayer. Cells were incubated at 37°C and 5%
CO2. After 20 h the transfected 293FT cells were mixed with MDCK cells
and transferred to a 25cm2 flask for incubation in 5 ml DMEM supplemented
with 10% FBS. To allow propagation of the virus the supernatant was
removed after 6 to 8 h and 5 ml serum-free DMEM containing 2.5 µg/ml
N-acetyl trypsin (Sigma) was added to the cells. Recombinant viruses
were harvested before cytopathic effect was 100%. Supernatants were
centrifuged at∼1000xg for 5 minutes and aliquoted into cryovials for storage
of the virus rescue stock at -70°C .
2.2.3 Preparation of IAV elite stocks by plaque
purification
A series of 10-fold dilutions of influenza A virus rescue stocks were
prepared. 6-well plates with 80% confluent MDCK cells were washed with
PBS before 200 µl of the virus dilutions were added to the cells. Cells were
incubated for absorption of the virus at 37°C . After 1 hour the inoculum
was removed and 2 ml of the overlay media (Table 2.7) was added to each
well. After the overlay had set, plates were inverted and incubated for 3
days at 37°C and 5% CO2. At day three plaques were clearly visible. The
agar overlaying the virus plaque was removed using a sterile pipette tip and
the plug was expelled into serum-free DMEM. Serum-free DMEM including
N-acetylated trypsin containing the plaque purified virus was added to
MDCK cells in a 25 cm2 flask for growing up elite stocks. Supernatants
were harvested after 2 or 3 days, when cytopathic effect was 70-80%. Cell
debris was removed by centrifugation (1000xg; 5 min) and virus solution
was aliquoted into cryovials for storage at -70°C .
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Overlay media 2 x DMEM
12.5 ml 2 x DMEM 13.4 g DMEM
12.5 ml 2% Agarose 3.7 g NaHCO3
2 µg/ml N-acetyl trypsin 10 mM HEPES pH 7.4
→ filter sterilization 485 ml H2O
Table 2.7: Chemical composition of the influenza A virus plaque assay
overlay media.
2.2.4 Preparation of virus working stocks
To prepare working stocks of influenza A viruses, 80% confluent monolayers
of MDCK cells (75cm2 flask) were washed with PBS to remove traces of
fetal bovine serum. Cells were inoculated in serum-free DMEM at an MOI
of 0.001 plaque-forming units (pfu). Cells were incubated at 37°C and 5%
CO2 and supernatants were harvested when cytopathic effect was 70-80%.
Cellular debris was removed by centrifugation (1000xg, 5min) and virus
working stocks were aliquoted into cryovials and stored at -70°C . Virus
titres were determined as described below (subsection 2.2.6).
2.2.5 Virus infections
Influenza A virus infections at any desired MOI were carried out in
serum-free DMEM. Prior to any infection, cells were washed with PBS to
remove traces of serum. 200 µl (per 6-well plate) of the virus dilution was
added to the confluent cell monolayer. Cells were incubated for 1 hour at
37°C / 5% CO2 with gentle rocking every 15 min. Inoculum was removed
and serum-free DMEM was added to the cells, with or without N-acetyl
trypsin and incubated at 37°C / 5% CO2 for the required time.
2.2.6 Virus titration
Influenza A virus titration was carried out on MDCK cells in 6-well plates.
DMEM was removed from the confluent monolayer and cells were washed
with PBS to remove traces of serum. Virus stocks were serially diluted
10-fold in serum-free DMEM and 200 µl of virus dilution was added to each
well before incubation at 37°C / 5% CO2. Plates were gently rocked every 15
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min. During this time, the overlay media was prepared, using Avicel instead
of Agarose. 2x DMEM (table 2.7) was mixed with 2.4% Avicel (2.4g Avicel /
100 ml H2O; autoclaved) at a ratio of 1:1 and 2 µg/ml N-acetyl trypsin was
added. After 1 hour inoculum was removed and 2 ml overlay media were
added to the cells following further incubation (∼ 3 days). Cells were fixed by
adding PBS / 4% formaldehyde to the cells. Fixing was left for several hours.
Overlay media was removed and cells were stained with crystal violet (0.1%
crystal violet, 3.6% formaldehyde, 1% methanol, 20% ethanol in H2O) or by
immunostaining as described below (Section 2.2.7). Plaques were counted
and virus titres were calculated as pfu/ml, taking into account the original
dilutions of the viruses.
number of plaques x dilution x 5 (200 µl virus added per dish) = pfu/ml
2.2.7 Immunostaining
Fixed cells were washed with PBS and 500 µl PBN (PBS, 1% BSA, 0.02%
sodium azide) was added to each well. Cells were placed on rocker for
1 hour at room temperature. PBN was removed and replaced with 500 µl
primary antibody (goat antisera raised against A/Udorn/72). After incubation
for 1 hour cells were washed with PBN and 500 µl secondary anti-goat
IgG alkaline phosphatase (AP)-conjugated antibody was added for 1 hour.
Cells were washed with PBN and incubated with 500 µl/well of alkaline
phosphatase substrate (as per manufacturer’s instructions; Sigma-Aldrich;
FAST BCIP/NBT) until plaques were visible. To stop the reaction, cells were
rinsed with water and placed to dry.
2.2.8 Virus yield assay
To determine replication of infectious virus over time, confluent MDCK cells
were infected with virus dilutions at an MOI of 3 for a single replication cycle
or at an MOI of 0.001 for a multi replication cycle. Infection was carried out
as described above (Section 2.2.5). Inoculum was left for 1 hour to absorb
and was subsequently replaced by serum-free DMEM (supplemented with
2.5 µg/ml N-acetyl trypsin for a multi replication cycle). Cells were incubated
at 37°C /5% CO2 and supernatants were harvested at specific time points
post infection. Virus titre was determined by plaque assays as described
earlier (Section 2.2.6).
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2.2.9 In vivo virulence assay
6-7 week old female BALB/c mice were inoculated intranasally with 5x103
pfu virus. Each mouse was weigthed and anaesthetised for a few seconds to
allow infection with one of the different virus strains. Eight or ten mice were
infected with the same virus and placed into one chamber. Infection with
PBS was used as a control. Mice were weighted ever day to monitor weight
loss. At day four and day seven, four mice of each group were culled using
CO2. Mice were also culled if weight loss was close to 25%. Lungs were
taken for virus titration. For this, 6-well-plates with confluent MDCK cells
were prepared. Frozen lungs were diced and placed in a pre-chilled plastic
bijoux with 1.5 ml cold serum-free DMEM. Lung tissue was homogenised
using an OMNI TH homogeniser: 5 bursts at 20,000 rpm for 3 seconds and
a final burst for 6 seconds were delivered. Supernatants were transferred
into a fresh cryovial and centrifuged at 3000 rpm at 4°C for 5 min. Clear
supernatants were transferred into a new cryovial and stored on ice until
titration. A series of 10-fold dilutions of each lung preparation was made.
6-well plates with confluent MDCK cells were washed twice with PBS before
400 µl of the virus dilutions were added to the cells. Cells were incubated
for absorbtion of the virus at 37°C and gently rocked every 10 min. After 1
hour the incoculum was removed and 2 ml of the overlay media (12.5 ml 2x
DMEM, 12.5 ml 1.2% Avicel, 2 µg/ml N-acetyl trypsin) was added to each
well. Plates were incubated for 3 days at 37°C and 5% CO2. At day 3, 2 ml
of 4% formaldehyde was added to each well for fixing. Overlay was removed
and cells were stained with crystal violet until plaques were clearly visible.
2.3 Plasmid DNAs
2.3.1 Plasmids used in this study
Plasmids to rescue A/WSN/33 and A/Udorn/72 were kindly provided by
David Jackson (University of St Andrews, UK). These plasmids were also
used as a template for mutagenesis of segment 1, 2, 3 and 6. Several other
plasmids were engineered during this study to allow performance of different
assays such as luciferase assay or transfections of 293FT cells.
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pcDNA 3.1(+) parental vector for protein expression
used in luciferase assays, transfections
and rescues; Invitrogen
pGEMT Easy / pGEMT linear vector with T-overhangs for PCR
cloning; Promega
pJC3 parental vector: pcDNA 3.1(+);
GFP-2A-mCherry under CMV promoter
pcDNA-PB2, pcDNA-PB1, plasmids expressing the three
pcDNA-PA, pcDNA-NP polymerase subunits (PB2, PB1, PA)
and the nucleoprotein (NP) of either
A/WSN/33 or A/Udorn/72
pHH21 parental vector for rescue plasmids
coding for the viral RNA (Neumann
et al., 1999)
pHH-PB2, pHH-PB1, pHH-PA, plasmids coding for the viral RNA
pHH-HA, pHH-NP, pHH-NA, segments 1-8 of either A/WSN/33 or
pHH-M, pHH-NS A/Udorn/72
pHH-∆ATG parental plasmid: pHH-PB1 WSN or
Udorn; PB1-F2 deleted by insertion of
three point mutations (T120C; C153G;
G291A)
pHH-F2-11 parental plasmid pHH-∆ATG WSN;
PB1-F2 deleted by two point mutations
(C153G; G291A)
pHH-∆ATG-StSt-F2 parental plasmid: pHH-∆ATG WSN;
PB1 gene connected to PB1-F2 by
an overlapping Stop-Start sequence
(TAATG)
pHH-∆ATG-3’UTR-F2 parental plasmid: pHH-∆ATG WSN;
PB1 gene connected to PB1-F2 by via
a duplicated promoter (3’UTR)
pHH-∆ATG-2A-F2 parental plasmid: pHH-∆ATG WSN;
PB1 gene connected to PB1-F2 by via
a FMDV self-cleavage 2A peptide
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pHH-NA-F2 original plasmid pHH-NA WSN; neuraminidase
gene is connected to PB1-F2 via a duplicated
promoter (3’UTR)
pHH-∆N40 original plasmid: pHH-PB1 WSN; Met40 → Leu40 to
delete N40
pHH-∆F2/∆N40 original plasmid: pHH-PB1 WSN; Met40 → Ile40 to
delete N40; two stop codons introduced at aa 9 and
58 to disrupt PB1-F2 ORF
pcDNA-∆ATG pcDNA3.1(+) vector with PB1-F2 deletion in PB1
(three point mutations as in pHH-∆ATG)
pcDNA-F2-11 pcDNA3.1(+) vector with WSN PB1-F2 deletion in
PB1 (two point mutations as in pHH-F2-11)
pcDNA-∆N40 pcDNA3.1(+) vector expressing WSN PB1 carrying
the mutation Met40 → Leu40 to delete N40
pcDNA-∆F2/∆N40 pcDNA3.1(+) vector expressing WSN PB1 with N40
and PB1-F2 deletion
pHH-Renilla pHH-backbone carrying renilla in a negative
orientation embedded in NP-UTRs
pCMV-FF plasmid carrying the firefly gene under the control
of a CMV promoter
pHH-PB2 V504I PB2 WSN with an aa change Val504 → Ile504
pHH-PA L550I PA WSN with an aa change Leu504 → Ile504
Table 2.8: List of plasmids used in this study.
2.3.2 Amplification of plasmid DNA
E. coli JM109 cells were grown in 5ml Luria-Bertani (LB) medium (10g/l
bacto-tryptone, 5g/l yeast extract, 10mM NaCl, pH 7.5), or plated on solid
LB medium supplemented with 1.5% (w/v) agar. Media was supplemented
with ampicillin (100 µg/ml) or kanamycin (50 µg/ml) for selection.
2.3.3 Preparation and transformation of competent E.coli
Competent E.coli JM109 were obtained using the ”Z-competent E.coli
Tranformation kit” (Zymo research) according to the manufacturer’s protocol.
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To transform competent E. coli JM109, 50-100 ng DNA was added to 100
µl competent cells and spread onto LB-agar plates containing ampicillin or
kanamycin. Plates were inverted and incubated at 37°C for 12-16 hours.
Single colonies were used to set up mini-cultures.
2.3.4 Preparation of plasmid DNA
For small-scale preparations of plasmid DNA, 10 ml of LB-media
supplemented with ampicilin (100 µg/ml) was inoculated with a single
E.coli colony and incubated overnight at 37°C in a shaking incubator.
DNA plasmid preparation was done either using the QIACube or manually
using the QIAprep Spin Miniprep Kit (QIAGEN Ltd., UK) according to the
manufacturer’s protocol. DNA was eluted in 50 µl H2O. For larger scale
DNA preparations 50 ml bacterial cultures were grown overnight at 37°C in
a shaking incubator. DNA was extracted using the QIAGEN Plasmid Maxi
Kit according to the manufacturer’s instructions.
2.3.5 Determination of DNA concentration
Concentration of dsDNA was determined by measurement of Abs260 using
a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Purity of the
DNA sample was estimated by calculating the Abs260/Abs280 ratio. Ratio
values greater then 1.8 were considered as acceptable.
2.4 Manipulation of plasmid DNA
2.4.1 Synthetic oligonucleotides
All synthetic oligonucleotides that were used throughout this study are listed
in the Tables 2.9 to 2.14.
name sequence 5’→ 3’ description
sv01 GAT CCT CCA TAC AGC CAC GGA ACA
GGA ACA
T120C PB1 Udo For
sv02 GTT CCT GTT CCG TGG CTG TAT GGA
GGA TC
T120C PB1 Udo Rev
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sv03 TGG ACA CAG TGA ACA GAA CAC ATC
AAT ATT
C153G PB1 Udo For
sv86 GGA ACA GGA TAC ACC ATG GAC ACA
GTG AAC AGA ACA C
C153G PB1 Udo Rev
sv05 ACA AAC AGA CTG TGT CCT AGA AGC
AAT GGC
G291A PB1 Udo For
sv06 GCC ATT GCT TCT AGG ACA CAG TCT
GTT TGT
G291A PB1 Udo Rev
sv09 ACC CTC CTT ACA GCC ACG GGA CAG
GAA CAG
T120C PB1 WSN For
sv10 CTG TTC CTG TCC CGT GGC TGT AAG
GAG GGT
T120C PB1 WSN Rev
sv11 GAT ACA CCA TGG ATA CTG TGA ACA
GGA CAC
C153G PB1 WSN For
sv12 GTG TCC TGT TCA CAG TAT CCA TGG
TGT ATC
C153G PB1 WSN Rev
sv13 CAA ACA GAT TGT GTA TTA GAA GCA
ATG GCC
G291A PB1 WSN For
sv14 GGC CAT TGC TTC TAA TAC ACA ATC
TGT TTG
G291A PB1 WSN Rev
Table 2.9: List of synthetic oligonucleotides used to delete PB1-F2 in
A/Udorn/72 and A/WSN/33.
name sequence 5’→ 3’ description
sv07 CAG ACG GCA AAA ATC TAG AAT TTA
GCT TGT
PB1 XbaI site For
sv08 ACA AGC TAA ATT CTA GAT TTT TGC
CGT CTG
PB1 XbaI site Rev
sv26 CTT GCG GGA GAC GTC GAG TCC
AAC CCC GGG CCC ATG GGA CAG
GAA CAG GAT AC
2A-PB1-F2 For 1 WSN
sv22 GTG ATG CGA TCT AGA CAG CTG
TTG AAT TTT GAC CTT CTT AAG CTT
GCG GGA GAC GTC GAG T
2A-PB1-F2 For 2
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sv27 GCG CTC ATC TAG AGT AGA AAC
AAG GCA TTT TTT CAT GAA GGA
CAA GCT AAA TTC ACT ATT TTT
GCC GT
PB1-F2 Rev 1 WSN
sv28 CAC TAT TTT TGC CGT CTG AGC
TCT TCA ATG GTG GAA CAG ATC
TTC AGC TTG TCC ACT CGT GTT
TGC
PB1-F2 Rev 2 WSN
sv32 CAG ACG GCA AAA ATA ATG CAT
TTA GCT TGT
PB1 Nsi I For
sv33 ACA AGC TAA ATG CAT TAT TTT
TGC CGT CTG
PB1 Nsi I Rev
sv34 ATC CTC CAT ATG CAT CAG GAA
CAG GAT AC
PB1-F2 Nsi I For
sv40 GGC TGA CAT GCA TGT AGA AAC
AAG GCA TTT TTT CAT GAA GGA
CAA GCT AAA TTC ACT ATT TTT
GCC GT
PB1-F2 Nsi I Rev 1 WSN
sv38 AGA CGG CAA AAA TAA TGG GAC
AGG AAC AG
TAATG For WSN
sv39 CTG TTC CTG TCC CAT TAT TTT
TGC CGT CT
TAATG Rev WSN
sv65 CGG CAA AAA TAG TGA ATC TAG
ATT GTC C
XbaI 3’UTR For WSN
sv66 GGA CAA TCT AGA TTC ACT ATT
TTT GCC G
XbaI 3’UTR Rev WSN
sv103 GAT GTC AGT CTC GAG ATG GGA
CAG GAA CAG GAT AC
XhoI-PB1-F2 For
sv104 ACT GAC ATC GCT AGC TCA GCT
TGT CCA CTC GTG
NheI-PB1-F2 Rev
sv105 GAT GTC AGT CTC GAG ATG GTG
AGC AAG GGC GAG GA
XhoI-mCherry For
sv106 ACT GAC ATC GCT AGC TTA TTT
GTA CAA TTC ATC CAT GCC GC
NheI-mCherry Rev
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sv117 CGT CTC AGG GAG CGA AAG
CAG GAG TTT AAA TG
BsmBI-NA For
sv118 CTC GAG TTA AAC TCC TGC
TTT CG CTG AAT TCC TAC
TTG TCA ATG GTG AAC GG
NA-XhoI Rev
sv119 TGG TGA ACG GCA ACT CAG
CAC CGT CTG GCC AGC TAG
CCT CGA GTT AAA CTC CTG
CTT TCG CT
adds 3’UTR to NA Rev 1
sv120 GTC TCC TAT TAG TAG AAA
CAA GGA GTT TTT TGA ACA
AAC TAC TTG TCA ATG GTG
AAC GGC AAC TCA G
adds 3’UTR to NA Rev 2
sv121 GGT TCC AAA GGT GAC GTT
TTT GTC
removes BsmBI from NA For
sv122 GAC AAA AAC GTC ACC TTT
GGA ACC
removes BsmBI from NA Rev
sv115 CGT CTC AGG GAG CAA AAG
CAG GTA GAT ATT G
BsmBI-M For
sv100 CTC GAG CTT TCA ATA TCT
ACC TGC TTT TGC TGA ATT
CTT ACT CCA GCT CTA TGT
TGA C
adds XhoI to M Rev
sv101 AGC TCT ATG TTG ACA AAA
TGA CCA TCG TCA ACA TCG
CTA GCC TCG AGC TTT CAA
TAT CTA CC
adds 3’UTR to M Rev
sv102 TTA TTG GAG ACG AGT AGA
AAC AAG GTA GTT TTT TAC
TCC AGC TCT ATG TTG ACA
AAA TGA CC
adds Mend and 5’UTR Rev
sv116 CGT CTC CTA TTA GTA GAA
ACA AGG TAG
BsmBI-M Rev
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sv129 ACC CTC CTT ACA GCC ATG GGA
CAG GAA CAG
C120T PB1 WSN For
sv130 CTG TTC CTG TCC CAT GGC TGT AAG
GAG GGT
C120T PB1 WSN Rev
Table 2.10: List of synthetic oligonucleotides used to insert PB1-F2 into
segment 2 (A/WSN/33) or segment 6 (A/WSN/33).
name sequence 5’→ 3’ description
sv19 GAG TAC TGG TCG ACC TCC GAA
GTT G
to sequence pHH For 1
sv78 GAC ACT TTC GGA CAT CTG G to sequence pHH For 2
sv29 GTA TAT CTT TCG CTC CGA GTC
GGC
to sequence pHH Rev 1
sv79 CAG GTG TCC GTG TCC GTG TC to sequence pHH Rev 2
sv20 CAG TCT GGA CTT CCA GTT GG PB1 internal Udorn For
sv21 GAT TGC CAG TTG GAG GCA ATG PB1 internal WSN For
sv30 GTC TTC CCT GAT AGT CCT CAT
CC
PB1 internal Udorn Rev
sv31 CAT AAA CGC CCC TGG TAA TCC
TC
PB1 internal WSN Rev
sv52 GGA TGT CAA TCC GAC TTT AC RT-PCR PB1 WSN For
sv45 GCA TCT TTG GTC ATT GTG TTC RT-PCR PB1 WSN Rev
Table 2.11: List of synthetic oligonucleotides used for sequencing or
RT-PCRs.
name sequence 5’→ 3’ description
sv172 GAAC AGG ATA CAC CTT
GGA TAC TGT CAA CAG
Met40 → Leu40 PB1 WSN For
sv173 CTG TTG ACA GTA TCC AAG
GTG TAT CCT GTT C
Met40 → Leu40 PB1 WSN Rev
sv174 GAA CAG GAT ACA CCA TAG Met40 → Ile40 PB1;
ATA CTG TCA ACA G PB1-F2 aa 9→ Stop WSN For
sv175 CTG TTG ACA GTA TCT ATG Met40 → Ile40 PB1;
GTG TAT CCT GTT C PB1-F2 aa 9→ Stop WSN Rev
Table 2.12: List of synthetic oligonucleotides used to delete N40.
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name sequence 5’→ 3’ description
sv87 CTA GTG CAA AGC TTA TGG ATG
TCA ATC CGA CTT TAC
Hind III-PB1 For WSN
sv88 GCA TCA CGA AGC TTC TAT TTT
TGC CGT CTG AG CTC TTC
Hind III-PB1 Rev WSN
sv89 CTA GTG CAA AGC TTA TGG
GAC AGG AAA GGA TAC
Hind III-PB1-F2 For WSN
sv90 CTA GTG CAA AGC TTT CAG CTT
GTC CAC TCG TG
Hind III-PB1-F2 Rev WSN
sv91 CTA GTG CAG ATA TCA TGG ATC
CAA ACA CTG TGT C
EcoRV-NS1 For
sv92 CTA GTG CAG ATA TCT CAA ACT
TCT GAC CTA ATT G
EcoRV-NS1 Rev
sv93 ATG GGA GGA GAC GAG CAA to insert Renilla-NP(UTRs)
AAG CAG GGT AGA TAA TCA into pHH WSN For
CTC ACA GAG TGA CAT CGA AAT
CAT GAC TTC GAA AGT TTA
sv94 TTA TTG GAG ACG AGT AGA AAC to insert Renilla-NP(UTRs)
AAG GGT ATT TTT CTT TAT TGT into pHH WSN Rev
TCA TTT TTG AGA ACT CGC T
Table 2.13: List of synthetic oligonucleotides used to prepare plasmids for
the luciferase assay and transfections of 293FT cells.
name sequence 5’→ 3’ description
sv181 CGT TTT TTG AGA ATT AGG
GAC CAA CGT GGG
PB2 Val504 → Ile504 WSN For
sv182 CCC ACG TTG GTC CCT AAT
TCT CAA AAA ACG
PB2 Val504 → Ile504 WSN Rev
sv183 GGA GAT ATG CTT ATA AGA
AGT GCC
PA Leu550 → Ile550 WSN For
sv184 GGC ACT TCT TAT AAG CAT
ATC TCC
PA Leu550 → Ile550 WSN Rev
Table 2.14: List of synthetic oligonucleotides used for site-directed
mutagenesis in order to study cellular polymerase II degradation.
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2.4.2 Amplification of DNA by PCR
PCR was done using the proofreading polymerase KOD hot start
polymerase or the GoTaq DNA polymerase. PCR reactions were set
up according to the manufacturer’s instructions in 0.5 ml thin-walled tubes
using a thermo cycler.
Standard reaction using KOD hot start polymerase (Merck) (50 µl):
10x Buffer 5 µl
dNTPs (10mM each) 5 µl
25 mM Mg2SO4 2.5 µl
template (10-50 ng) X µl
forward oligo (20 µM) 1.25 µl
reverse oligo (20 µM) 1.25 µl
KOD polymerase (1U/µl) 1 µl
dH2O (fill up to 50 µl) Y µl
PCR programme for KOD hot start polymerase:
Polymerase activation 95°C 2 min
Denaturation 95°C 30 sec
Annealing adjust to primers 30 sec 18 - 40 cycles
Elongation 70°C 30 sec/kb
Final extension 70°C 10 min
Soak 10°C ∞
Standard reaction using GoTaq DNA polymerase (Promega) (50 µl):
5x green or colorless Buffer 10 µl
dNTPs (10mM each) 1 µl
template (10-50 ng) X µl
forward oligo (20 µM) 1.25 µl
reverse oligo (20 µM) 1.25 µl
GoTaq polymerase (5U/µl) 0.25 µl
dH2O (fill up to 50 µl) Y µl
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PCR programme for GoTaq DNA polymerase:
Polymerase activation 95°C 2 min
Denaturation 95°C 30 sec
Annealing adjust to primers 30 sec 25 - 35 cycles
Elongation 72°C 1 min/kb
Final extension 72°C 10 min
Soak 10°C ∞
2.4.3 QuikChange site-directed mutagenesis
To introduce point mutations into influenza viral segments, QuikChange
site-directed mutagenesis was used. Therefore, two complementary
oligonucleotide primers carrying the desired mutation were used in a PCR
reaction. KOD hot start polymerase (Merck) was used as DNA polymerase.
Before transformation of the plasmids, the mix was treated with DpnI to
digest parental methylated plasmids. Newly synthesised plasmid are not
methylated and therefore not targeted by DpnI. DNA was transformed into
E.coli JM109 cells. After amplification and preparation of plasmid DNA (as
described in Section 2.3.4), the nucleotide sequences were determined to
ensure the insertion of the point mutation.
Standard QuikChange reaction using KOD hot start polymerase (50 µl):
10x Buffer 5 µl
dNTPs (10mM each) 5 µl
25 mM Mg2SO4 2.5 µl
template (10-50 ng) X µl
forward oligo (20 µM) 1.25 µl
reverse oligo (20 µM) 1.25 µl
KOD polymerase (1U/µl) 1 µl
dH2O (fill up to 50 µl) Y µl
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PCR programme for QuikChange site-directed mutagenesis:
Polymerase activation 95°C 2 min
Denaturation 95°C 30 sec
Annealing adjust to primer 1 min 18 - 20 cycles
Elongation 70°C 30 sec/kb
Final extension 70°C 10 min
Soak 10°C ∞
2.4.4 A-overhang PCR and T/A cloning
For sequencing or cloning purposes, DNA fragments had to be cloned into
pGEM-T or pGEM-T Easy vector (Promega). To add a single adenine to a
blunt end PCR fragment, reaction was set up as followed:
10x Taq DNA polymerase Buffer 5 µl
dATP (5mM) 5 µl
vector DNA (PCR) 50 µl
Taq DNA polymerase (0.5U/µl) 1 µl
Incubate for 15 min at 72°C
Subsequently 1-2 µl of the DNA fragments were cloned into pGEM-T
or pGEM-T Easy vectors according to the manufacturer’s instructions.
2.4.5 Restriction endonuclease digestion of DNA
Restriction digests were done in 20 µl reactions according to the protocols
of the respective enzymes. Enzymes were used from different companies,
such as Fermentas, New England Biolabs and Promega. A standard
reaction contained 2 µl 10x reaction buffer, 1 µl BSA, 1 unit enzyme /µg
DNA. dH2O was added to obtain a final volume of 20 µl. The reaction
was incubated at room temperature, 30°C , 37°C or 55°C according to the
manufacturer’s protocol.
2.4.6 Agarose Gel electrophoresis
Separation of DNA fragments was carried out in a horizontal electrophoresis
containment using 1% (w/v) agarose - TAE solutions with 4 µg/ml ethidium
bromide. Gels were covered with 1x TAE buffer and samples containing
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loading dye were added into the wells before applying 100V for 30-60 min.
Gels were analysed using an ultra-violet transilluminator.
2.4.7 Extraction of DNA from agarose gels
PCR products or endonuclease digestion reactions were separated on an
agarose gel as described above (Section 2.4.6). DNA fragments of interest
were excised from the gel using a scalpel. Extraction of DNA was carried
out using the SV Gel and PCR purification kit (Promega) by following the
manufacturer’s instructions. Products were diluted in water.
2.4.8 Dephosphorylation of DNA and DNA ligation
Digested DNA fragments with sticky or blunt ends were combined using
the Rapid DNA Ligation Kit (Roche). To prevent self-ligation of linearised
vectors with overlapping sticky ends, DNA was dephosphorylated before
DNA ligation using the Rapid DNA Dephos & Ligation Kit (Roche) according
to the manufacturer’s protocol. Ligated DNA was transformed into E.coli
JM109 competent cells and plated on LB-Agar plates containing ampicillin
or kanamycin.
Dephosphorylation (20 µl):
10x rAPid Alkaline Phosphatase Buffer 2 µl
rAPid Alkaline Phosphatase (1U/µl) 1 µl
vector DNA (up to 1 µg) X µl
H2O (fill up to 20 µl) Y µl
Incubation for 10 - 30 min at 37°C and inactivation for 2 min at 75°C .
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DNA ligation (20 µl):
5x DNA Dilution Buffer 2 µl
vector DNA (50 ng) X µl
insert DNA (150 ng) Y µl
H2O fill up to 10 µl
Mix thoroughly
Add:
2x T4 DNA Ligation Buffer 10 µl
T4 DNA Ligase (5U/µl) 1 µl
Mix thoroughly
Incubate for 5 min at room temperature
2.5 Manipulation of RNA
2.5.1 Total cellular RNA extraction
To obtain viral RNA, confluent MDCK or A549 cells were infected with
different virus strains at an MOI of 1 or 3 and incubated o/n. Viral RNA was
extracted from infected cells using the RNeasy Mini Kit (Qiagen) following
the manufacturer’s instructions.
2.5.2 Determination of RNA concentration
Concentration of RNA was determined by measurement of Abs260 using a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Purity of the
RNA sample was estimated by calculating the Abs260/Abs280 ratio. Ratio
values ∼ 2.0 were considered as acceptable.
2.5.3 RNA reverse transcription
Generation of complementary DNA (cDNA) and further amplification was
done in a two-step-reaction using the Moloney Murine Leukemia Virus
(M-MLV) Reverse Transcriptase (Promega) for the cDNA synthesis and the
GoTaq DNA polymerase (Promega) for further amplification.
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1. cDNA synthesis (50 µl):
RNA 3 µl
forward oligo (20 µM)) 1 µl
H2O 11 µl
Incubate 5 min at 72°C and 5 min on ice
Add 35 µl RT-PCR mix:
dNTPs (10mM each) 1 µl
5x M-MLV buffer 10 µl
M-MLV (reverse transcriptase) (200U/µl) 1 µl
H2O 23 µl
Incubate 90 min at 42°C
2. PCR (50 µl):
cDNA 5 µl
forward oligo (20 µM)) 1 µl
reverse oligo (20 µM) 1 µl
H2O 3 µl
5xGoTaq Buffer 10 µl
dNTPs (10mM each) 1 µl
GoTaq polymerase (5U/µl) 0.25 µl
H2O 28.75 µl
PCR programme for GoTaq DNA polymerase as described in Section 2.4.2.
2.5.4 Primer extension assay
For primer extension analysis, primers were labelled using [γ- 32P]ATP. All
primers are listed in Table 2.15. Reactions were set up as followed:
Primer labelling (49 µl):
primer (10 mM) 0.5 µl
10x T4 PNK buffer 5 µl
[γ-32P]ATP 1 µl
H2O 41.5 µl
Incubate 5 min at 70°C
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Add:
T4 PNK (10 U/µl) 1 µl
Label for 30 min at 37°C
Denature for 20 min at 65°C
cool on ice
name sequence 5’→ 3’ description
PB2-2198 TGCTAATTGGGCAAGGAGAC vRNA segment 1
182-PB2 GCCATCATCCATTTCATCCT mRNA/cRNA segment 1
NA-1280 TGGACTAGTGGGAGCATCAT vRNA segment 6
160-NA TCCAGTATGGTTTTGATTTCCG mRNA/cRNA segment 6
NS-734 TGATTGAAGAAGTGAGACACAG vRNA segment 8
226-NS CGCTCCACTATTTGCTTTCC mRNA/cRNA segment 8
5SrRNA TCCCAGGCGGTCTCCCATCC 5SrRNA
Table 2.15: List of synthetic oligonucleotides used for Reverse transcription
in Primer extension analysis. Sequences taken from the dissertation by Philip
Kerry.
To label a DNA ladder, a plasmid was digested with multicutter enzyme
and DNA fragments were cleaned using the SV Gel and PCR purification
kit (Promega). 5 µl of this digested DNA mix was used for labelling
as described above. Labelled primers and DNA ladder were purified
using microspin column G-25 (Fisher/GEHealthcare) as described on
manufacturer’s instructions. For primer extension analysis, 2.5 µg RNA were
mixed with labelled primers in a final volume of 5 µl. After incubation at
90°C for 5 min, RNA-primer mix was cooled on ice before the transcription
reaction mix was added (as described below).
Add 5 µl of 2x transcription reaction mix:
dNTPs (10mM) 1 µl
5x M-MLV buffer 10 µl
M-MLV Reverse Transcriptase (200U/µl) 1 µl
H2O 13 µl
Incubate at 42°C for 2 h
8 µl formamide loading buffer (95% formamide, 20mM EDTA, bromophenol
blue, xylene cyanol-FF) were added to the reaction mix and incubated at
95°C for 3 min. After cooling the mixture on ice and a short centrifugation,
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samples were separated on a 6 %- polyacrylamide gel containing 6M Urea
(Geneflow SequaGel 6). Before detecting signals by autoradiography, gels
were dried using a geldryer at 80 °C for 2.5 h. Quantification was done
by a Fujifilm FLA-5000 fluorescent image analyzer and data were analysed
using the ImageGauge software (Quant mode). Therefore, intensity was
measured within a specified region by enclosing the desired band with a
rectangle. Same size of rectangles were used for all bands and background
intensity was subtracted from the measured values (Figure 2.1). For
primer extension, intensities of vRNA, cRNA, mRNA and 5S rRNA were
determined and expression levels of all viral RNA species were quantified
and normalised against cellular 5S rRNA levels. Calculated ratios of viral
RNA species of rWSN WT were set to 100 %.





Figure 2.1: Quantification using ImageGauge
software:Desired regions were enclosed by
rectangular boxes of the same size. Background
intensity was subtracted from the other intensities
and expression levels of RNA species were
normalised against 5S rRNA.
2.6 Protein analysis
2.6.1 SDS polyacrylamide gel electrophoresis
Cell lysates were prepared by adding 100 - 300 µl loading buffer
(120 mM Tris; 4% SDS; 0.1% bromphenol blue; 20% glycerol, 10%
2-mercaptoethanol). Samples were treated with Benzonase (Novagen)
or sonicated to reduce viscosity. Proteins were separated through
4-12% NuPAGE polyacrylamide gradient gels (Invitrogen), 8%, 12.5%
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or 15% Bis-Tris polyacrylamide gels (as described below) or 16%
Tricine-SDS-PAGE (as described in Scha¨gger (2006)).
Bis-Tris polyacrylamide Gels were prepared as followed:
Resolving Gel
8% 12.5% 15%
30% Acrylamide/BIS 3.2 ml 5 ml 6 ml
RGB 3 ml 3 ml 3 ml
H2O 5.8 ml 4 ml 3 ml
10 % APS 100 µl 100 µl 100 µl
TEMED 10 µl 10 µl 10 µl
Stacking Gel
30% Acrylamide/BIS 1.0 ml
SGB 1.5 ml
H2O 3.5 ml
10 % APS 55 µl
TEMED 10 µl
Resolving Gel Buffer Stacking Gel Buffer
(RGB) / 1l (SGB) / 1l
TRIS 181.5 g 59.0 g
SDS 4.0 g 4.0 g
pH 8.9 6.7
Tricine-SDS-PAGE were prepared as followed:
Resolving Gel 16% Sample Gel 4%
30% Acrylamide/BIS 13.2 ml 1.5 ml
3x Gel buffer 10 ml 3 ml
H2O 6.8 ml 7.5 ml
10 % APS 100 µl 90 µl
TEMED 10 µl 9 µl
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3x Gel buffer 10x Anode buffer 10x Cathode buffer
TRIS 3.0 M 1.0 M 1.0 M
Tricine - - 1.0 M
HCl 1.0 M 0.225 M -
SDS 0.3% - 1.0%
pH 8.45 8.9 ∼ 8.25
MOPS or MES buffers were used for Bis-Tris gels and Gradient gels
depending on the aspired separation of proteins. For Tricine-SDS-PAGE, 1
x Anode buffer was added as the lower electrophoresis buffer, 1 x Cathode
buffer was used as the upper electrophoresis buffer.
2.6.2 Immunoblotting
Polypeptides were separated by electrophoresis as described above
(Section 2.6.1) before transferring to nitrocellulose membrane (Hybond-C
Extra, GE Healthcare) using the Trans-Blot SD semi-dry electrophoretic
transfer cell (BIORAD) according to the manufacturer’s instructions. After
transfer, membranes were incubated for 2 h in PBS supplemented with 5%
(w/v) skimmed milk powder and 0.1% (v/v) Tween 20 (blocking buffer) and
incubated 2 h to overnight with primary antibody, diluted in blocking buffer
according to the manufacturer’s instructions. Membranes were washed with
blocking buffer multiple times before incubation with horseradish peroxidase
(HRP) - conjugated secondary antibody for 1 or 2 h. Membranes were
washed again multiple times with blocking buffer before proteins were
detected using the SuperSignal West Pico Chemiluminescent substrate
(Thermo Scientific) according to the manufacturer’s recommendations. The
membrane was exposed to Kodak X-Omat film.
Accumulation of proteins was measured with the luminescence image
analyzer (Fujifilm LAS 4000) and data were analysed using the ImageGauge
software (Quant mode). Therefore, intensity was measured within a
specified region by enclosing the desired area with a rectangle. Same
size of rectangles were used for all bands and background intensity was
subtracted from the measured values. Intensities for each protein was
determined and normalised against α-tubulin.
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2.6.3 Antibodies
Antibodies were used in immunoblotting and immunostaining. Primary and
secondary antibodies used in this study are listed below in Tab 2.16.
Target protein Manufacturer
PB1-F2 (PR8) polyclonal A kind gift from D. Mitzner
(ViroLogik GmbH, Erlangen,
Germany)
PB1 V19 (aa 50-370 PR8) polyclonal A kind gift from Paul Digard
(University of Cambridge, UK)
PB1 (vC-19) polyclonal Santa Cruz Biotechnology,
Inc.
α-tubulin Sigma
RNA Polymerase II H5 monoclonal Covance
RNA Polymerase II 8WG16 monoclonal Covance
α-Udorn polyclonal A kind gift from D. Jackson
(University of St Andrews, UK)
DsRed polyclonal Clontech Laboratories, Inc.
Anti-Mouse-HRP Sigma
Anti-Rabbit-HRP Cell Signalling
Anti-Sheep-HRP Abcam
Anti-Goat-AP Santa Cruz Biotechnology,
Inc.
Table 2.16: Antibodies used in this study.
2.6.4 Metabolic [35S] methionine radio-isotopic labelling
of proteins
Confluent MDCK cell monolayers (6-well plate) were infected with influenza
A virus at an MOI of 3 as described previously (Section 2.2.5). At the desired
time points, culture media was removed and cells were washed with PBS.
To starve the cells, 1 ml of methionine-free medium was added. After 30
min, medium was replaced with methionine-free medium supplemented with
30 µCi/ml [35S] methionine. Cells were incubated at 37°C for 1 h before
adding 300 µl loading buffer for further analysis via SDS polyacrylamide gel
electrophoresis (Section 2.6.1).
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2.7 Miscellaneous assays
2.7.1 Luciferase assay
The Dual-Luciferase Reporter Assay System (Promega) was used. 24-well
plates with confluent 293FT cells were transfected with different amounts
of plasmids (Table 2.17). Total concentration of plasmids was kept equal
by adding different amounts of pcDNA3.1(+) vector. Transfections were
done using the FuGene 6 reagent (Roche) according to the manufacturer’s
protocol. Measurements were done after an incubation time of 24 h
according to the manufacturer’s instructions. Firefly was used as a
transfection control. Measured values were normalised against wild type
(pcDNA-PB1) firefly values and percentage for each transfection mix was
calculated relative to cells transfected with pcDNA-PB1.
Plasmid amount (ng):
pcDNA-PB2 50
pcDNA-PB1 50
pcDNA-PA 12.5
pcDNA-NP 50
pcDNA-PB1 or different PB1-F2 and N40 mutants 50
pcDNA-PB1-F2 50
pcDNA-N40 50
pHH-Renilla 20
pCMV-FF 20
pcDNA-3.1(+) add up to total
amount of 450
Table 2.17: Plasmids used for luciferase assays: A total amount of 450 ng was
transfected into 293FT cells.
2.7.2 Cell viability assay
WST-1 (Roche) was used as a substrate to measure cell viability. 96-well
plates with confluent MDCK, A549 or RAW/W cells were infected with
different virus strains at an MOI of 30. 100 µl of the infection mix was added
to the cells and left at 37°C for 1 h. Inoculum was removed and serum-free
DMEM was added. After 8 h incubation at 37°C DMEM was replaced with
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colorless DMEM containing 5 µl/well WST-1. Cells were further incubated
until significant color had developed. Measurement was done using an
ELISA microplate reader at 450 nm (690 nm reference wavelength). The
assay was done in triplicates and results were averaged.
2.7.3 Flow cytometry
Cells were washed with PBS without Ca2+ / Mg2+. 250 µl ice cold EDTA
was added to detach the cells. After 20 min incubation on ice, cells were
harvested into FACS tubes and washed with PBS containing Ca2+ / Mg2+.
To assess apoptosis (AxV+ / PI-) and necrosis (AxV+ / PI+) cells were
stained with FITC-conjugated annexin (Roche: AnxA5-FITC) in binding
buffer (HBSS containing 2 mM CaCl2) for 15 min on ice. Propidium iodide
(Sigma, 3 µg/ml) was added 1 min before analysis of the sample. Data
were measured using the FL1 and FL2 detectors on a FACSCalibur flow
cytometer (BD Biosciences). Data were analysed using the CELLQUEST
software and FlowJo software (Tree Star).
2.7.4 Hematoxylin and eosin stain
To prepare the lungs for H&E staining, they were incubated in 70% ethanol
for 1 hour followed by incubation in 100% ethanol for 1 hour (2x). Lungs
were immersed in an ethanol:chloroform mixture (50:50) for 2 hours, before
incubation in chloroform for 1 hour (2x). Lungs were finally placed 3 times
in a low melting point paraffin wax bath for 1 hour each. After sectioning,
sections were deparaffinized in xylene twice for 10 min each. To rehydrate
the sections, they were immersed in a series of graded ethanol to water.
Sections were stained in Harris Haematoxylin (Sigma HHS32) for 10 min
and washed in water, before they were differentiated in 1% acid alcohol for
30 sec. Blueing was done using Scott’s Tap Water Substitute. Sections
were washed for 10 min in water and then stained in 0.5% aqueous Eosin
(Eosin Yellowish) for 2 min. Sections were dehydrated in 95% ethanol and
cleared with xylene. Sections were mounted on glass slides using DPX
(BDH 360294H).
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A NEW WAY TO DELETE PB1-F2
Aims of Chapter 3
PB1-F2 knockout viruses have been reported previously. However, these
were based on a strategy that also influenced the expression level of an
additional protein encoded by segment 2. To overcome this problem, a new
way to delete PB1-F2 was developed. The two versions of PB1-F2 knockout
viruses were engineered using site-directed mutagenesis and the rescued
recombinant viruses were analysed and compared using different in vitro
and in vivo studies.
67
CHAPTER 3 A new way to delete PB1-F2
3.1 Introduction
3.1.1 Previous work on PB1-F2
When PB1-F2 was first discovered in 2001, it was suggested that the
protein may be involved in the induction of apoptosis in immune cells (Chen
et al., 2001). In the following years several other functions were associated
with PB1-F2. Because the protein was not only found in the mitochondria
of infected cells but also in the cytoplasm and the nucleus, the question
arose whether another function exists besides the induction of apoptosis.
Consequently, an interaction of PB1-F2 and the polymerase subunit PB1
was observed (Mazur et al., 2008). Deletion of PB1-F2 was shown to
decrease viral polymerase activity, however, this effect was only detected for
some virus strains (Mazur et al., 2008; McAuley et al., 2010b; Chen et al.,
2010).
The induction of apoptosis and the upregulation of viral RNP activity are
thought to have some influence on virulence (Zamarin et al., 2006; Mazur
et al., 2008). Additionally, a connection between PB1-F2 expression and
the levels of cytokines and chemokines was suggested, with the focus on
one particular amino acid. PB1-F2 with a serine at position 66 was reported
to increase virulence and inhibit the innate immune response at early time
points in infection (Conenello et al., 2007, 2011). Most of these findings
were based on the behaviour of mutant viruses in cells and mice.
In order to delete PB1-F2, two or three point mutations were inserted into
segment 2 to abolish its expression. Most strategies had in common the
mutation of the start codon of PB1-F2 and the creation of one or two stop
codons further downstream.
In 2009 a third protein expressed from segment 2 was discovered. Since it
is an N-terminally truncated version of the polymerase subunit PB1 lacking
the first 39 amino acids, it was named N40 (Wise et al., 2009). The
two internal proteins from segment 2 are translated by leaky ribosomal
scanning and reinitiation (Wise et al., 2011). Alterations of start codons
within the N-terminus therefore were thought to have consequences on the
expression level of downstream proteins. This became noticeable when
PB1-F2 deletion strains were tested to monitor the expression level of N40.
Deletion of the PB1-F2 start codon resulted in an increased expression level
of N40 (Wise et al., 2009). Other strategies to abolish PB1-F2 were based
on insertion of a stop codon after amino acid 8 (Chen et al., 2001). This
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mutation led to a change in the PB1 ORF: amino acid 40 was changed
from a methionine to an isoleucine, which coincidentally also abolished N40
expression. In both cases no PB1-F2 was expressed, but both strategies
had consequences on the expression level of N40 (Figure 3.1), which makes
it difficult or even impossible to support some of the conclusions drawn in
previous publications as they can not be clearly associated to PB1-F2.
PB1
N40
PB1-F2
Influenza A virus segment 2
PB1 PB1
N40
Met -> Ile
Deletion of the start codonT120C
Insertion of a stop codon after aa 8G144A
Figure 3.1: Overview of the strategies to delete PB1-F2 in different
publications and their effect on PB1 and N40. The strategy on the left hand
side shows the deletion of PB1-F2 by removing the start codon. This led to an
increase in the expression level of N40. The second used strategy to delete PB1-F2
introduces a stop codon into PB1-F2 ORF after aa 8, but this mutation also has an
effect on the PB1 ORF. A methionine is changed to an isoleucine which abolishes
the expression of N40.
To address this problem, two different strategies were chosen to
abrogate PB1-F2 expression (Figure 3.2). As discussed in more detail in
Section 3.2, the first PB1-F2 deletion version was adopted from previously
published work, where three point mutations were introduced with the
disadvantage of increasing the expression level of N40 (Zamarin et al.,
2006). The second strategy involved introducing two stop codons and no
change to the PB1-F2 start codon was made. Using this approach the
expression level of N40 should remain unaffected.
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(A)
(B)
Figure 3.2: Overview of the strategies used to delete PB1-F2. (A) Three point
mutations were inserted into the plasmid pHH-PB1 via site directed mutagenesis in
order to delete PB1-F2. The first point mutation deleted the start codon of PB1-F2,
the two mutations downstream inserted stop codons to abolish translation of the
C-terminal end of PB1-F2. All mutations were silent with respect to the PB1 ORF.
The obtained plasmid was termed pHH-∆ATG. (B) The plasmid pHH-∆ATG was
used as a template to reinsert the start codon of PB1-F2 to maintain the wild type
expression level of N40. The resulting plasmid was named pHH-F2-11. Translation
of PB1-F2 will stop at amino acid 12, where the first stop codon was inserted.
3.2 Two ways to prevent PB1-F2 expression
3.2.1 Deletion of PB1-F2 by inserting three point
mutations
Three point mutations were inserted in order to fully delete PB1-F2 as
described previously (Zamarin et al., 2006). Knockout of the protein was
planned for two virus strains, the H1N1 mouse adapted strain A/WSN/33
and the human strain A/Udorn/1972 (H3N2). Three consecutive PCRs were
performed with primers containing one mutation each (Table 3.1). The first
mutation changed the start codon from AUG to ACG (T120C), the second
and third mutation (C153G and G291A) introduced two stop codons further
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downstream (Figure 3.2). Introducing two stop codons was shown to be
necessary in order to prevent the expression of the C-terminal domain
of PB1-F2 from a downstream start codon (Zamarin et al., 2006). The
C-terminus is thought to be the main inducer of apoptosis as it carries the
mitochondrial targeting signal. The introduced point mutations did not alter
the amino acid sequence of PB1 and N40.
Mutation Forward primer Reverse primer Annealing temperature
Udorn
T120C sv01 sv02 60°C
C153G sv03 sv86 61°C
G291A sv05 sv06 61°C
WSN
T120C sv09 sv10 60°C
C153G sv11 sv12 62°C
G291A sv13 sv14 61°C
Table 3.1: Oligonucleotide primers used to delete PB1-F2 in A/WSN/33 and
A/Udorn/1972. Primer Sequences are listed in Table 2.9 in Chapter 2.
PCR-mediated site-directed mutagenesis was performed using the
proofreading polymerase KOD hot start. Because the three mutation
sites were far from each other, three separate and sequential PCRs had
to be done using specific oligonucleotide primers carrying the desired
mutations. PCRs were performed according to the manufacturer’s protocol;
the annealing temperature for each primer pair and elongation times were
adjusted empirically. Conditions for each PCR are summarised in Tables 3.1
and 3.2.
PCR products were gel purified and treated with the restriction enzyme
DpnI to digest the parental DNA. Plasmids were transformed into competent
E.coli cells for further amplification. Several colonies were scanned by
restriction enzyme analysis using the enzyme NheI before they were used
in a subsequent PCR or before their nucleotide sequence was determined
(Figure 3.3). The correct plasmid with three integrated mutations was
termed pHH-∆ATG.
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Step Temperature Time # of cycles
Polymerase activation 95°C 2 min 1
Denaturation 95°C 30 sec
20Annealing adjust to primers 30 sec
Elongation 70°C 2.5 min
Final extension 70°C 10 min 1
Hold 10°C ∞
Table 3.2: Cycling conditions for site-directed mutagenesis using KOD Hot
Start Polymerase. The Annealing temperature varied between the PCR reactions
depending on the primers used. Annealing temperatures are listed in Table 3.1.
Figure 3.3: Deletion of PB1-F2 by introducing three point mutations into
segment 2. (A) Site-directed mutagenesis PCR was used to introduce three
mutations into the plasmid pHH-PB1. PCR products were electrophoresed through
a 1% agarose gel and visualized on a UV transilluminator. DNA was recovered from
the gel followed by a DpnI digest and amplification in E.coli. (B) Obtained plasmids
were digested using the enzyme NheI and electrophoresed through a 1% agarose
gel. The obtained fragments showed the expected length of 1327 and 3851 bp.
Marker: Promega 1kb DNA ladder.
3.2.2 Deletion of PB1-F2 by inserting two point mutations
Due to the interdependency of PB1, PB1-F2 and N40 expression, removal
of the PB1-F2 start codon led to an increase in the expression level of
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N40 (Wise et al., 2009). Other approaches to delete PB1-F2 involved the
insertion of a stop codon after amino acid 8 which led to the abolition of
N40 expression (Chen et al., 2001; Zamarin et al., 2006). To overcome this
problem and to keep N40 protein levels comparable to that of WT, the start
codon of PB1-F2 was regenerated and deletion of PB1-F2 was obtained by
two stop codons further downstream with the first stop codon after aa 11
(Figure 3.2 B).
Site-directed mutagenesis was performed using PCR to regenerate the start
codon into the sequence. The previously described plasmid pHH-∆ATG
carrying all three mutations was used as a template. Instead of starting
with the WT segment 2 and inserting two point mutations by subsequent
PCR reactions this approach was chosen to keep the number of PCRs, and
therefore the possibility of introducing errors to a minimum as the plasmid
pHH-∆ATG was already sequenced. The oligonucleotide primers used for
this reaction and the conditions for the PCR are listed in Table 3.3. The
correct plasmid, named pHH-F2-11, was verified by nucleotide sequencing
to ensure the correct insertion of the mutations. The plasmid pHH-F2-11
was only created for the H1N1 strain A/WSN/33.
Mutation Forward primer Reverse primer Annealing temperature
Start-F2 sv129 sv130 66°C
Table 3.3: Oligonucleotide primers used to regenerate the start codon into
pHH-∆ATG to create pHH-F2-11. Primer Sequences are listed in Table 2.9 in
Chapter 2.
3.3 Rescue and characterisation of the PB1-F2
deletion viruses
3.3.1 Rescue of the PB1-F2 deletion viruses
Viruses were rescued using the 12-plasmid rescue system described
by Neumann et al. (1999). Eight plasmids contained the cDNA to
express viral RNA corresponding to each segment of either influenza
A virus A/WSN/33 or A/Udorn/1972 (pHH-PB2, pHH-PB1, pHH-PA,
pHH-HA, pHH-NP, pHH-NA, pHH-M and pHH-NS). Viral sequences in
the negative-sense orientation were flanked by the human polymerase
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I promoter and a murine polymerase I terminator. RNA polymerase
I transcribes cellular genes into ribosomal RNA (rRNA) and does not
introduce 5’ and 3’ modifications to the RNA like 5’ cap or poly(A) structures.
The use of this approach allowed the generation of specific viral RNA
segments indistinguishable from authentic viral RNAs. To ensure the
formation of ribonucleoproteins within the cell, four additional plasmids
expressing the three polymerase subunits and the nucleoprotein were also
transfected (pcDNA-PB2, pcDNA-PB1, pcDNA-PA and pcDNA-NP). These
four genes were in the positive orientation and under the control of a
polymerase II promoter to allow immediate expression of the viral proteins
(Figure 3.4). Virus rescues were carried out for the WT and the deletion
mutants ∆AUG and F2-11 (rUdo WT, rUdo ∆AUG, rWSN WT, rWSN ∆AUG
and rWSN F2-11). Transfection lacking the cDNA for segment 5 (pHH-NP)
was always used as a negative control for virus rescues. Transfections were
done in human embryonic kidney cells (293FT). After 24h, 293FT cells were
co-cultivated with MDCK cells in a small tissue culture flask in the presence
of trypsin. MDCK cells support efficient replication of influenza A viruses,
whereas 293FT cells do not. Supernatant was harvested when cytopathic
effect (CPE) was 80-100%.
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Plasmids expressing viral proteins
PB2 PB1
PA NP
PB2 PB1 PA HA
NP NA M NS
Plasmids expressing influenza vRNA
293FT
293FT MDCK
Day 1: Transfection
Day 2 (A): Mix 293FT and 
                  MDCK cells
Day 2 (B): Media change after 6h
Day 4-6: 80-100% CPE  
                Harvest supernatent
Figure 3.4: Influenza A virus rescue using a 12-plasmid rescue system: A
total of 12 plasmids were transfected into 293FT cells. 8 plasmids expressing the
vRNA for each segment. Additionally 4 plasmids were transfeted expressing the
viral polymerase proteins and the nucleoprotein. On day 2 the 293FT cells were
mixed with MDCK cells to ensure virus propagation. Media was changed to DMEM
containing trypsin 6 hours later. When CPE is 80-100% supernatant was harvested.
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To monitor segment 2 and the inserted mutations, RNA was isolated
from the supernatant of infected MDCK cells and used in an RT-PCR
reaction in order to sequence the obtained PCR product. Results for all
three A/WSN/33 viruses are shown in Figure 3.5 with nucleotides of interest
indicated by green and red boxes. Viruses that contained the expected
mutations were used for further experiments.
PB1-F2 PB1
sv52 sv45
690 bp
RT-PCR   oligos sv52 and sv45
RT-PCR rWSN ΔAUG
RT-PCT rWSN WT
RT-PCR rWSN F2-11
Figure 3.5: Sequencing data from RT-PCR reactions to verify the inserted
mutations in rWSN ∆AUG and rWSN F2-11. RNA of MDCK cells - infected with
either rWSN WT, rWSN ∆AUG or rWSN F2-11 viruses - was isolated and used
in an RT-PCR reaction to amplify the beginning of segment 2. The obtained PCR
products were sequenced for examination of inserted mutations. The green boxes
indicate original sequences and red boxes show nucleotide sequences changed by
site-directed mutagenesis.
The presence or absence of the PB1-F2 protein in infected cells was
determined by Western blot analysis. MDCK cells were infected with the
different viruses at an MOI of 3 and incubated for 8 h. Proteins were
separated by different acrylamide gels - 16% Tricine-SDS-PAGE or 4-12%
Gradient Bis-Tris gels, depending on the protein to be examined (Figure
3.6). As seen in Figure 3.6 (A), PB1-F2 was only expressed in cells
infected with rWSN WT viruses whereas PB1-F2 was absent in cells infected
with either of the PB1-F2 deletion viruses. Infection was monitored by
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detecting the polymerase subunit PB1. A protein of slightly smaller weight
corresponding to N40 was easily seen in cells infected with rWSN ∆AUG,
but a similar band was poorly detected in rWSN WT and rWSN F2-11
infected cells. The increased expression level of N40 in cells infected with
rWSN ∆AUG is most likely caused by the deleted start codon of PB1-F2
as described previously (Wise et al., 2009). Differences in the expression
levels were quantified by measuring the chemiluminescence as can be
seen in Figure 3.7. Similar expression levels of PB1 were observed for all
three recombinant viruses, whereas cells infected with recombinant ∆AUG
showed a strong increase in N40 expression. α-tubulin was used as a
cellular loading control.
Figure 3.6 (B) shows the Western blot for the rUdorn WT and the ∆AUG
mutant. Antibodies used to detect PB1 and PB1-F2 were raised against
proteins from the H1N1 strain A/PR8/34. Unfortunately the antibody for
PB1-F2 did not cross react with the Udorn protein in Western blots. Most
likely this is due to the low sequence similarity between PB1-F2 from
A/PR8/34 and A/Udorn/72, as seen in Figure 3.6 (D), whereas PR8 is much
closer related to WSN (Figure 3.6 (C)). Because the N40 level was markedly
increased in cells infected with rUdo ∆AUG compared to WT, it could only
be speculated that PB1-F2 was successfully deleted. Although the antibody
used to detect PB1 and N40 was also raised against the PR8 protein,
it detected both WSN and Udorn proteins as the amino acid sequence
similarity of residues 50-370 is about 96% (data not shown).
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Figure 3.6: Western blot to confirm deletion of PB1-F2 in cells infected with (A)
WSN and (B) Udorn PB1-F2 deletion viruses. 4 - 12% gradient Bis-Tris gels were
used for PB1 and N40 detection, whereas 16% Tricine-SDS-PAGE was used for WB
to detect the small hydrophobic protein PB1-F2. α-tubulin was used as an internal
loading control. (C and D) Sequence alignment for PB1-F2 protein sequences. (C)
A/PR8/34 versus A/WSN/33; (D) A/PR8/34 versus A/Udorn/72.
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PB1
N40
PB1-F2
4 6 8 10 12 4 6 8 10 12 4 6 8 10 12MO
CKrWSN WT rWSN ΔAUG rWSN F2-11
hpi
α-tubulin
Figure 3.7: Analysis of expression levels of PB1 and N40: MDCK cells were
infected at an MOI of 3 with rWSN WT, rWSN ∆AUG or rWSN F2-11 and cell
lysates were collected at indicated time points. Proteins were separated using a
4-12% gradient Bis-Tris gel or 16% Tricine-SDS-PAGE and analysed by Western
blot for indicated proteins. Expression levels of PB1 and N40 were quantified and
normalized against α-tubulin.
3.3.2 The two deletant viruses show differences in their
plaque phenotype
Plaque assays are widely used to measure the virus titre in a sample stock,
but they can also be a first indication on viral fitness and viral replication.
Adding a solid or semi-solid overlay onto infected cells prevents the virus
from spreading through the media indiscriminately. Plaques represent an
area of destroyed and dead cells. Therefore the size of the plaque can
indicate possible attenuation.
Plaques were identified either indirect by staining cells using crystal-violet
or by direct immunostaining of virus infected cells. The diameters of several
plaques for each virus mutant were measured and compared (Figure 3.8
and 3.9). Previously, WSN viruses not expressing PB1-F2 were shown to
possess a small plaque phenotype compared to WT (Mazur et al., 2008).
This result could be confirmed for ∆AUG viruses. rWSN ∆AUG produced
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significantly smaller plaques in MDCK cells, with a plaque diameter reduced
by ∼30% (Student’s t-test P=0.0009). Plaque size by rUdo ∆AUG was also
reduced, however this reduction was only about 22% and not significant
(Student’s t-test P=0.0643). When comparing the plaques produced by the
second PB1-F2 deletion strain rWSN F2-11, plaque size appeared similar
to those measured for WT (Figure 3.8). No difference in size compared to
WT was observed at 24 hpi or 3 days post infection. As both PB1-F2 mutant
viruses are deficient for their PB1-F2 expression, this can only be explained
by their different expression level for N40.
3.3.3 Effects of the loss of PB1-F2 on viral growth
To further evaluate the phenotypes of the different viruses, viral growth
curves were determined in cultured cells for single-step and multi-step
infection conditions. For the single-step growth curve, monolayers of MDCK
cells were infected with the different recombinant viruses at an MOI of 3 in
the absence of trypsin. After an incubation time of 2, 4, 6, 8, 10 and 12
h, virus in the supernatant was titrated by plaque assay. For the multi-step
growth curve, MDCK cells were infected at an MOI of 0.001 and incubated in
the presence of trypsin for 48 hours. At indicated time points, supernatants
were harvested and titrated as described in Section 2.2.6.
Under multi-step growth condition the virus yield of rWSN ∆AUG was ∼
100 times lower than rWSN WT virus. On the other hand the rWSN F2-11
virus grew similarly to the recombinant WT virus (Figure 3.10(A)). A different
result was observed in a single-step cycle (Figure 3.10(B)): whereas rWSN
F2-11 was comparable to WT, rWSN ∆AUG showed an increased growth.
Unlike the growth characteristics of rWSN ∆AUG, rUdo ∆AUG showed a
similar growth behaviour to WT virus, both in single-step and multi-step
cycles (Figure 3.11).
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rWSN WT rWSN ΔAUG rWSN F2-11
Figure 3.8: Plaque phenotype by recombinant WSN viruses lacking PB1-F2
expression: MDCK cells were infected with recombinant viruses. Cells were
overlayed with 1.2% Avicel-DMEM and incubated for 3 days (top panel) or 24 h
(middle and lower panel) at 37°C . Mean values for ∼30 plaques/recombinant virus
(3 dpi) are plotted and error bars represent the SEM. Differences in plaque sizes are
significant between rWSN WT and rWSN ∆AUG virus (P<0.01) but not between
rWSN WT and rWSN F2-11 virus.
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rUdo WT rUdo ΔAUG
Figure 3.9: Plaque phenotype by recombinant Udorn viruses lacking PB1-F2
expression. MDCK cells were infected with recombinant viruses. Cells
were overlayed with 1.2% Avicel-DMEM supplemented with N-acetyl trypsin and
incubated for 3 days (top panel) or 24 h (lower panel) at 37°C . Mean values for
∼30 plaques/recombinant virus (3 dpi) are plotted and error bars represent the
SEM.
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(A)
(B)
Figure 3.10: WSN virus growth: Triplicate MDCK monolayers were infected with
the recombinant WSN viruses WT, ∆AUG and F2-11 at an (A) MOI of 0.001 for
multi-step growth curve and (B) MOI 3 for single-step growth curve. For multi-step
growth curve, media was supplemented with N-acetyl trypsin. Supernatants were
harvested at indicated time points post infection and virus titres were determined
by plaque assay. Error bars represent the SEM of each set of triplicates.
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(A)
(B)
Figure 3.11: Udorn virus growth: Triplicate MDCK monolayers were infected with
the recombinant Udorn viruses WT and∆AUG at (A) an MOI of 0.001 for multi-step
growth curve and (B) MOI 3 for single-step growth curve. Media was supplemented
with N-acetyl trypsin. Supernatants were harvested at indicated time points post
infection and virus titres was measured by plaque assay.
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3.3.4 ∆AUG viruses are attenuated in their ability to
induce apoptosis in vitro
PB1-F2 was shown previously to be involved in the induction of apoptosis,
specifically in immune cells (Chen et al., 2001; Zamarin et al., 2005). By
creating knockout mutants, the induction of apoptosis in immune cells was
reduced significantly (Chen et al., 2001). Later, this function was shown to
be specific for only a number of strains (Chen et al., 2010; McAuley et al.,
2010a). It was not known if PB1-F2 from the A/WSN/33 strain is involved
in the induction of apoptosis. To test this, a mouse macrophage cell line
(RAW/W) was infected with rWSN WT and 8 hours later cells were tested for
cell viability (Figure 3.12) using a commercially available cell viability assay.
In comparison to mock infected cells, RAW/W cells treated with rWSN WT
were less viable (-25%), assuming that cells died from apoptosis or necrosis
due to the viral infection.
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Figure 3.12: Cell viability assay: Monolayers of MDCK, A549 and RAW/W cells
in 96-well plates were infected with either rWSN WT, rWSN ∆AUG or rWSN F2-11
at an MOI of 30 and tested for their viability after 8 h according to the manufacturers
protocol. PBS was used as a control. Mean values ± SEM are plotted. **, P<0.01;
***, P<0.001.
To examine the role of WSN virus PB1-F2 in apoptosis, both WSN
viruses with PB1-F2 deletions were analysed. As seen in Figure 3.12, only
one of the deletant viruses was attenuated (rWSN ∆AUG), whereas rWSN
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F2-11 showed a similar reduction as rWSN WT in the number of viable
cells after infection. In MDCK cells, all viruses showed a similar loss of
viability. These cells are known to be a permissive cell line for influenza A
virus replication and were previously shown not to be targeted by PB1-F2
apoptosis (Chen et al., 2001). The loss of cell viability could be therefore
connected to apoptosis due to NS1 expression and viral replication. A549
cells on the other hand are a cell line that does not support viral replication
to the same extent as MDCK cells, reflected by the results in the cell viability
assay.
To test the difference in apoptosis induction in immune cells by the more
human relevant strain A/Udorn/72, human macrophages were separated
from fresh blood. By adding different cytokines to the growth media,
macrophages were divided into classical macrophages (Mϕ1) or alternative
macrophages (Mϕ2) (Verreck et al., 2004). Infection was done using
rUdo WT and rUdo ∆AUG at different MOI (0.1, 1 and 5) and cells were
collected at indicted time points (Figure 3.13). Levels of apoptosis were
measured by staining cells with FITC-conjugated AnnexinV and propidium
iodide (PI) followed by flow cytometry. Uninfected cells and cells infected
with UV-treated influenza viruses were used as controls. As can be seen
in Figure 3.13 (A), levels of apoptosis were similar for both macrophage
subsets and at all virus MOI, suggesting that the 6 hpi time point was
too early. At the later time point (20 hpi), an increase in apoptosis
was observed (Figure 3.13 (B)). Several common features were noticed
for both macrophage subsets: (1) Induction of apoptosis depended on
viral replication as cells treated with UV-inactivated viruses did not show
an increase in apoptosis compared to uninfected cells. (2) Induction of
apoptosis was dose-dependent. With increasing MOI, levels of apoptosis
also increased. (3) Viruses deficient in PB1-F2 (rUdo ∆AUG) induced
apoptosis in macrophages less efficiently. Differences were also observed
between the two subsets of macrophages. Mϕ2 seemed to be more
susceptible to infection as an increase in apoptosis was already noticed at
MOI 0.01. At higher MOIs, only small differences were observed between
Mϕ1 and Mϕ2 infected with rUdo WT. However, PB1-F2 deletion viruses
induced apoptosis in Mϕ1 only at the highest MOI, whereas at this MOI
the difference between rUdo WT and rUdo ∆AUG infected cells almost
disappeared.
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Figure 3.13: Macrophage assay: Human macrophages were divided into subsets
by specific cytokines and infected with A/Udorn/72 WT or ∆AUG at indicated MOI.
UV-treated influenza virus or MOCK infected cell served as control. (A) 6 hpi or
(B) 20 hpi, cells were analysed by flow cytometry for apoptotic markers. (C) At 20
hpi, supernatant of infected cells was used for virus titration by plaque assay. Mean
values ± SEM of triplicate measurements are plotted. This experiment was done
in collaboration with M. Hoeve; University of Edinburgh.
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Viral titres were measured by plaque assays at 20 hpi. An opposite effect
was observed. Mϕ1 were more susceptible for influenza A virus infection,
however rUdo WT viruses replicated better in both subsets. The decrease
in replication of rUdo ∆AUG could also be the cause of a less efficient
induction of apoptosis.
3.3.5 Effects of PB1-F2 deletion on virulence in mice
PB1-F2 was the subject of several in vivo experiments to investigate its
influence on viral replication and pathogenicity. Previous reports showed
an enhancing effect of PB1-F2 on virulence for some virus strains and
an influence of one particular amino acid (aa 66) on viral pathogenicity
(Zamarin et al., 2006; Conenello et al., 2007, 2011). For A/WSN/33 it was
reported that the loss of PB1-F2 increased the survival rate and lowered
weight loss and viral lung titres in infected mice (Zamarin et al., 2006).
However this work was done using chimeric viruses or viruses with the
deleted start codon for PB1-F2, which also alters the expression level of
N40. To test whether the difference was due to PB1-F2 or N40, 6-7 week-old
female BALB/c mice were infected with the two distinct mutant viruses as
well as the WT virus. Inoculation was done intranasally using 5 x 103 pfu.
Each group consisted of 8-10 mice, and weight was measured daily. Four
mice per group were culled at day 4 to measure virus titre in the lungs. The
remaining mice were culled on day 7 or when weight loss reached a critical
point of -25%. Lung titres were measured for each group by plaque assay.
Figure 3.14(A) shows the weight loss of mice infected with rWSN WT,
rWSN ∆AUG or rWSN F2-11. PBS treated mice served as a control group,
where no weight loss was observed. As expected, mice infected with the WT
virus started to lose weight from day 2. Several clinical signs were observed
such as staring coat and increased respiratory effort. The same symptoms
and a similar weight loss were observed for mice infected with rWSN F2-11
viruses. However, mice infected with rWSN ∆AUG viruses did not show any
symptoms and no weight loss was measured. Viral titres for all groups were
determined. Lungs of PBS infected mice were, as expected, negative for
virus detection (data not shown). As seen in Figure 3.14(B), viral titres for
rWSN WT and rWSN F2-11 were similar at both tested time points. Lung
titres for rWSN ∆AUG infected mice however were significantly reduced (*
P<0.05; ** P<0.01). It is not known if viral titres were reduced throughout
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the infection, as viral titres might have peaked earlier or later in infection and
therefore remained undiscovered.
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Figure 3.14: Virulence of the recombinant WSN viruses WT, ∆AUG and F2-11
in mice: Groups of 8 female BALB/c mice were infected with the recombinant WSN
viruses WT,∆AUG and F2-11 with 5x103 pfu. (A) Weight loss was measured every
day over a period of 7 days. Day 0 was set as 100% for each group. (B) At day 4
and day 7, 4 mice of each group were culled and lung virus titres were determined
by plaque assay. Mean values ±SEM are plotted. * P<0.05; ** P<0.01. Mouse
infections were done in collaberation with B. Dutia and her lab at the University of
Edinburgh.
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Two mice per group were used for lung histology at day 7 pi (Figure 3.15).
WT and F2-11 infected mice showed very similar signs of infection including
infiltrations of immune cells into interstitial regions and alveoli. Areas of
necrosis were detected in terminal airways, which contained cellular debris.
This reflects the symptoms of the mice such as increased respiratory
effort. However, mice infected with rWSN ∆AUG showed partial acute
haemorrhage into alveoli. This was however restricted to small areas of the
lung and terminal airways seemed to be unaffected. Almost no neutrophiles
and macrophages were detected in the interstitial regions and alveoli. This
could explain the missing clinical signs, as gas exchange in alveoli may be
largely unaffected. The lack of infiltrated immune cells could be evidence for
less production of cytokines caused by these viruses. As for the virus titre,
comparing different time points will be required to understand pathology
of these viruses better. It is not known if the observed phenotypes would
be observed throughout the experiment or if virus pathology by ∆AUG is
delayed and therefore different to what is seen in WT and F2-11 infected
mice.
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Figure 3.15: Histological section of lungs from BALB/c mice infected with WT
WSN or PB1-F2 deletion viruses: Mice were infected intranasally with 5x103 pfu
of the panel of recombinant WSN viruses - WT,∆AUG and F2-11. PBS served as a
negative control. At day 7 p.i. lung sections were stained with Hematoxylin & Eosin.
Mice infected with WT and F2-11 viruses showed significant increased numbers of
neutrophils in the alveoli as well as necrosis of the bronchus epithelial wall. Mice
infected with ∆AUG viruses on the other hand showed signs of acute hemorrhage,
but less cellular infiltration. Bronchus epithelial wall remained mainly intact. This
work was done with the help of Jill McVee, University of St Andrews.
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3.4 Discussion
The aim of this Chapter was the analysis and comparison of two PB1-F2
deletion strains. Previous work on PB1-F2 used deletion viruses including
a deleted start codon to abolish PB1-F2 expression (Zamarin et al., 2006).
When this project was started, we decided to introduce the same mutations
into PB1-F2. However, in 2009, a third protein (N40), translated from
the very same mRNA, was described and it was shown that removal
of the PB1-F2 start codon influenced the downstream protein expression
level (Wise et al., 2009). Therefore we decided to create the second
PB1-F2 deletion mutant to compare phenotypes and, if possible, dissect
effects caused by PB1-F2 or N40. This second method abolished PB1-F2
translation after amino acid 11. A similar mutation is present in recent
pandemic H1N1 viruses from 2009 (Ramakrishnan et al., 2009). In previous
reports, PB1-F2 was shown to be involved in the induction of apoptosis in
a cell-type dependent manner (Chen et al., 2001; Zamarin et al., 2006).
However, these findings were mainly based on the analysis of only one
virus strain - A/PR8/34. Comparison of several other influenza A virus
strains showed that the induction of apoptosis is a strain specific feature
(McAuley et al., 2010a). It was suggested that an ILV motif (amino acids
68-70) in the C-terminus is involved, because it is present in A/PR8/34, but
absent in most other virus strains which do not induce apoptosis. Amino
acid sequence alignments showed that this motif is also present in PB1-F2
of the closely related strain A/WSN/33 (Figure 3.6). Indeed, apoptosis was
induced in mouse macrophages by rWSN WT viruses, however the loss of
PB1-F2 alone did not show any alteration of this ability. RAW cells infected
with rWSN F2-11 also underwent apoptosis to the same extent as WT
(Figure 3.12). It seems likely that induction of apoptosis is not the main
function of PB1-F2 but it may be an accessory feature of some individual
strains to counteract the immune response and gain virulence. Similar
observations were made in the human macrophage experiments (Figure
3.13). Both subsets of human macrophages infected with A/Udorn/72
underwent apoptosis in a dose-dependent manner, although levels of
apoptosis were reduced in cells infected with rUdo ∆AUG virus. However,
to draw a firm conclusion, the experiment should be repeated including a
virus deficient for PB1-F2 but expressing normal N40 levels. Additionally,
it should be noted that viruses with an increased N40 expression level in a
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PB1-F2 deficient background showed reduced viral growth (Figure 3.13).
Consistent with the findings on plaque phenotype, rWSN ∆AUG viruses
showed an attenuation in viral growth when cells were infected with a low
MOI (Figure 3.8; 3.10 (A)). However, when cell monolayers were infected
with a high MOI, this attenuation was no longer observed (Figure 3.10 (B)).
It could be hypothesised that high levels of N40 have a negative impact
on counteracting the immune system. In this case, no differences would
be expected at infection with a high multiplicity when every cell in a dish is
infected, but would be disadvantageous in infections with a low MOI. One
possibility to test this hypothesis would be to measure viral growth in immune
incompetent cells. It was noted that single-step growth curves did not follow
a typical exponential curve (Figure 3.10(B)). It is known that infections at
high MOI can support production of defective interfering particles (DIs).
Although DIs usually arise after serial passages, single mutations may be
sufficient to induce the production of DIs at high multiplicity infection (Odagiri
and Tobita, 1990; Odagiri et al., 1994). In the reported case, viruses also
grew normally in multi-step growth curves. Viruses in the present study
were plaque purified and only passaged once to grow up viral stocks to use
for further investigations. However, it can not be ruled out that (1) these
stocks acquired single mutations or (2) rescue plasmids already carried a
mutation, which supported the formation of DIs. This mutation would be
subsequently present in all viruses rescued. Alternatively, the experimental
designs and conditions may be suboptimal and lower MOI (MOI 1) could be
used to reduce formation of defective interfering particles.
Animal models are critical for influenza research. The most commonly
used model systems are mice, hamsters, ferrets and non-human primates.
Although mice are not naturally infected by influenza viruses, they have
a lot of advantages because they are easy to handle, small and have a
known genetic background that can also be modified. Mouse adapted
virus strains made it possible to infect mice and to study effects on
pathogenicity or immune response. Different inbred mouse strains were
shown to have different susceptibility and both the host and virus genetic
background influence the outcome of an infection (Srivastava et al., 2009;
Boon et al., 2009; Blazejewska et al., 2011). In this study, BALB/c mice
were used to test the effect of PB1-F2 deletions on viral pathogenicity. As
described previously, deletion of PB1-F2 (∆AUG) caused an attenuation
in these mice (Zamarin et al., 2006). These results were confirmed in
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the present study. No weight loss was observed in mice infected with
rWSN ∆AUG. However, WT and F2-11 virus-infected mice rapidly lost
weight and developed symptoms (Figure 3.14). Lung virus titres confirmed
the attenuation of rWSN ∆AUG viruses. However, it requires further
investigations whether an increased N40 protein level caused decreased
titre in the lung and if this decrease was present throughout the infection
cycle. Viral titres may reach those of WT infected mice, but at a different
time point. Also, other viral strains and the effect of PB1-F2 deletions in
combination with varying N40 levels should be tested to better understand
the role of PB1-F2 in pathogenicity.
The reasons for an attenuation of overexpressed N40 in a PB1-F2
deficient background are still unknown. N40 lacks the N-terminal 39 amino
acids of PB1, but most of the interaction sites with viral and cellular proteins
are probably still available. A number of interaction partners for PB1 have
been described, although the sites within the protein remain unidentified
for many of them. The NFκB pathway was shown to be important for an
infection of influenza A viruses (Nimmerjahn et al., 2004). Induction of IKK
leads to the activation and translocation of NFκB into the nucleus, where
it regulates the expression of more than 150 genes such as cytokines and
pro-apoptotic genes (Pahl, 1999). A search for host cell interacting partners
revealed a number of viral proteins interacting with members of this pathway,
including HA, M1 and NP, but also the polymerase subunits (Flory et al.,
2000; Shapira et al., 2009). The expression of single influenza virus proteins
was sufficient to induce this pathway (Flory et al., 2000). NFκB activation
also results through RIG-I activation as part of the host cell immune
response (Figure 1.8). RIG-I is activated by binding to 5’ triphosphorylated
RNA and the CARD domain of RIG-I subsequently interacts with the CARD
domain of MAVS. This protein is an mitochondrial membrane protein that
activates IKKα/β and IKKγ which leads to the activation of NFκB and
IRF-3. Recently, an interaction of PB1-F2 and MAVS was described (Varga
et al., 2011). The authors found a suppression of IFN-β expression due to
PB1-F2. This suppression was even enhanced if PB1-F2 carried a serine
at position 66. Surprisingly, an opposite effect was seen in epithelial cells
infected with the PB1-F2-deficient virus overexpressing N40 (∆AUG) (Goffic
et al., 2010; Varga et al., 2011). The conflicting results may be an effect of
increased level of N40 in the experiments carried out with the ∆AUG virus.
A hypothesised model of MAVS signalling and the influence of PB1-F2 is
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Figure 3.16: Model of the effect the Influenza A virus has on the MAVS
signalling : (A) A dual mechanism was reported for MAVS proteins, inducing
apoptosis or activating NFκB leading to the expression of IFN-β. PB1-F2 was also
found to be involved in both events, however PB1-F2 suppresses the induction of
IFN-β upon interaction with MAVS. (B) In cells infected with a virus deficient for
PB1-F2 but overexpressing N40, a lack of apoptosis in immune cells was reported
as well as a decrease in IFN-β expression. Latter may be due to the higher levels
of N40. The picture was adapted from (Lei et al., 2009).
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shown in Figure 3.16. Beside IFN-induction, MAVS proteins were also
shown to be involved in the regulation of apoptosis (Lei et al., 2009).
Interestingly, it was shown that MAVS regulate apoptosis by suppressing
the mitochondrial membrane protein VDAC1, which is also an interaction
partner of PB1-F2 (Xu et al., 2010; Zamarin et al., 2005).
The question arises whether the PB1-F2 ORF is in place to regulate the
expression levels of the downstream N40. When Zell et al. analysed the
sequences available in databases, they only found 5 strains out of >2200
that did not have a start codon for PB1-F2 (Zell et al., 2007). About 87%
do encode an ORF >78 amino acids, however human H1N1 strains after
1950 in particular possess a truncated PB1-F2. Classical swine viruses
have a stop codon introduced after amino acid 11. The recently emerged
pandemic H1N1 (2009) carries a segment 2 that originates from swine
influenza strains and only has a truncated PB1-F2 ORF with stop codons
at amino acid 12, 58 and 88. Efforts were made to introduce PB1-F2 into
these 2009 pandemic strain in order to determine any possible effects of
the full-length protein on viral pathogenicity. The viruses did not significantly
benefit of the presence of the protein (Hai et al., 2010). Therefore, if and to
what extent, PB1-F2 and N40 are important remains unknown. To date, data
are partly controversial whether PB1-F2 increases viral pathogenicity or not.
But it has become more evident that PB1-F2 functions in a highly strain and
cell type specific manner and an overall conclusion might be difficult. What
can be said from the findings made in this Chapter is that the design of
mutants is critically important and some of the published results made with
PB1-F2 deletion viruses may need to be reconsidered.
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3.5 Summary of Chapter 3
Two PB1-F2 deletion viruses were engineered (overview in Table 3.4).
Virus Mutation Protein levels Phenotype
∆AUG T120C PB1: WT small plaques
C153C PB1-F2: null attenuation in vitro
G291A N40: overexpression attenuation in vivo
F2-11 C153G PB1: WT
G291A PB1-F2: null WT phenotype
N40: WT
Table 3.4: Summary Chapter 3: Introduced mutations into PB1 abolished PB1-F2
ORF. Whereas the PB1 level appears unaffected for both strains, ∆AUG viruses
overexpress N40. This led to a major attenuation both in vitro and in vivo.
The removal of the start codon of PB1-F2 had a dramatic effect on the
virus both in vitro and in vivo. The only difference between ∆AUG viruses
and F2-11 is the altered level of N40, which seems to have detrimental
effects on plaque size, growth and especially on virulence. This findings are
important as many previous studies to determine the function of PB1-F2 are
based on the deletion of the PB1-F2 ORF by removing the start codon. Here
it was shown that N40 needs to be taken into consideration when designing
PB1-F2 mutants.
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CELLULAR POLYMERASE II
DEGRADATION
Aims of Chapter 4
The viral RNA dependent RNA polymerase was reported to bind to the
largest subunit of cellular RNA polymerase II (Engelhardt et al., 2005). This
interaction resulted in degradation of the hypophosphorylated form of the
cellular polymerase. Two single point mutations within the viral polymerase
subunits were tested for their influence on degradation and host cell protein
shut-off.
The first mutation was located in the polymerase subunit PB2 (V504I), a
second mutation was introduced in the polymerase subunit PA (L550I). The
effects of the individual single point mutations were analysed as well as the
effect of a double mutation.
98
CHAPTER 4 RNAPII degradation
4.1 Interaction of the influenza A virus RdRp
and cellular RNA polymerase II and the
consequences of this interaction
Cellular mRNA synthesis is performed by a multiprotein complex called
RNA polymerase II (RNAP II). The carboxy-terminal domain (CTD) of
the largest subunit plays a major role during the transcription cycle.
It contains over 50 repeats of a heptapeptide YSPTSPS, which are
differentially phosphorylated during the transcription process (Figure
4.1). Upon phosphorylation of serine-5 residues, the RNAPII initiates
transcription. Following further phosphorylation at serine-2 residues,
transcription proceeds into elongation (Komarnitsky et al., 2000). Coupled
with these different phosphorylation stages are varying affinities for
transcription factors and factors involved in 5’ and 3’ end processing of
pre-mRNAs (Schroeder et al., 2000; Komarnitsky et al., 2000; Kim et al.,
1997; McCracken et al., 1997).
Figure 4.1: Differential phosphorylation of the CTD of cellular RNAPII: The
hypophosphorylated form of the CTD gets phosphorylated at serine-5 residues
which initiates transcription. Proceeding into elongation is realised by serine-2
phosphorylation. Taken from Phatnani and Greenleaf (2006).
Although influenza A viruses encode their own RNA-dependent RNA
polymerase (RdRp), it was assumed for a long time that viral replication
depends on a functional cellular RNA polymerase II. Two events in the viral
life cycle are thought to be coupled to cellular transcription:
(1) Viral transcription depends on the availability of 5’ cap structures of
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cellular mRNAs (Bouloy et al., 1978; Plotch et al., 1981).
(2) Influenza A virus segments 7 and 8 produce spliced mRNAs, and splicing
is performed by the cellular splicing machinery (Inglis et al., 1979; Lamb
et al., 1981).
Viral RdRp was found to interact with the largest subunit of cellular RNAPII
(Engelhardt et al., 2005). More specifically, this interaction was shown to
be between the viral polymerase trimer and the C-terminal domain (CTD).
None of the polymerase subunits alone nor one of the dimers were able
to bind to and degrade the RNAPII. Interaction was confirmed between the
RdRp and the CTD in its hyperphosphoryated form, more specifically with
the Serine-5-phosphorylated form (Engelhardt et al., 2005). It is believed
that this provides the viral polymerase with 5’ capped pre-mRNAs that are
needed to initiate viral transcription. However, following interaction, the
largest subunit of the RNAPII in its hypophosphorylated form was shown
to be degraded (Rodriguez et al., 2007).
When this project was started, the involvement of the individual viral
polymerase segments was not known. Hence, the impact of PB1-F2 was
determined by evaluating the degradation of RNAPII in rWSN WT or rWSN
∆AUG infected cells. Specific antibodies were used to differentiate between
the different phosphorylated forms of the CTD (Table 4.1).
Antibody Epitope Recognition
8WG16 Non-phosphorylated Non-phosphorylated repeats
H5 Ser2-P Ser-2P, Ser5-P, Ser2-P + Ser5-P
Table 4.1: Anti-CTD monoclonal antibodies recognising specific epitopes
depending on their phosphorylation state. (Jones et al., 2004; Rodriguez et al.,
2007)
Confluent monolayers of MDCK cells were infected with one of the two
viruses and cells were lysed at the indicated time points. Results of the
western blot analysis are shown in Figure 4.2. Consistent with previous
reports (Rodriguez et al., 2007), a decrease in the accumulation of the
hypophosphorylated RNAPII in rWSN WT infected cells was observed from
6 hpi onwards. In contrast, no decrease was observed in the accumulation
level of Serine-2-phosphorylated RNAPII, detected by the antibody H5.
The degradation correlated with the onset of viral protein synthesis. No
difference was observed in cells infected with the rWSN ∆AUG virus,
suggesting that PB1-F2 and N40 are not involved in the process.
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Figure 4.2: Degradation of cellular polymerase II did not depend on PB1-F2:
Confluent monolayers of MDCK cells were infected with rWSN WT, rWSN ∆AUG
or Mock infected at an MOI of 3 and cells were lysed at the indicated time points.
8% Bis-Tris gels were used to detect the cellular polymerase using the antibodies
8WG16 and H5. 4 - 12% gradient Bis-Tris gels were used for PB1 detection,
whereas 16% Tricine-SDS-PAGE was used to detect the small hydrophobic protein
PB1-F2. α-tubulin was used as an internal loading control.
More recently the involvement of PB2 and PA were suggested, when
comparing low-virulence (lvPR8) and high-virulence (hvPR8) strains of
A/PR/8/34 for their ability to degrade the largest subunit of RNAPII
(Rodriguez et al., 2009). It was shown that the degradation was restricted to
non-attenuated viral strains, because the lvPR8 and a cold-adapted strain
(A/Ann Arbor/6/60) were found not to degrade the cellular polymerase.
When comparing recombinant viruses, segment 1 and 3 gene products
were identified to contribute to the degradation whereas segment 2 did not
have an influence.
It is not fully understood how the interaction between cellular RNAPII
and viral RdRp is maintained. A recent study suggested the kinase
cyclinT1/CDK9 to function as a mediator between the CTD and the viral
polymerase complex (Zhang et al., 2010a). CDK9 was shown to bind to all
three polymerase subunits, PB2, PB1 and PA, and the interaction promoted
viral transcription. Cyclin T1/CDK9 phosphorylates serine-2 residues in
the CTD of the large subunit (Marshall et al., 1996). Previously, binding
was especially suggested between RdRp and the Ser-5P form of the
CTD (Engelhardt et al., 2005), but phosphorylation of serine-5 residues
is performed by a different kinase (TFIIH). If the viral polymerase complex
binds directly to the CTD with Serine-5-phosphorylation or if this interaction
is also mediated by an adaptor protein is unknown.
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4.2 Mutations in the polymerase subunit PB2
and PA involved in degradation of cellular
polymerase II
It was shown by Rodriguez et al., that the hvPR8 strain induced degradation
of cellular RNAPII, whereas the lvPR8 variant had no influence (Rodriguez
et al., 2009). Segment 1 and 3 gene products were identified as the key
components for the differences, although only three amino acids in PB2 and
two residues in PA differed between the two variants (Grimm et al., 2007).
A/WSN/33 is a closely related strain also inducing RNAPII degradation. To
determine whether any of the above mentioned amino acids were involved
in degradation, recombinant WSN viruses were engineered to analyse the
influence of the residues individually. First, mutation sites were chosen.
Therefore, an alignment was performed for segment 1 and 3, comparing the
amino acid sequence of both PR8 variants and WSN (Figures 4.3 and 4.4).
Two residues - one in each segment - were identified to be identical in hvPR8
and WSN, but differed from lvPR8. The remaining three different residues
were either different in all three viruses or WSN shared the sequence with
lvPR8 (Table 4.2). Amino acid 504 in PB2 and 550 in PA were mutated to
isoleucine in order to change the sequence of WSN to the sequence found
in the lvPR8 variant. Oligo nucleotide sequences are listed in Table 2.14.
Mutations were introduced by PCR-mediated site-directed mutagenesis
(Section 2.4.3).
Amino acid
Viral protein lvPR8 hvPR8 A/WSN/33
PB2 aa105 Ile Met Val
PB2 aa456 Asn Asp Asn
PB2 aa504 Ile Val Val
PA aa193 Gln His Gln
PA aa550 Ile Leu Leu
Table 4.2: Comparison
of residues that differed
between lvPR8, hvPR8
and WSN: The two residues
that were mutated in WSN
are shown in bold.
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A/lvPR8/34_H1N1_  MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITAD 60
A/hvPR8/34_H1N1_  MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITAD 60
A/WSN/1933_H1N1_  MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITAD 60
************************************************************
A/lvPR8/34_H1N1_  KRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRNGPITNTVHYPKIYKTYFE 120
A/hvPR8/34_H1N1_  KRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRNGPMTNTVHYPKIYKTYFE 120
A/WSN/1933_H1N1_  KRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRNGPVTSTVHYPKIYKTYFE 120
********************************************:*.*************
A/lvPR8/34_H1N1_  RVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAKEAQDVIMEVVFPNEVGARILTSE 180
A/hvPR8/34_H1N1_  RVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAKEAQDVIMEVVFPNEVGARILTSE 180
A/WSN/1933_H1N1_  KVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAKEAQDVIMEVVFPNEVGARILTSE 180
:***********************************************************
A/lvPR8/34_H1N1_  SQLTITKEKKEELQDCKISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCW 240
A/hvPR8/34_H1N1_  SQLTITKEKKEELQDCKISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCW 240
A/WSN/1933_H1N1_  SQLTTTKEKKEELQGCKISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCW 240
**** *********.*********************************************
A/lvPR8/34_H1N1_  EQMYTPGGEVRNDDVDQSLIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQ 300
A/hvPR8/34_H1N1_  EQMYTPGGEVRNDDVDQSLIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQ 300
A/WSN/1933_H1N1_  EQMYTPGGEARNDDVDQSLIIAARNIVRRATVSADPLASLLEMCHSTQIGGVRMVNILRQ 300
*********.********************:********************:***:****
A/lvPR8/34_H1N1_  NPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGY 360
A/hvPR8/34_H1N1_  NPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGY 360
A/WSN/1933_H1N1_  NPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGY 360
************************************************************
A/lvPR8/34_H1N1_  EEFTMVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNF 420
A/hvPR8/34_H1N1_  EEFTMVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNF 420
A/WSN/1933_H1N1_  EEFTMVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNF 420
************************************************************
A/lvPR8/34_H1N1_  VNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDNVMGMIGILPDMTPSIEMSMRGVRI 480
A/hvPR8/34_H1N1_  VNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDDVMGMIGILPDMTPSIEMSMRGVRI 480
A/WSN/1933_H1N1_  VNRANQRLNPMHQLLRHFQKDAKVLFQNWGIESIDNVMGMIGILPDMTPSTEMSMRGVRI 480
******************************:*.**:************** *********
A/lvPR8/34_H1N1_  SKMGVDEYSSTERVVVSIDRFLRIRDQRGNVLLSPEEVSETQGTEKLTITYSSSMMWEIN 540
A/hvPR8/34_H1N1_  SKMGVDEYSSTERVVVSIDRFLRVRDQRGNVLLSPEEVSETQGTEKLTITYSSSMMWEIN 540
A/WSN/1933_H1N1_  SKMGVDEYSSAEKIVVSIDRFLRVRDQRGNVLLSPEEVSETQGTEKLTITYSSSMMWEIN 540
**********:*::*********:************************************
A/lvPR8/34_H1N1_  GPESVLVNTYQWIIRNWETVKIQWSQNPTMLYNKMEFEPFQSLVPKAIRGQYSGFVRTLF 600
A/hvPR8/34_H1N1_  GPESVLVNTYQWIIRNWETVKIQWSQNPTMLYNKMEFEPFQSLVPKAIRGQYSGFVRTLF 600
A/WSN/1933_H1N1_  GPESVLVNTYQWIIRNWETVKIQWSQNPTMLYNKMEFEPFQSLVPKAVRGQYSGFVRTLF 600
***********************************************:************
A/lvPR8/34_H1N1_  QQMRDVLGTFDTAQIIKLLPFAAAPPKQSRMQFSSFTVNVRGSGMRILVRGNSPVFNYNK 660
A/hvPR8/34_H1N1_  QQMRDVLGTFDTAQIIKLLPFAAAPPKQSRMQFSSFTVNVRGSGMRILVRGNSPVFNYNK 660
A/WSN/1933_H1N1_  QQMRDVLGTFDTAQIIKLLPFAAAPPKQSGMQFSSLTINVRGSGMRILVRGNSPVFNYNK 660
***************************** *****:*:**********************
A/lvPR8/34_H1N1_  ATKRLTVLGKDAGTLTEDPDEGTAGVESAVLRGFLILGKEDRRYGPALSINELSNLAKGE 720
A/hvPR8/34_H1N1_  ATKRLTVLGKDAGTLTEDPDEGTAGVESAVLRGFLILGKEDRRYGPALSINELSNLAKGE 720
A/WSN/1933_H1N1_  TTKRLTVLGKDAGPLTEDPDEGTAGVESAVLRGFLILGKEDRRYGPALSINELSNLAKGE 720
:************.**********************************************
A/lvPR8/34_H1N1_  KANVLIGQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN 759
A/hvPR8/34_H1N1_  KANVLIGQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN 759
A/WSN/1933_H1N1_  KANVLIGQGDVVLVMKRKRNSSILTDSQTATKRIRMAIN 759
*******************:*******************
PB2
Figure 4.3: Alignment of polymerase subunit PB2. Two A/PR8/34 variants
and A/WSN/33 were compared for their amino acid sequence of the polymerase
subunit PB2. The high virulent (hv) PR8 strain was shown to be more potent in the
degradation of cellular polymerase than the low virulent (lv) PR8 variant. A/WSN/33
is known to degrade cellular polymerase. One amino acid (highlighted in dark red)
differed between hvPR8 and lvPR8, but not between hvPR8 and A/WSN/33 and
was therefore chosen for site-directed mutagenesis. Amino acids in light red show
sites that differed between all three strains or between hvPR8 and WSN and were
therefore not chosen for site-directed mutagenesis.
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A/lvPR8/34_H1N1_  MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFHFINEQGES 60
A/hvPR8/34_H1N1_  MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFHFINEQGES 60
A/WSN/1933_H1N1_  MEDFVRQCFNPMIVELAEKAMKEYGEDLKIETNKFAAICTHLEVCFMYSDFHFIDEQGES 60
*******************:**********************************:*****
A/lvPR8/34_H1N1_  IIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFLPDLYDYKENRFIEI 120
A/hvPR8/34_H1N1_  IIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFLPDLYDYKENRFIEI 120
A/WSN/1933_H1N1_  IVVELGDPNALLKHRFEIIEGRDRTIAWTVINSICNTTGAEKPKFLPDLYDYKKNRFIEI 120
*:***********************:****:**********************:******
A/lvPR8/34_H1N1_  GVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQ 180
A/hvPR8/34_H1N1_  GVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQ 180
A/WSN/1933_H1N1_  GVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQ 180
************************************************************
A/lvPR8/34_H1N1_  EMASRGLWDSFRQSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNG 240
A/hvPR8/34_H1N1_  EMASRGLWDSFRHSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNG 240
A/WSN/1933_H1N1_  EMASRGLWDSFRQSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNG 240
************:***********************************************
A/lvPR8/34_H1N1_  YIEGKLSQMSKEVNARIEPFLKTTPRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGE 300
A/hvPR8/34_H1N1_  YIEGKLSQMSKEVNARIEPFLKTTPRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGE 300
A/WSN/1933_H1N1_  YIEGKLSQMSKEVNARIEPFLKSTPRPLRLPDGPPCSQRSKFLLMDALKLSIEDPSHEGE 300
**********************:********:****************************
A/lvPR8/34_H1N1_  GIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNM 360
A/hvPR8/34_H1N1_  GIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNM 360
A/WSN/1933_H1N1_  GIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPRTKNM 360
*******************************************************:****
A/lvPR8/34_H1N1_  KKTSQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDS 420
A/hvPR8/34_H1N1_  KKTSQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDS 420
A/WSN/1933_H1N1_  KKTSQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDS 420
************************************************************
A/lvPR8/34_H1N1_  SWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYINTALLNASCAAMDDF 480
A/hvPR8/34_H1N1_  SWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYINTALLNASCAAMDDF 480
A/WSN/1933_H1N1_  SWIELDEIGEDAAPIEHIASMRRNYFTAEVSHCRATEYIMKGVYINTALLNASCAAMDDF 480
***********.***************:********************************
A/lvPR8/34_H1N1_  QLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKY 540
A/hvPR8/34_H1N1_  QLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKY 540
A/WSN/1933_H1N1_  QLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKY 540
************************************************************
A/lvPR8/34_H1N1_  CVLEIGDMLIRSAIGQVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAES 600
A/hvPR8/34_H1N1_  CVLEIGDMLLRSAIGQVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAES 600
A/WSN/1933_H1N1_  CVLEVGDMLLRSAIGHVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAES 600
****:****:*****:********************************************
A/lvPR8/34_H1N1_  SVKEKDMTKEFFENKSETWPIGESPKGVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSA 660
A/hvPR8/34_H1N1_  SVKEKDMTKEFFENKSETWPIGESPKGVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSA 660
A/WSN/1933_H1N1_  SVKEKDMTKEFFENKSETWPVGESPKGVEEGSIGKVCRTLLAKSVFNSLYASPQLEGFSA 660
********************:*********.*****************************
A/lvPR8/34_H1N1_  ESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS 716
A/hvPR8/34_H1N1_  ESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS 716
A/WSN/1933_H1N1_  ESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALR 716
*******************************************************
PA
Figure 4.4: Alignment of polymerase subunit PA. Two A/PR8/34 variants
and A/WSN/33 were compared for their amino acid sequence of the polymerase
subunit PA. The high virulent (hv) PR8 strain was shown to be more potent in the
degradation of cellular polymerase than the low virulent (lv) PR8 variant. A/WSN/33
is known to degrade cellular polymerase. One amino acid (highlighted in the red
box) differed between hvPR8 and lvPR8, but not between hvPR8 and A/WSN/33
and was therefore chosen for site-directed mutagenesis. The amino acid in light
red shows the site that differed between hvPR8 and WSN and was therefore not
chosen for site-directed mutagenesis.
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4.3 Rescue and characterisation of the mutant
viruses
Two viruses carrying individual mutations in segment 1 (PB2→ V504I) and
3 (PA→ L550I) were engineered as well as a virus carrying both mutations.
Virus rescues were done using the 12-plasmid rescue system, which is
described in more detail in Section 2.2.2. Viruses were plaque purified and
the nucleotide sequence of the appropriate segment was determined before
they were used in further experiments. Viral replication was shown to be
coupled to cellular transcription and the influence of the inserted mutations
on this association was tested. As a first indicator for the efficiency of viral
replication, plaque assays were performed and plaque sizes were measured
and compared. Confluent MDCK cells were infected with serial dilutions of
the three mutant viruses as well as the WT virus. Cells were covered with
1.2% Avicel-DMEM and incubated for three days. As shown in Figure 4.5,
no differences were observed regarding plaque size.
rWSN WT rWSN PB2504
rWSN PA550 rWSN PB2504/PA550
Figure 4.5: Plaque phenotype of the three polymerase II degradation mutants.
Confluent MDCK cells were infected with serial dilutions of rWSN WT, rWSN
PB2504, rWSN PA550 or rWSN PB2504/PA550. Cells were covered with 1.2%
Avicel-DMEM and incubated at 37 °C for three days. Cells were fixed with
formaldehyde and stained for plaques using crystal violet. Mean values for ∼30
plaques/recombinant virus are plotted and error bars represent the SEM.
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(A)
(B)
Figure 4.6: Growth of the three polymerase mutant viruses: Triplicate
MDCK monolayers were infected with the recombinant WSN viruses WT, PB2504,
PA550 or PB2504/PA550 at an (A) MOI of 0.001 and (B) MOI 3. For multi-step
growth conditions, media was supplemented with N-acetyl trypsin. Supernatants
were harvested at the indicated time points post infection and virus titres were
determined by plaque assay. Error bars represent the SEM of each set of triplicates.
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To assess viral replication under multi-step and single-step growth
conditions, confluent MDCK cells were infected with MOI of 0.001 or MOI
of 3, respectively. At the indicated time points, supernatants were harvested
and viral growth was determined by plaque assay. As can be seen in Figure
4.6, all three recombinant viruses were attenuated under both conditions.
However, major differences were observed in the single-step growth curve
(Figure 4.6 (B)). Viruses carrying the mutation in segment 1 (rWSN PB2504
and rWSN PB2504/PA550) were markedly attenuated compared to WT virus.
The virus with a single-point mutation in segment 3 showed an intermediate
phenotype.
4.4 Degradation of cellular RNA polymerase II
To determine the influence of the two residues on the degradation of cellular
RNAPII, confluent A549 cells were infected with the WSN viruses carrying
single point mutations in segment 1 or 3, or with the double mutant, at
an MOI of 3. At indicated time points, cells were lysed and the amount
of cellular RNAPII was compared to that in WT infected cells (Figure 4.7
(A)). Accumulation of RNAPII was measured by chemiluminescence. As
can be seen in Figure 4.7 (B), no difference was observed regarding the
hypophosphorylated form of the cellular RNAPII, which decreased similarly
in all virus-infected cells. The Ser2-P form detected by antibody H5 was not
degraded (Figure 4.7 (C)). Virus growth was determined by measuring the
synthesis of the viral protein NS1 and by measuring the viral titre. Although
NS1 accumulated to similar levels in all virus infected cells (Figure 4.7 (D)),
lower viral titres were observed in cells infected with viruses carrying a point
mutation in PB2 and / or PA (Figure 4.7 (E)). However, this decrease was
not due to a defect in the degradation of the cellular polymerase II.
Degradation of RNAPII was thought to have an influence on host cell
protein shut off. The three mutant viruses carrying mutations in the
polymerase subunits PB2 or PA were therefore analysed for their ability to
shut off host cell protein synthesis. Confluent MDCK cells were infected with
rWSN WT, rWSN PB2504, rWSN PA550 or rWSN PB2504/PA550 at an MOI of
3 or mock infected. At the indicated time points, proteins were labelled with
[35S] methionine (Figure 4.8). All viruses produced efficient levels of viral
proteins and host cell protein synthesis was shut-off by all mutant viruses to
a similar degree compared to WT virus (Figure 4.8(A and B)).
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(B)
Figure 4.7: Degradation of cellular polymerase II . Confluent monolayers of
A549 cells were infected with rWSN WT, rWSN PB2504, rWSN PA550 or rWSN
PB2504/PA550 at an MOI of 3 or Mock infected and cells were lysed at the indicated
time points. (A) 8% Bis-Tris gels were used to detect the cellular polymerase
using the antibodies 8WG16 and H5. 4 - 12% gradient Bis-Tris gels were used to
detect NS1. α-tubulin was used as an internal loading control. (B) Analysis of the
accumulation of the hypophosphorylated form of the cellular RNAPII. Mean values
of three independent experiments are plotted. Error bars represent the SEM. (C)
Analysis of the accumulation of the Ser2-P form of the cellular RNAPII. (D) Analysis
of the accumulation of NS1. Mean values of three independent experiments
are plotted and error bars represent the SEM. (E) At 24 hpi, supernatants were
harvested and viral titres were determined by plaque assay.
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Synthesis of the viral proteins was determined by measuring the
accumulation of NP and NS1/M1. The latter two proteins did not
separate efficiently on a 4-12% Gradient Bis-Tris gel to measure them
individually. When viral protein synthesis was quantified, slight differences
were observed. Early in infection, NS1/M1 and NP were produced to similar
levels or even at higher levels in cells infected with the polymerase mutant
viruses. However, later in infection de novo synthesis seemed to drop, and
less viral proteins were made, which could explain the attenuation seen in
viral growth (Figure 4.8 (C and D)).
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Figure 4.8: Host cell protein shut-off and de novo synthesis of viral proteins
by polymerases mutant viruses: MDCK cells were infected with the panel of
viruses at an MOI of 3. Proteins were labelled with [35S] methionine. (A) Cells were
lysed at 5 or 8 hpi and proteins were separated using a 4-12% gradient Bis-Tris gel.
(B) Host cell protein shut-off was quantified. (C and D) De novo synthesis of viral
proteins M1/NS1 and NP were quantified.
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4.5 Discussion
The aim of this work was the identification of amino acids in viral polymerase
proteins that are critical for the degradation of cellular RNA polymerase
II. Previous work showed that two variants of the influenza A virus strain
PR8 differed in their ability to induce degradation of the CTD of RNAPII.
Segment 1 and 3 gene products were identified to be involved in the
process (Rodriguez et al., 2009). Two amino acids were determined by
sequence alignments that differed between WSN and lvPR8 but were
identical between WSN and hvPR8 (Figure 4.3, 4.4). These two sites
were changed by site-directed mutagenesis and three mutant viruses were
rescued: two viruses with a single point mutation either in segment 1 or 3
and one double mutant virus. Although the mutant viruses showed defects
in viral growth (Figure 4.6), they did not show major differences in the
degradation of the cellular RNA polymerase II (Figure 4.7) or in shutting
off host cell protein synthesis (Figure 4.8). However, de novo synthesis of
viral proteins was impaired later in infection.
The degradation of the cellular RNA polymerase II was in the center
of several recent studies. However, findings varied regarding the
phosphorylation state that was targeted for degradation (Rodriguez et al.,
2007; Vreede et al., 2009). Whereas Rodriguez et al. only found that
the hypophosphorylated CTD was degraded, Vreede et al. also observed
a decrease of the phosphorylated forms of the RNAPII. However, this
latter finding was only seen in virus infected cells, but was absent in cells
transfected with plasmids that expressed the viral polymerase subunits. This
strongly suggests the involvement of other viral proteins in the process. A
recent report described an interaction between the viral RdRp and the cyclin
T1/CDK9 (Zhang et al., 2010a). Cyclin T1/CDK9 is a kinase responsible for
the phosphorylation of Serine 2-residues in the CTD and it was shown to
serve as an adaptor between the RdRp and the cellular RNAPII. If and to
what extent this interaction is involved in degradation of the phosphorylated
form of RNAPII is not known. The authors only reported degradation of
the non-phosphorylated RNAPII. If binding of the RdRp to the CTD in its
non-phosphorylated or Ser5-P forms is mediated directly, or via an adaptor
protein, could not be answered by their study (Zhang et al., 2010a).
Here, I only observed degradation of the hypophoshorylated form of the
CTD as shown by Rodriguez et al. and Zhang et al. (Rodriguez et al.,
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2007; Zhang et al., 2010a). It can be excluded that the differences seen
by Vreede et al. were due to virus strain specificities as all the mentioned
studies analysed A/WSN/33 (Rodriguez et al., 2007; Vreede et al., 2009;
Zhang et al., 2010a). However, the cause of the variations remain unknown.
The observation that the RdRp binds to the hyperphosphorylated CTD, but
degrades the non-phosphorylated RNAPII, needs further investigations to
understand the process in more detail.
A study by Rolling et al. demonstrated that the amino acids 504 in
PB2 and 550 in PA contribute to viral polymerase activity in A/PR/8/34
(Rolling et al., 2009). Isoleucine→valine (PB2504) and isoleucine→leucine
(PA550) increased polymerase activity, and led to enhanced virulence in
mice. Similarly, when changing the two residues in WSN to residues
that are present in the lvPR8 variant, the virus was less efficient in
replication as seen by the reduced viral titres. However, degradation of
cellular RNA polymerase II was not affected. Previously other sites in
the viral polymerase subunits were identified to contribute to the RNAPII
degradation. One residue within the polymerase subunit PA (T157A) was
reported to delay polymerase II degradation (Rodriguez et al., 2007). This
particular amino acid is identical in WSN, hvPR8 and lvPR8 and was
therefore not chosen in this experiment (Figure 4.4). However, it makes it
likely that additional residues are involved in the process of degradation
and a combination of several amino acids may be important. Therefore
changing one or two residues in A/WSN/33 might not have the desired
effect and further studies are needed to understand the mechanism and to
identify amino acids that are involved.
Degradation of cellular RNAPII is believed to add to the observed host
cell protein shut-off. This is a very powerful but also rigorous way for the
virus to prevent antiviral responses. Influenza A viruses have developed
a number of strategies that act in combination. Beside degrading cellular
RNA polymerase II, the non-structural protein NS1 in particular was found to
interfere with the expression of host cell proteins. For instance, the protein
was shown to interact with CPSF30, which leads to a general inhibition
of 3’ end processing of cellular pre-mRNA (Nemeroff et al., 1998). Also,
NS1 is involved in inhibition of the nuclear export of cellular mRNA (Fortes
et al., 1994). Because several mechanisms add to host cell shut-off, small
differences may be difficult to observe as they would be covered by other
strategies. One possible way to look at slight differences in host protein
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shut-off induced by degradation of RNAPII would, therefore, be the use of
an NS1 free system that could be realised by the use of an NS1-deletion
virus.
Taken together, the changes in viral replication observed by the
described recombinant viruses with mutations in PB2 and PA are likely due
to an altered polymerase activity rather than the loss of the ability to degrade
the cellular RNAPII. This attenuation may be caused by altered affinities
of the viral polymerase complex for cellular or viral interaction partners,
which led to the observed decrease in viral growth. The identification of
amino acids involved in the degradation of the RNAPII is likely to be more
complex. The process of degradation combines the requirement of correct
trimerisation of the viral polymerase subunits and binding to the CTD either
directly or via adaptor proteins which may be even different depending on
the phosphorylation state of the CTD.
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4.6 Summary Chapter 4
Three viruses carrying changes in segment 1 and 3 were engineered
(summarised in Table 4.3). The viruses with a single-point mutation and
the virus with a double mutation were analysed for their ability to degrade
the cellular RNAPII and to induce host cell protein shut-off.
Virus Mutation Degradation Phenotype
of RNAPII
rWSN PB2504 V504I + reduced levels of viral proteins
growth attenuation
rWSN PA550 L550I + reduced levels of viral proteins
growth attenuation
rWSN PB2504/PA550 PB2: V504I + reduced levels of viral proteins
PA: L550I growth attenuation
Table 4.3: Summary chapter 4: Mutations that were introduced into segment 1
and 3 to identify residues involved in the cellular polymerase II degradation.
The tested amino acid changes caused a growth attenuation and
the levels of de novo synthesised proteins were changed. However,
this attenuation was not due to a defect in the ability to degrade the
hypophosphorylated form of the CTD.
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GENERATION OF VIRUSES
EXPRESSING PB1-F2 AS A
SEPARATE ORF
Aims of Chapter 5
In order to freely study PB1-F2, it was planned to separate the PB1-F2
ORF from the PB1 ORF. This would allow the introduction of mutations and
deletions, without affecting the polymerase subunit PB1. Several strategies
were designed and tested for their expression of PB1-F2.
Insertion into segment 2 was done by three different strategies: the use of
an overlapping Stop-Start codon, the use of the self-cleaving 2A peptide
and the insertion of an internal viral promoter. Insertion into segment 6 and
7 was only done using the internal viral promoter.
It should be noted that the existence of N40 was not known when PB1-F2
was first separated from its original ORF and expressed in segment 2 as an
individual gene.
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5.1 Introduction
Insertion of foreign epitopes or even foreign genes into a viral genome has
become a powerful strategy to study virus replication in general, as well as
to design vaccines and therapeutics. Genome manipulation technologies
and reverse genetic systems are now available for many DNA and RNA
viruses (for a general overview see Section 1.3). A favoured method is
the engineering of a bicistronic gene and the rescue of infectious viruses
expressing the gene of interest. Often viral translation strategies are
exploited to secure the expression of the foreign gene. These strategies
include internal ribosomal entry sites (IRES), internal promoters, short
self-cleaving peptides or overlapping Stop-Start sequences (Garcı´a-Sastre
et al., 1994; Flick and Hobom, 1999b; Machado et al., 2003; Percy et al.,
1994; Kittel et al., 2005).
For the present study, three of these strategies were used in order
to introduce PB1-F2 into the viral genome as an individual gene. The
separation of the two ORFs was necessary to allow the study of PB1-F2
in more detail, as insertion of mutations would be restricted in the original
sequence context. Every point mutation would have to be carefully chosen
in order not to change the PB1 amino acid sequence. Therefore, the
PB1 and PB1-F2 coding sequences were separated. First, segment 2
was chosen for the insertion. It was hypothesised that expression of the
two genes from the same segment would be closer to the natural infection
situation as PB1 and PB1-F2 are both originally translated from segment 2.
In addition, PB1 and PB1-F2 have been shown to interact (Mazur et al.,
2008) and therefore expression at the same time and place within the
cell may be important. However, it is not known if, and to what extent,
this is essential. Three strategies were used for the insertion of PB1-F2
downstream of PB1: (1) via an internal promoter; (2) by using the short
self-cleaving 2A peptide derived from foot-and-mouth disease virus; and (3)
by introducing an overlapping UAAUG Stop-Start codon.
It was published before that insertion of a foreign gene into segment 6 using
an internal promoter was successful and the expression of the foreign gene
was stable over several passages. Therefore this strategy was also chosen
(Machado et al., 2003, 2006). All the mentioned strategies and the cloning of
the bicistronic segments are explained in more detail in the sections below.
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5.2 Strategies to express PB1-F2 separately in
segment 2
5.2.1 Inserting PB1-F2 via an overlapping Stop-Start
codon
Viruses have developed a number of strategies to initiate translation from
one messenger RNA. One of these strategies is termination-reinitiation by
an overlapping Stop-Start codon. The stop codon is in close proximity to the
downstream or even upstream start codon and this can lead to a coupled
termination-reinitiation process. It is known that this process also controls
the amount of the downstream product as the second ORF is translated at
low frequency (5-10%) (Child et al., 1999). In eukaryotic systems, upstream
ORFs are short (<13 codons) and they do not code for a full length protein.
However, they may downregulate the expression level of the second protein
(Kozak, 2001). Termination-reinitiation in viruses is different as the upstream
ORF can be much longer, often encoding a full-length functional protein.
This was first described for influenza B virus segment 7 (Horvath et al.,
1990). A pentanucleotide sequence UAAUG regulates the translation of the
matrix protein 1 (M1) and the ion channel protein BM2. The overlapping
Stop-Start strategy was later also described for several other virus families
including Caliciviridae and Paramyxoviridae (Figure 5.1) (Meyers, 2003,
2007; Ahmadian et al., 2000; Gould and Easton, 2005). The positions of
the stop and start codons vary in different viruses.
The insertion of a foreign gene into influenza A virus segment 8
using the overlapping Stop-Start mechanism was previously shown to be
successful (Kittel et al., 2005). GFP or the human interleukin gene IL-2
were inserted downstream of NS1. The virus was shown to be stable
over at least 5 passages in its ability to express the foreign gene and was
therefore chosen as one strategy. A bicistronic segment 2 was engineered
carrying the UAAUG Stop-Start pentanucleotide between PB1 and PB1-F2.
First, PB1-F2 expression in its original position was deleted by inserting
three point mutations as described in Section 3.2.1. This construct was
used as a template for inserting the PB1-F2 ORF downstream of PB1.
Two subsequent PCR reactions were performed to add the overlapping
Stop-Start pentanucleotide upstream of PB1-F2 as well as inserting 40 nt
of the 5’end of PB1 downstream of PB1-F2 (Figure 5.2). This was shown to
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Figure 5.1: Termination-reinitiation strategies: Overlaps showing the Stop-Start
cassette. They vary between the different viruses. Upstream motifs have been
shown to be important for the reinitiation event. Taken from (Powell et al., 2008b).
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be important for efficient packaging of the segment into viral particles (Liang
et al., 2005). Oligo sv34 containing the UAAUG pentamer sequence and the
two reverse oligos sv28 and sv40 including 40 nt of the PB1-sequence were
used for the PCR reactions. Nsi I was chosen as restriction enzyme and
sites were included in the newly created PB1-F2 construct. This site was
also introduced into pHH-∆ATG by site-directed mutagenesis using oligo
primers sv32 and sv33 (Figure 5.2 PCR 1-3). All primer sequences are
listed in Table 2.10. PCRs were done using the KOD hot start polymerase.
Following restriction enzyme digestion with Nsi I, the StSt-PB1-F2 construct
and pHH-∆ATG were fused. The Nsi I site between PB1 and PB1-F2 was
removed from the plasmid in a final PCR reaction (Figure 5.2). The obtained
plasmid was termed pHH-∆ATG-StSt-F2. After amplification in E.coli,
plasmids were screened by restriction enzyme digestion and promising
plasmids were sequenced to ensure correct insertion of the insert into
pHH-∆ATG.
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PCR 1 & 2   Creating StSt-PB1-F2 fragment
sv 34 sv  28
PCR 1
PCR 2
sv 34 sv 40
PCR 3   Introduction of NsiI restriction site
NsiI digestion of the fragment StSt-PB1-F2 and the plasmid pHH-delATG(NsiI) and Ligation
following a PCR to remove the NsiI restriction site
sv 32
sv 33
PB1-F2
PB1-F2
PB1-F2 end PB1
NsiI NsiI
PCR 4
sv38 / sv39
Figure 5.2: Schematic overview of the cloning of pHH-∆ATG-StSt-PB1-F2:
Two separate PCRs (PCR 1 and 2) were performed to create the fragment
StSt-PB1-F2. This fragment has an Nsi I restriction site near both ends.
Downstream of PB1-F2, 40 nt of the PB1 gene were inserted to ensure
correct packaging of the modified segment into viral particles. To prepare the
plasmid pHH-∆ATG for inserting the StSt-PB1-F2 fragment, an Nsi I restriction
site was created via site directed mutagenesis PCR (PCR 3). Nsi I digestion of
pHH-∆ATG(Nsi I) and the fragment StSt-PB1-F2 following ligation led to the plasmid
pHH-∆ATG-StSt-F2. Removal of the Nsi I sites via site directed mutagenesis
changed the second codon of PB1-F2 back into the original sequence (PCR 4). The
developed final plasmid pHH-∆ATG-StSt-F2 was used to rescue viruses carrying
PB1-F2 on segment 2 as an individual gene.
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5.2.2 The usage of the short self-cleaving 2A peptide
The self-cleaving 2A peptide derives from the foot-and-mouth disease virus
(Ryan et al., 1991). This (+) sense RNA virus belongs to the Picornaviridae
family and the genome serves as an mRNA in infected cells. After, but also
during translation, the polyprotein is cleaved into individual proteins by viral
proteases. One of these ’proteases’ is the short 2A sequence (Ryan et al.,
1991). Cleavage occurs at the C-terminus of 2A between a glycine and a
proline residue, by a process described as ribosomal skipping (Donnelly
et al., 2001). It was shown that 2A can be used to cleave the artificial
polyprotein CAT-2A-GUS (Ryan and Drew, 1994). Percy et al. adapted this
strategy and used it to express CAT from segment 6 in influenza A viruses
(Percy et al., 1994). Whereas this strategy was successful and viruses were
stable when passaged in MDCK cells, an attempt to insert GFP downstream
of a truncated NS1 gene using the 2A peptide was not (Lu et al., 2004).
Recently, a new attempt was made to insert GFP into the viral genome
by introducing the gene into segment 6 upstream or downstream of NA (Li
et al., 2010). The 2A autocleavage sequence was inserted between NA and
GFP. Addition of the N-terminus including the transmembrane domain of NA
fused to GFP made it possible to incorporate GFP into viral particle, which
may be a useful tool to study antiviral therapeutics.
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  

 
Figure 5.3: Sequence of the FMDV self-cleaving 2A peptide: PB1-F2 was fused
to PB1 via a FMDV self-cleaving 2A peptide. A XbaI restriction enzyme site was
introduced downstream of PB1 to insert the 2A-PB1F2 construct. 2A cleavage
occurs at its own C-terminus between a glycine and a proline. As a consequence,
PB1 has a C-terminal extension of 21 aa after cleavage and PB1-F2 carries a
proline at its N-terminus.
Here, I used the FMDV 2A sequence to express PB1-F2 from segment
2 as an individual ORF (Figure 5.3). PB1 and PB1-F2 were fused together
via 2A, creating one single ORF; 22 amino acids were inserted in total. This
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also included an XbaI restriction enzyme site between PB1 and 2A. During
translation, 2A is thought to cleave at its own C-terminus between a glycine
and proline residue. As a consequence, the released PB1 protein has an
addition of 21 amino acids at its C-terminus, and PB1-F2 carries a proline
at its N-terminus (Figure 5.3).
Cloning was done in several steps as summarised in Figure 5.4. PB1-F2
was amplified in two PCR reactions, in which the 2A sequence was added
upstream of PB1-F2 and 40 nt of the 5’end of PB1 were added downstream
of PB1-F2. This was shown to be necessary for efficient packaging of the
segment into viral particles (Liang et al., 2005). XbaI restriction enzyme
sites were used to insert the 2A-PB1-F2 construct into pHH-∆ATG. To do
this, an XbaI restriction enzyme site was introduced into the plasmid by site
directed mutagenesis PCR (PCR 3). Thereby, the stop codon was removed
from PB1 to create one long open reading frame that which will be ”cleaved”
by the 2A peptide during translation. Following ligation of 2A-PB1-F2 and
pHH-∆ATG, the obtained plasmid was further amplified in E. coli. All PCRs
were done using a KOD hot start polymerase according to the protocol
described in Section 2.4.2. A list of all primer sequences can be found
in Table 2.10. The plasmid obtained was named pHH-∆ATG-2A-F2 and
sequenced to ensure to correct insertion of the fragment 2A-PB1-F2.
121
CHAPTER 5 Insertion of PB1-F2 into Segment 2 and 6
PCR 1 & 2   Creating 2A-PB1-F2 fragment
sv 26 sv  28
PCR 1
PCR 2
sv 22 sv 27
PCR 3   Introduction of XbaI restriction site
XbaI digestion of the fragment 2A-PB1-F2 and the plasmid pHH-delATG(XbaI) following
Ligation to create the plasmid pHH-delATG-2A-F2
sv 07
sv 08
PB1-F2
PB1-F2
PB1-F22A end PB1
XbaI XbaI
Figure 5.4: Schematic overview of the cloning of pHH-∆ATG-2A-F2: Two
seperate PCRs (PCR 1 and 2) were performed to create the fragment 2A-PB1-F2.
This fragment has XbaI restriction enzyme sites near both ends. Downstream of
PB1-F2, 40 nt of the PB1 gene were inserted in order to ensure correct packaging of
the segment into viral particles. To prepare the plasmid for inserting the 2A-PB1-F2
fragment, an XbaI restriction site was created via site directed mutagenesis PCR
(PCR 3). This PCR also removed the stop codon of PB1. XbaI digestion of the
plasmid pHH-∆ATG(XbaI) and the fragment 2A-PB1-F2 following ligation led to the
final plasmid pHH-∆ATG-2A-F2 which was used to rescue viruses carrying PB1-F2
on segment 2 as an individual ORF.
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5.2.3 Use of an internal promoter
The demonstration that internal promoters are functional allowed a new
strategy for engineering bicistronic segments (Flick and Hobom, 1999b).
The 3’ and 5’ UTRs of each segment are highly conserved and serve as
viral promoters for vRNA, cRNA and mRNA synthesis. They interact with
each other to form a panhandle or corkscrew structure which is necessary
for transcription and replication of the viral genome (Hsu et al., 1987; Flick
et al., 1996). The insertion of a duplicated 3’UTR between two foreign genes
showed that both 3’UTRs can interact with the 5’UTR (Flick and Hobom,
1999b). This approach was used by Machado et al. to insert foreign genes
into segment 6 of A/WSN/33 (Machado et al., 2003). The insertion of CAT
was shown to be stable upon several passages. However, viral growth and
plaque size were restricted. An optimised strategy was published in 2006,
where 42 nt of the native neuraminidase ORF were added to the 5’UTR.
This helped efficient replication and packaging of the bicistronic segment
(Machado et al., 2006).
PB1-F2 with a 3’UTR upstream and 40 nt of the PB1-end coding sequence
was synthesised by the company GenScript. XbaI restriction enzyme sites
flanked the construct. This site was chosen to insert the PB1-F2 fragment
into the plasmid pHH-∆ATG. Before fusion of PB1-F2 and pHH-∆ATG was
possible, an XbaI restriction enzyme site also had to be inserted into the
plasmid pHH-∆ATG by site directed mutagenesis PCR (Figure 5.5 PCR 1).
Following ligation, the XbaI site between PB1 and the internal promoter
was removed by site-directed mutagenesis PCR (Figure 5.5). All primer
sequences are listed in Table 2.10. PCR reactions were done using the
KOD hot start polymerase (see Section 2.4.2). The plasmid obtained was
sequenced and named pHH-∆ATG-3’UTR-F2.
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3'UTR PB1-F2 end PB1
XbaI XbaI
Synthesis of the fragment 3'UTR-PB1-F2 PCR1    Introduction of XbaI restriction site
sv07
sv08
XbaI digestion of the fragment 3'UTR-PB1-F2 and the plasmid pHH-delATG(XbaI) and Ligation 
following a PCR to remove the XbaI restriction site to create the plasmid 
pHH-delATG-3'UTR-F2
PCR 2
sv61
sv62
Figure 5.5: Schematic overview of the cloning of pHH-∆ATG-3’UTR-F2: The
fragment 3’UTR-PB1-F2 was synthesised by the company GenScript. Beside XbaI
restriction sites on both ends, the fragment also holds 40 nt of the 5’end of the
PB1 gene downstream of the PB1-F2 ORF for packaging of the segment into virus
particles. To insert the fragment into pHH-∆ATG, an XbaI restriction enzyme site
was introduced via site directed mutagenesis PCR (PCR 1). After XbaI digestion of
the plasmid pHH-∆ATG(XbaI) and the fragment, both were combined to create the
plasmid pHH-∆ATG-3’UTR-F2. The XbaI site was removed from the intermediate
plasmid in a subsequent PCR by site directed mutagenesis (PCR 2).
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5.3 Rescue and characterisation of viruses
carrying PB1-F2 as an independent ORF in
segment 2
5.3.1 Rescue of viruses with a bicistronic segment 2
Virus rescues were done as before using the 12-plasmid rescue system (see
Section 2.2.2 and 3.3.1). The plasmid encoding WT segment 2 (pHH-PB1)
was individually exchanged with either of the plasmids containing
PB1-F2 in a separate ORF (pHH-∆ATG-StSt-F2; pHH-∆ATG-2A-F2;
pHH-∆ATG-3’UTR-F2). Rescue supernatants were used for plaque assay
and single plaques were picked to grow up viral stocks.
Viruses with an overlapping Stop-Start cassette and the self-cleaving
2A peptide were successfully rescued. However, the rescues using
pHH-∆ATG-3’UTR-F2 did not show any CPE after several days and
no plaques were observed following plaque assay. Therefore, only
rWSN ∆AUG-StSt-F2 and rWSN ∆AUG-2A-F2 were available for further
characterisation. To ensure the correctness of the viral stocks, MDCK cells
were infected at an MOI of 3 and RNA was isolated and used in an RT-PCR
reaction in order to sequence the obtained PCR product. Two parts of
segment 2 were amplified and sequenced: (1) the original PB1-F2 location
to ensure the inserted mutations to delete PB1-F2 were still in place, and
(2) the junction of PB1 and PB1-F2.
5.3.2 Characterisation of viruses with a bicistronic
segment 2
Expression of both proteins from the biscistronic segment was determined
by western blot analysis. MDCK cells were infected with the different viruses
at an MOI of 3 and at 8 hpi, cells were lysed and proteins were separated by
SDS-PAGE. As can be seen in Figure 5.6(A), viral proteins NS1 and PB1 are
expressed in all infected cells to similar quantities. As expected, N40 was
overexpressed in cells infected with the bicistronic segment 2 viruses, as
they carry a deletion of the start codon to abolish PB1-F2 in the original ORF
(∆AUG). This mutation caused an up-regulation of N40 as shown in Chapter
3. It was also tested if PB1-F2 can be expressed from the additional ORF
(Figure 5.6(B)). Unfortunately only WT infected cells showed expression of
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PB1-F2. However, it is possible that the level of expressed PB1-F2 from the
individual ORF was low and therefore below the detection limit.
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Figure 5.6: Western blot analysis of viruses with a bicistronic segment 2:
MDCK cells were infected with a panel of recombinant viruses and viral protein
expression was determined 8 hpi. (A) 4 - 12% Bis-Tris gradient Bis-Tris gels were
used to detect PB1, N40 and NS1. (B) 16% Tricine-SDS-PAGE was used to detect
PB1-F2. α-tubulin was used as an internal loading control.
Monolayers of MDCK cells were infected with serial dilutions of the virus
and 1 or 3 dpi tested for their ability to form plaques (Figure 5.7). All viruses
were capable of inducing CPE in immuno-competent cells. However, striking
differences were observed regarding plaque size. Recombinant viruses with
an overlapping Stop-Start cassette were ∼ 22% smaller on day 3 compared
to WT plaques. rWSN ∆AUG-2A-F2 viruses showed a reduction of 40%
in plaque size. The differences between WT and mutant virus plaque size
were significant, when analysed by Student’s t-test (* P<0.05; *** P<0.001).
To further investigate the characteristics of the recombinant viruses
carrying PB1-F2 as an individual ORF in segment 2, the growth properties
were analysed. MDCK cells were infected with the different viruses at
either low or high MOI (0.001 or 3, respectively) for multi-step or single-step
growth curve. At indicated time points, supernatants were harvested and
viral growth was measured by plaque assay. As can be seen in Figure
5.8, viruses with an extended genome length grew to lower titres under
both conditions. In agreement with plaque sizes, rWSN ∆AUG-StSt-F2 was
less attenuated than rWSN ∆AUG-2A-F2. Viruses with the self-cleaving 2A
peptide grew more slowly especially early in infection.
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rWSN WT rWSN ΔAUG-StSt-F2 rWSN ΔAUG-2A-F2
Figure 5.7: Plaque Assay of viruses with a bicistronic segment 2: Confluent
monolayers of MDCK cells were infected with recombinant viruses. Cells were
overlayed with 1.2% Avicel-DMEM and incubated for 3 days (top panel) or 24 h
(bottom panel) at 37°C . Mean values for ∼30 plaques/recombinant virus (3 dpi)
are plotted and error bars represent the SEM. Differences in plaque sizes are
significant between rWSN WT and rWSN ∆AUG-StSt-F2 or rWSN ∆AUG-2A-F2
virus ( Student’s t-test : * P<0.05; *** P<0.001).
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(A)
(B)
Figure 5.8: Growth of viruses with a bicistronic segment 2: Triplicate MDCK
monolayers were infected with the recombinant WSN viruses WT, ∆AUG-StSt-F2
and ∆AUG-2A-F2 at an (A) MOI of 0.001 for multi-step growth curve and (B) MOI 3
for single-step growth curve. For multi-step growth curve, media was supplemented
with N-acetyl trypsin. Supernatants were harvested at the indicated time points post
infection and virus titres were determined by plaque assay. Error bars represent the
SEM of each set of triplicates.
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One reported function of PB1-F2 was the induction of apoptosis
specifically in immune cells. As shown in Chapter 3 (Figure 3.12),
recombinant viruses lacking the PB1-F2 ORF (∆AUG) were attenuated in
their ability to reduce cell viability in a mouse macrophage cell line (RAW/W).
Although no expression of PB1-F2 was detected by western blotting, an
attempt was made to test if the reinsertion of PB1-F2 into the viral genome
had any effect. Monolayers of MDCK cells and RAW/W cells in 96 well
plates were infected with the recombinant viruses at an MOI of 30 and cell
viability was measured 8 h later using a commercially available assay. As
shown in Figure 5.9, MDCK cells show a similar reduction in cell viability
for all viruses. These cells were not targeted for apoptosis by PB1-F2. A
different pattern was observed for infected RAW/W cells. rWSN WT viruses
reduced cell viability, but no difference was observed between rWSN∆AUG,
rWSN ∆AUG-StSt-F2 and rWSN ∆AUG-2A-F2 viruses.
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Figure 5.9: Induction of apoptosis by viruses with a bicistronic segment 2:
Triplicate monolayers of MDCK and RAW/W cells in 96-well plates were infected
with the panel of viruses at an MOI of 30 and tested for their viability after 8 h. PBS
was used as a control. Mean values ± SEM are plotted.
Various possibilities could explain the observed phenotypes: (1) PB1-F2
is not expressed from a bicistronic segment 2; (2) the expression level of
PB1-F2 is too low; (3) PB1-F2 itself is not responsible for the attenuation; or
(4) the extended genome length counteracts any impact of PB1-F2.
To insert mutations into PB1-F2 and study the effects of these changes, it is
an absolute requirement to restore the phenotype of WT viruses compared
to deletion viruses. However, no PB1-F2 was detected and phenotypes
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were still comparable to rWSN ∆AUG virus. Introduction of PB1-F2 into
segment 2 therefore may not be ideal. Additionally, when these constructs
were made, N40 had not yet been identified and all viruses were made in
the ∆AUG background.
5.4 Strategies to express PB1-F2 separately in
segment 6 and segment 7
5.4.1 Insertion of PB1-F2 into segment 6 via duplicated
3’UTR sequence
No PB1-F2 was detected in cells infected with viruses carrying a bicistronic
segment 2. Therefore a different strategy was evaluated. Insertion of foreign
genes into segment 6 has been reported previously (Machado et al., 2003,
2006). Different ORFs were successfully introduced downstream of NA
(Figure 5.10). To insert VP01, CAT or GFP into segment 6, the 3’UTR was
duplicated and inserted as an internal promoter between NA and the gene
of interest. The foreign gene itself was inserted via a multiple cloning site.
70 nucleotides containing the end of the neuraminidase gene and the 5’UTR
were added
the inserted gene to ensure the correct packaging and functionality of
the segment (Figure 5.10).
Figure 5.10: Schematic structure of bicistronic segment 6: VP0c, CAT or GFP
was inserted between XhoI and NheI. Downstream of the internal promoter and
the second ORF is an extended 5’ region containing the last 42 nt of NA and the
5’UTR. Taken from Machado et al. (2006).
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The strategy of Machado et al. was used as a model for the insertion
of PB1-F2 downstream of NA and M2 in segment 6 and 7, respectively.
As proof of principle to show functionality of the construct, mCherry was
inserted instead of PB1-F2. Figure 5.11 shows the cloning strategy for
inserting PB1-F2 or mCherry into segment 6. First, an internal BsmBI
restriction site was removed by an overlap PCR. At the same time, the
internal promoter and the multi-cloning site were added downstream of NA.
Before the construct was ligated into pGEMT Easy, 42 nt of the end of the
NA ORF plus the 5’UTR were added (Figure 5.11(A)). In parallel, restriction
enzyme sites XhoI and NheI were added upstream and downstream of
PB1-F2 or mCherry by PCR (Figure 5.11(B)). pGEMT Easy-NA and the
insert were fused together and subsequently inserted into pHH21 via BsmBI
sites (Figure 5.11(C)). All primer sequences are listed in Chapter 2 in Table
2.10. PCRs were done using the KOD hot start polymerase according to the
protocol described in Section 2.4.2.
5.4.2 Insertion of PB1-F2 into segment 7 via duplicated
3’UTR
Similar to segment 6, segment 7 was prepared for the insertion of PB1-F2
or mCherry. As can be seen in Figure 5.12(A), 4 sequential PCR reactions
were performed to introduce the internal promoter, the multiple cloning
site and 42 nt of the end of the ORF of M2. The construct was flanked
by BsmBI restriction enzyme sites and it was inserted into pGEMT Easy.
PB1-F2 or mCherry were prepared as described above for the insertion into
segment 6. After ligation of pGEMT Easy-M and the insert, the bicistronic
segment 7 was inserted via BsmBI into pHH21 (Figure 5.12(C)). All primer
sequences are listed in Table 2.10. PCRs were done using the KOD hot
start polymerase according to the protocol described in Section 2.4.2.
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(A)
PCR 1-3 Removal of an internal BsmBI restriction site in segment 2
NA3'UTR BsmBI
sv117 sv122
PCR 1
sv121 sv118PCR 2
3'UTR
BsmBI
XhoI
3'UTR
sv121 sv119
3'UTR
XhoINheI
PCR 3
overlap-PCR
sv117 sv119
3'UTR 3'UTRNA
BsmBI XhoI
NheI
PCR 5
sv120sv117
NA3'UTR 3'UTR
BsmBI BsmBIXhoI
NheI
NAend
Ligation into pGEMT Easy
Restriction digest of pGEMT Easy-NA with XhoI and NheI and insertion 
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Figure 5.11: Schematic overview of the engineering of pHH-NA-3’UTR-F2: (A)
Several PCR reactions were performed to insert the internal promoter, a multiple
cloning site and 42 nt of NA downstream of NA. At the same time, an internal
BsmBI restriction site was removed from NA. The construct was finally inserted
into pGEMT Easy. (B) PB1-F2 was amplified and restriction enzyme sites were
introduced upstream and downstream of the ORF to allow insertion into segment
6. As an alternative to PB1-F2, mCherry was amplified. (C) PB1-F2 was inserted
via XhoI and NheI into pGEMT Easy-NA. The bicistronic segment 6 was finally
inserted into pHH21 via BsmBI restriction sites.
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Figure 5.12: Schematic overview of the engineering of pHH-M-3’UTR-F2: (A)
Several PCR reactions were performed to insert the internal promoter, a multiple
cloning site and 42 nt of M downstream of M. The construct was finally inserted
into pGEMT Easy. (B) PB1-F2 was amplified and restriction enzyme sites were
introduced upstream and downstream of the ORF to allow insertion into segment
7. Additional to PB1-F2, mCherry was amplified. (C) PB1-F2 was inserted via XhoI
and NheI into pGEMT Easy-M. The bicistronic segment 7 was finally inserted into
pHH21 via BsmBI restriction sites.
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5.5 Virus rescue and characterisation of the
viruses with an internal promoter
5.5.1 mCherry and PB1-F2 expression from biscistronic
segments 6 and 7
To determine if the constructs were functional, a mini-genome assay was
performed. Four plasmids expressing the polymerase subunits and the
nucleoprotein were transfected into 293FT cells together with plasmids
expressing viral RNA for bicistronic segment 6 or 7. As shown in Figure
5.13, mCherry was expressed successfully from segment 7, whereas no
expression of mCherry was observed from segment 6. Plasmid pJC3, that
expresses GFP-2A-mCherry under the control of a CMV promoter, served
as a positive control and western blot analysis confirmed expression of
mCherry from segment 7.
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Figure 5.13: Expression of mCherry and PB1-F2 from bicistronic segment
6 and 7: (A) Transfection of four plasmids expressing the polymerase subunits
and the bisistronic segment 6 or 7 into 293FT cells. (B) M-Cherry expression was
determined by immunofluorescence of the transfected 293FT cells. No bisistronic
segment was transfected as a negative control. pJC3 was used as a positive
control, which expressed GFP-2A-mCherry under a CMV promoter. (C) Western
blot analysis to confirm expression of mCherry.
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virus segment 2 bicistronic segment
rWSN ∆AUG/NA-F2 ∆AUG NA-F2
rWSN F2-11/NA-F2 F2-11 NA-F2
rWSN NA-mCherry WT NA-mCherry
rWSN ∆AUG/M-F2 ∆AUG M-F2
rWSN M-mCherry WT M-mCherry
Table 5.1: Viruses rescued with bicistronic segments 6 or 7
Although the bicistronic segment 6 was negative for the expression of
mCherry in the minigenome assay, all bicistronic segments were used to
rescue recombinant viruses. Rescues were performed using the 12-plasmid
rescue system described in Sections 2.2.2 and 3.3.1. Table 5.1 shows
the plasmid combinations used to rescue viruses expressing mCherry or
PB1-F2 from segment 6 and 7. All viruses could be rescued, however no
mCherry expression was observed in cells infected with rWSN NA-mCherry
or rWSN M-mCherry viruses (data not shown).
Different recombinant virus versions were rescued carrying PB1-F2 in
segment 6 or 7 (Table 5.1). The PB1-F2 ORF in its original position
was always deleted by either three or two mutations (∆AUG or F2-11,
respectively). To determine expression of PB1-F2 from segment 6 and
segment 7, MDCK cells were infected with recombinant viruses rWSN
∆AUG/NA-F2, rWSN F2-11/NA-F2 or rWSN∆AUG/M-F2 at an MOI of 3 and
cell lysates were analysed 8h later by western blotting. As shown in Figure
5.14, only viruses with a bicistronic segment 6 expressed PB1-F2. No
PB1-F2 was detected in cells infected with rWSN ∆AUG/M-F2. Compared
to WT infected cells, PB1-F2 was produced at much higher levels in cells
infected with NA-F2 viruses. As seen before, the level of N40 was much
higher in cells infected with viruses that have a ∆AUG mutation.
5.5.2 Phenotypic characterisation of viruses with a
bicistronic segment 6
Viruses with the bicistronic segment 7 did not show any expression of
PB1-F2, therefore only recombinant viruses with segment 6-F2 were used
135
CHAPTER 5 Insertion of PB1-F2 into Segment 2 and 6
PB1
N40
PB1-F2
long exposure
PB1-F2
short exposure
NS1
α-tubulin
MO
CK
rW
SN
 ΔA
UG
/
NA
-F2
rW
SN
 F2
-11
/
NA
-F2
rW
SN
 W
T
MO
CK
rW
SN
 W
T
rW
SN
 ΔA
UG
rW
SN
 ΔA
UG
/
NA
-F2
rW
SN
 ΔA
UG
/
M-
F2
PB1
N40
PB1-F2
α-tubulin
Figure 5.14: Expression of PB1-F2 from bicistronic segment 6 and 7: MDCK
cells were infected with a panel of recombinant viruses and at 8 hpi, viral protein
expression was determined. 4 - 12% gradient Bis-Tris gels were used to detect
PB1, N40, NS1 and α-tubulin. 16% Tricine-SDS-PAGE was used to detect
PB1-F2. Because PB1-F2 is overexpressed in cells infected with viruses carrying
a bicistronic segment 6, short and long exposures of the blot are shown.
for further analyses. Confluent monolayers of MDCK cells were infected with
serial dilutions of NA-F2 viruses and overlayed with 1.2% Avicel-DMEM.
Incubation for 24 or 72 h was followed by fixing and staining either of the
cell monolayers with crystal violet or immunostaining of virus infected cells
using anti-Udorn antibodies (Figure 5.15). The plaque sizes were different
to those of WT observed at 24 or 72 hpi and measurement of the diameter
of several plaques (3 dpi) showed that viruses with a bicistronic segment 6
had a significant reduction in plaque size by ∼40 % (Students t-test : P <
0.0005).
Although PB1-F2 was overexpressed from segment 6, no increase in
plaque size compared to rWSN ∆AUG was observed. Furthermore, plaque
size of viruses with two point mutations in segment 2 (rWSN F2-11/NA-F2)
was also reduced, whereas rWSN F2-11 viruses had a plaque phenotype
comparable to WT viruses. Confluent MDCK cells were infected with
bicistronic viruses at an MOI of 0.001 and cell supernatants were taken for
virus growth analysis. As can be seen in Figure 5.16, viruses containing a
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rWSN WT rWSN ΔAUG/NA-F2 rWSN F2-11/NA-F2 Figure 5.15: Plaque assay
of viruses with a bicistronic
segment 6: Confluent
monolayers of MDCK cells
were infected with the panel
of recombinant viruses.
Cells were overlayed with
1.2% Avicel-DMEM and
incubated at 37°C for 3 days
(top panel) or 24 h (bottom
panel). Mean values for ∼30
plaques/recombinant virus
(3 dpi) are plotted and error
bars represent the SEM.
Differences in plaque sizes
are significant between rWSN
WT and rWSN ∆AUG/NA-F2
or rWSN F2-11/NA-F2 virus
(*** P<0.001)
bicistronic segment in combination with segment 2 -∆AUG were attenuated
by about 100-fold compared to WT viruses. Viruses with segment 2-F2-11
grew similar to WT viruses. This phenotype had already been seen for
viruses with PB1-F2 deletions (Figure 3.10(A)).
5.5.3 Bicistronic segment 6 and the consequences on
virulence
It was suggested that PB1-F2 is involved in the virulence of influenza A
viruses (Zamarin et al., 2006; McAuley et al., 2007). Viruses not expressing
PB1-F2 were shown to be attenuated, but only if the start codon of PB1-F2
was removed (Chapter 3). Viruses with a bicistronic segment 6 were shown
to overexpress PB1-F2 compared to WT viruses. These viruses were used
to test any effect PB1-F2 may have in vivo. Female BALB/c mice, 6-7 weeks
old, were infected with the different viruses or with PBS as negative control;
8 mice per group were inoculated intranasally with 5x103 pfu. The weight
of each mouse was observed daily. On day 4 and day 7, 4 mice per group
were culled and lungs were used to measure the virus lung titre.
As can be seen in Figure 5.17(A), both bicistronic viruses did not cause
any weight loss in infected mice. No difference was observed compared to
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Figure 5.16: Growth of viruses with a bicistronic segment 6: Triplicate MDCK
monolayers were infected with the recombinant WSN viruses WT, ∆AUG/NA-F2
and F2-11/NA-F2 at an MOI of 0.001 for multi-step growth curve. Media was
supplemented with N-acetyl trypsin. Supernatant was harvested at indicated time
points post infection and virus titres were determined by plaque assay. Error bars
represent the SEM of each set of triplicates.
PBS infected mice. WT infected mice on the other hand lost weight rapidly.
Virus titres in lungs of mice infected with WT viruses were up to 107 pfu/ml
on day 4 and only decreased to ∼106 pfu/ml on day 7. Mice infected with
the NA-F2 viruses had a 100-1000-fold difference in virus lung titres on day
4. On day 7, almost no virus was detectable and the titre of 2 or 3 mice
infected with rWSN ∆AUG/NA-F2 and rWSN F2-11/NA-F2 was below the
detection limit (Figure 5.17(B)). It seems that these viruses were not able to
efficiently replicate in a host under the pressure of the immune system. As
seen for growth curves in MDCK cells before, rWSN F2-11/NA-F2 viruses
grew slightly better in lungs of infected mice than rWSN ∆AUG/NA-F2
viruses, however both recombinant viruses were almost cleared from lungs
of infected mice by day 7.
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Figure 5.17: Weight and virus lung titres of mice infected with bicistronic
segment 6 viruses: Groups of 8 female BALB/c mice were infected with the
recombinant WSN viruses WT, ∆AUG/NA-F2 and F2-11/NA-F2 with 5x103 pfu. (A)
Weight loss was measured every day over a period of 7 days. Day 0 was set as
100% for each group. (B) At day 4 and day 7, 4 mice of each group were culled and
lung virus titres were determined by plaque assay. Mean values ±SEM are plotted.
Student’s t-test : * P<0.05; ** P<0.01. Mouse infections were done in collaberation
with B. Dutia and her lab at the University of Edinburgh.
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5.6 Stability of bicistronic segments over 10
passages
Genetic stability of the bicistronic segments is critical for the functional
analysis of the inserted ORF and the foreign gene may be lost over time
(Kittel et al., 2004; Lu et al., 2004). However, previous work showed that it
is possible to stably insert a foreign ORF into segment 6 of the viral genome
(Percy et al., 1994; Machado et al., 2003, 2006). The arrangement of the
chimeric segment was thereby important for the stability.
The four bicistronic viruses encoding PB1-F2 as a separate ORF were
passaged 10 times in MDCK cells at low MOI. Besides western blot analysis
to detect PB1-F2 expression and analysis of the plaque phenotype, segment
2 or 6 RNA was amplified in an RT-PCR reaction to determine the stability
of the segment.
Figure 5.18 shows the plaque phenotype of all viruses at passages 1, 5
and 10. Recombinant viruses with an additional ORF gave smaller plaques
than WT at passage 1. However, at passage 10 all viruses, except rWSN
∆AUG-2A-F2, had increased their plaque size significantly (Figure 5.18).
This suggests that the viruses may have accumulated mutations that helped
to replicate the bicistronic segment or the additional ORF was removed from
the viral genome.
To test this, MDCK cells were infected with the panel of recombinant viruses
and cell lysates were analysed for the expression of PB1-F2 and NS1 by
Western blotting (Figure 5.19). As shown by detection of NS1, viruses were
propagated efficiently until passage 10. One exception was the recombinant
virus ∆AUG-2A-F2 where no viral proteins could be measured at passage
10. The reason for this is unknown, as plaques were obtained using the
supernatant of the same passage. As before, no PB1-F2 was detected
in cells infected with viruses with a bicistronic segment 2. Therefore, no
conclusion could be made as to whether PB1-F2 still existed as a separate
ORF.
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Figure 5.18: Plaque phenotype of viruses with bicistronic segments after
serial passages: MDCK cells were infected with a serial dilution of the recombinant
viruses. Passage 1 is shown on the top, passage 5 in the middle, passage 10 at the
bottom. Mean values for ∼20 plaques per virus and passage number (3 dpi) are
plotted and error bars represent the SEM. Student’s t-test : * P<0.05; *** P<0.001
141
CHAPTER 5 Insertion of PB1-F2 into Segment 2 and 6
For viruses with a bicistronic segment 6, high levels of PB1-F2 were
observed at a low passage number. However, the level of PB1-F2
decreased by passage 5 and at passage 10 almost no PB1-F2 was detected
in cells infected with rWSN F2-11/NA-F2 viruses. Cells infected with rWSN
∆AUG/NA-F2 viruses showed a different pattern for passage 10. Two bands
were observed, one at the expected size of PB1-F2, but also a smaller band.
This may be due to the loss or the deletion of part of the ORF (Figure 5.19).
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Figure 5.19: Western blot analysis of viruses with bicistronic segments after
serial passage: MDCK cells were infected with a panel of recombinant viruses
and at 8 hpi viral protein expression was determined. 4 - 12% gradient Bis-Tris gels
were used to detect NS1 and α-tubulin. 16% Tricine-SDS-PAGE was used to detect
PB1-F2.
The observed phenotypes suggested that the PB1-F2 ORF was removed
from the bicistronic segments. To evaluate this, MDCK cells were infected
with the panel of viruses derived from the different passages. Total RNA was
extracted from cells and used in an RT-PCR reaction to amplify segment
2 or 6 (Figure 5.20). Oligonucleotides used for the PCRs were designed
to anneal within PB1 or NA and the corresponding 5’UTR. Viruses with a
full-length bicistronic segment 2 were expected to give products of 488 nt
or 552 nt (StSt-F2 or 2A-F2, respectively). WT segment 2 was expected to
give a product of only 175 nt. Figure 5.20(A) shows the result of the RT-PCR
reaction for biscistronic segment 2 viruses. Viruses with an overlapping
Stop-Start codon seem to lose PB1-F2 after several passages. RT-PCR
products of RNA extracted from viruses at passage 2 had the expected
size of 488 nt, by passage 5, two bands were observed. The shorter band
corresponds to the size of WT segment 2. At passage 10, only the WT
band remained. On the other hand, rWSN ∆AUG-2A-F2 virus seemed to
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be stable up to passage 10 in MDCK cells. All bands were extracted from
the gel and the nucleotide sequence was determined.
Figure 5.20: RT-PCR analysis of viruses with bicistronic segments after serial
passages: The stability of (A) a bicistronic segment 2 and (B) a bicistronic segment
6 was analysed by RT-PCR using oligonucleotides binding at the end of PB1 or NA
and within the 5’UTR. Expected product size are shown in the graphics. Products
were extracted from the 1% agarose gel and sequenced.
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This confirmed the loss of the PB1-F2 ORF in rWSN ∆AUG-StSt-F2
virus. It was also confirmed that rWSN ∆AUG-2A-F2 virus was stable
up to passage 10. All bicistronic segment 6 carrying viruses show a
pattern that would suggest a partial loss of the downstream ORF (Figure
5.20(B)). The large band with an approximate size of 500 bp matches the
expected size of the bicistronic segment and the lower band is about the
size of the WT segment. Both bands were extracted from the agarose gel
and their nucleotide sequence was determined. As expected, the upper
band represents a bicistronic segment 6. However, the smaller band did
not align with any part of segment 6 or PB1-F2 but it was found to be
a non-specific product corresponding to segment 3. A thin intermediate
size product was also found for rWSN∆AUG/NA-F2 at passage 10, which
may be a degradation product of PB1-F2. Although this PCR product was
not sequenced, it would explain the finding observed in the western blot
analysis (Figure 5.19). In summary, it seems that RNA segments with an
internal promoter are stable until at least passage 5, but a fraction may
partially lose the downstream ORF after that.
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5.7 Discussion
The aim of this Chapter was the engineering of a virus that expressed
PB1-F2 from an independent ORF. This detachment from the PB1 ORF
would make PB1-F2 accessible for inserting mutations or deletions. Also,
PB1-F2 could be tagged by short sequences (e.g. V5 epitope tag),
because the applications of the available antibody were limited. This would
allow the study of its localisation within the cell by immunofluorescence
in the context of a viral infection or the search for interacting partners by
immunoprecipitations.
Three segments with different options were tested for expressing PB1-F2
or mCherry (overview in Table 5.2). However, only PB1-F2 expression from
segment 6 was efficient.
A variety of potential reasons why the expression of mCherry from segment
6 and 7 and PB1-F2 from segment 2 and 7 was not successful will be
discussed.
Until now, only insertions of foreign genes into segment 6 and 8 have been
reported. Here, I inserted PB1-F2 into segment 2, which is one of the largest
segments in the viral genome. This was chosen because of the supposed
advantage the expression of PB1-F2 from its original segment may have
had. Strategies tested were: (1) an internal promoter, (2) an overlapping
Stop-Start cassette, and (3) a short self-cleaving 2A peptide that derived
from foot-and-mouth disease virus. Although viruses with a 2A sequence
and the Stop-Start cassette could be rescued, none of the recombinant
viruses expressed PB1-F2.
Termination-reinitiation is naturally used by influenza B viruses. Recently, it
was shown that the success of reinitiation depends on the sequence directly
upstream the Stop-Start-cassette. This sequence is now known as TURBS
(termination upstream ribosome binding site) (Powell et al., 2008a, 2011).
The combination of two facts may be the reason why expression from this
segment was not successful: (1) naturally only ∼10% of the ribosomes
reinitiate at the downstream start codon and therefore the expression level
of PB1-F2 may be too low for detection, and (2) the upstream sequence of
PB1 does not contain TURBS. Additionally, this bicistronic segment was not
stable and PB1-F2 sequence was lost gradually following passage in MDCK
cells.
Although PB1-F2 ORF was stably inserted into segment 2 using the FMDV
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(1) ∆AUG: Segment 2 with three point mutations
Bicistronic segment Virus Strategy
segment 2 ∆AUG-F2 rWSN ∆AUG-StSt-F2 overlapping StopStart
segment 2 ∆AUG-F2 rWSN ∆AUG-2A-F2 self-cleaving 2A peptide
segment 6 NA-F2 rWSN ∆AUG/NA-F2 internal promoter
segment 7 M-F2 rWSN ∆AUG/M-F2 internal promoter
(2) F2-11: Segment 2 with two point mutations
Bicistronic segment Virus Strategy
segment 6 NA-F2 rWSN F2-11/NA-F2 internal promoter
(3) WT: Segment 2 without mutations
Bicistronic segment Virus Strategy
segment 6 NA-mCherry rWSN NA-mCherry internal promoter
segment 7 M-mCherry rWSN M-mCherry internal promoter
Table 5.2: Summary of viruses rescued with a bicistronic segment: PB1-F2
or mCherry were inserted into segment 2, 6 or 7 and rescued in combination with
segment 2 with or without mutations to knock-out PB1-F2.
2A peptide, no PB1-F2 protein was detected in infected cells. The efficiency
of the cleavage of artificial proteins was previously reported to be ∼80%
(Ryan and Drew, 1994). However, the immediate sequence upstream of 2A
was shown to have some importance in the efficiency of cleavage (Donnelly
et al., 1997). Also, 2A and ’2A-like’ sequences form an α-helix which may be
important for the ribosomal skipping process (Donnelly et al., 1997, 2001).
The secondary structure of the nascent PB1 may interfere with the correct
formation of the secondary structure of 2A and therefore with the cleavage.
The amounts of PB1-F2 produced may also be very low and below the
detection limit because of the severe attenuation of the virus, especially at
early times in infection. The antibody used to detect PB1-F2 often resulted
in high background in western blot analysis, and long exposure times to
detect small amounts of proteins were challenging. Previously, the insertion
of a CAT gene upstream of segment 6 with the use of 2A was shown to
be successful, however, the attempt to engineer a bicistronic segment 8
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containing GFP was not (Percy et al., 1994; Lu et al., 2004). This suggests
that the segment as well as the inserted gene may be important for the
success of this strategy.
It was suggested that the genome size may limit the application of inserting
foreign genes into the influenza A virus genome (Garcı´a-Sastre et al.,
1994; Machado et al., 2003). Insertion of PB1-F2 downstream PB1 via 2A
increased the segment size to over 2700 nt. Regardless, the virus appeared
very flexible and the bicistronic segment was packed into virus particles and
viruses stably maintained the segment.
Figure 5.21: Replication and transcription of bicistronic segments: Scheme of
replication and transcription of a bicistronic segment carrying GFP and CAT joint by
an internal promoter. The 5’UTR can interact with the outer 3’UTR and transcription
leads to the formation of a bicistronic mRNA and GFP expression (left). Interaction
of the 5’UTR with the internal promoter results in the transcription and replication
of a monocistronic RNA and the expression of CAT (right). Taken from Flick and
Hobom, 1999.
Another approach that was chosen to insert PB1-F2 into the viral genome
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was the use of an internal promoter in segment 2 or segment 6. Whereas a
bicistronic segment 2 carrying an internal promoter could not be rescued,
a bicistronic segment 6 was successful and PB1-F2 was expressed in
high quantities. Expression levels even exceeded WT levels. One reason
for this may be a different activity of the segment 6 promoter. PB1-F2
was inserted downstream of the original ORF, so that the second ORF
would be maintained during replication. It was shown by Flick et al. that
internal promoters result in the formation of subgenomic RNAs expressing
the downstream gene (Figure 5.21) (Flick and Hobom, 1999b; Machado
et al., 2006). This would subsequently lead to the loss of the upstream
gene if this was not essential for the virus. A short subgenomic segment,
only encoding PB1-F2, is likely to be generated in infected cells, which
could be also included as a ninth segment into viral particles. It also could
compete with the full-length bicistronic segment, which would, if selected
instead of the long bicistronic segment, lead to the formation of defective
interfering (DI) particles (Figure 5.21). Additionally, it was reported that the
expression levels of neuraminidase were lower compared to WT infected
cells (Machado et al., 2003).
The plaque sizes of rWSN ∆AUG/NA-F2 and rWSN F2-11/NA-F2 were
smaller compared to WT viruses, which can be explained by the points
discussed above. However, plaque size increased after several passages.
Although the insertion of a foreign gene into segment 6 was previously
shown to be stable up to passage 6, PB1-F2 may be partially removed
from segment 6 after passage 5. This would explain the increase in plaque
size after several passages as well as the appearance of a short PB1-F2
fragment detected in Western blot analysis. The attempt to insert a foreign
gene into segment 7 was not successful. Although mCherry expression was
observed in a minigenome assay, the rescued viruses did not express the
fluorescent protein. The insertion of a gene downstream of M2 may interfere
with the splicing of M1 mRNA. A different reason was discussed by Machado
et al. (Machado et al., 2003, 2006). The authors suggested that the high
GC content of GFP may inhibit viral replication. A similar GC content of over
60% was calculated for mCherry, whereas the WSN genome only has a GC
content of ∼ 42%.
The initial approach to study PB1-F2 by separating the ORFs and insert
PB1-F2 downstream of PB1 was made before N40 was discovered. It was
hypothesised at the time that any attenuation caused by PB1-F2 may be
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restored by inserting PB1-F2 and expressing it from an independent ORF.
This would allow the characterisation of the protein and its role in the viral
life cycle. However, it was shown in Chapter 3, that the loss of PB1-F2 alone
is not responsible for the attenuation of PB1-F2 knockout viruses. In fact,
it was shown to be due to an overexpression of N40 in a PB1-F2 deletion
background. Additionally, no real advantage of viruses expressing PB1-F2
from segment 6 was observed, independent of the strategy used to delete
PB1-F2 in segment 2. Nevertheless, the separation of the two ORF can
be a useful tool to study the role of PB1-F2. PB1-F2 stable integrated in the
influenza A virus genome could help to identify motifs for interaction partners
or important amino acids for virulence and PB1-F2 could be tagged with
a short peptide (FLAG-tag, V5-tag). A combined strategy of the methods
discussed in this Chapter may be a possible approach by inserting PB1-F2
downstream of NA via a 2A peptide. Regarding the disadvantages of
2A, alternative methods may be examined, such as the use of a caspase
recognition site (CRS). This artificial site is only nine amino acids long and
the introduction was genetically stably over several passages (Kittel et al.,
2004). Cellular caspases are thought to recognise the sites and cleave
the polyprotein into the individual proteins posttranslationally. This would
minimise the amino acids remaining at the C- or N-terminus of the cleaved
proteins.
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5.8 Summary of Chapter 5
PB1-F2 was inserted as an independent ORF into the influenza A virus
genome. The following strategies were used and verified for their success:
(1) Insertion into Segment 2
Virus Phenotype Stability
rWSN ∆AUG-StSt-F2 no PB1-F2 expression PB1-F2 lost after
attenuated in growth passage 5
small Plaque size
fitness increase after P5
rWSN ∆AUG-2A-F2 no PB1-F2 expression stable up to
attenuated in growth passage 10
small Plaque size
rWSN ∆AUG-3’UTR-F2 not possible to rescue
(2) Insertion into Segment 6
Virus Phenotype Stability
rWSN ∆AUG/NA-F2 PB1-F2 overexpression PB1-F2 lost partially
attenuated in growth before P10
small Plaque size
attenuation in vivo
fitness increase after P5
rWSN F2-11/NA-F2 PB1-F2 overexpression PB1-F2 lost partially
attenuated in growth before P10
small Plaque size
attenuation in vivo
fitness increase after P5
(3) Insertion into Segment 7
Virus Phenotype Stability
rWSN ∆AUG/M-F2 no PB1-F2 expression not tested
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Chapter 6
N40 AND PB1-F2 KNOCKOUT
AND THE INFLUENCE ON VIRAL
REPLICATION
Aims of Chapter 6
Overexpression of N40 caused an attenuation of viral replication in vitro
and in vivo. For a better understanding of segment 2 gene products,
N40 deletion viruses were engineered and rescued in the context of either
PB1-F2 expression or PB1-F2 knockout.
The deletion of N40 was achieved by a single point mutation which changed
amino acid 40 within the PB1 ORF from methionine to leucine (∆N40).
Deletion of N40 and PB1-F2 was obtained by introducing two point
mutations (∆F2/∆N40). The first mutation led to an amino acid change
within the PB1 ORF at residue 40 (M40I) which removed the N40 start
codon. Simultaneously, a stop codon was introduced into the PB1-F2 ORF.
Additionally a second stop codon was introduced into the PB1-F2 sequence
further downstream which had no effect on the amino acid sequence of PB1.
The influence of these segment 2 mutant viruses with different expression
levels of PB1-F2 and/or N40 on viral replication was analysed.
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6.1 Introduction on N40
In 2009, a 12th influenza A virus protein was described (Wise et al., 2009).
Translation occurs from the same mRNA as the polymerase subunit PB1
and PB1-F2. The protein, called N40, is a shorter version of PB1 lacking
the N-terminal 39 amino acids. As a consequence, N40 cannot interact with
the polymerase subunit PA, however the ability to bind PB2 remains (Wise
et al., 2009). Other PB1 binding partners are also likely to retain their ability
to interact with N40. Figure 6.1 shows a diagram of the 5’ end of segment
2 of A/WSN/33. Five AUGs are present in this region with different Kozak
consensus sequences, but only ORF 1, 4 and 5 encode a full length protein.
A strong consensus sequences was defined as gccRccAUGG with a purine
at position -3 and guanine at position +4 (Kozak, 1986), however only ORF
4 and 5 fulfil this condition. Ribosomes are thought to bind to the 5’ cap of
mRNAs and scan along the mRNA until they reach the first suitable AUG to
start translation. Because of the poor sequence context of AUG1, translation
is likely to bypass this first AUG codon.
segment 2
PB1 (25-2298)
PB1 N40 (142-2298)
PB1-F2 (119-391)
Frame 1
Frame 2
5'UTR 3'UTR
* *2 3 4
*
*
1,5
Kozak consensus
strongintermediate weak
ORF1   PB1              
ORF5   N40
                  
ORF2                       
ORF3                       
ORF4   PB1-F2      
AUUUGA AUG GAU 
UACACC AUG GAU 
GAAUGG AUG UCA 
CACAAA AUG UAU 
ACAGCC AUG GGA 
  -3  +1  +4Frame 1
Frame 2
Figure 6.1: Analysis of the sequence context of the AUGs in segment 2 of
A/WSN/33: Five AUG codons are present in the 5’ end of segment 2. AUG1
initiates translation of PB1, AUG4 starts PB1-F2 and AUG5 N40. The short second
and third ORFs do not encode a protein. Stop codons of the corresponding ORFs
are shown within the graphic (*1-5). The Kozak consensus sequences of all 5 AUGs
are listed and shown in different colors according to their strength. Modified from
Wise et al. (2009).
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The function of N40 is not known, but because most viral strains contain
the ORF, it was suggested that N40 is of some importance. Wise et al.
reported that expression of N40 is not essential for the viral life cycle.
However, deletion of N40 in combination with an intact PB1-F2 ORF delayed
viral replication of influenza A virus strain A/PR/8/34 in vitro. Although viral
polymerase activity was increased in this context, these viruses showed a
small plaque phenotype and a delay in a single-cycle growth curve (Wise
et al., 2009).
Overexpression of N40 in combination with the deletion of PB1-F2 had a
dramatic effect on virulence of A/WSN/33. Therefore, the impact of the loss
of N40 for this virus strain was analysed. In addition to the N40 mutant, a
double mutant was engineered lacking both PB1-F2 and N40 ORFs.
6.2 Deletion of N40 and deletion of N40 in
combination with a PB1-F2 knockout
6.2.1 Constructing the plasmids with N40 deletions
Two N40 deletion viruses were engineered using oligonucleotide primers
listed in Table 6.1. The first mutation resulted in the deletion of N40, but
the PB1-F2 ORF was left unaffected (Figure 6.2(1)). A point mutation within
the start codon abolished N40 expression and led to an amino acid change
from methionine to leucine in the PB1 ORF. The second mutant virus was
designed in such a way that besides N40, PB1-F2 was also knocked out
(Figure 6.2(2)). To achieve this, methionine was changed into isoleucine
within the PB1 ORF and PB1-F2 expression was terminated after amino
acid 8. To fully abolish PB1-F2 expression, a second point mutation was
introduced into segment 2 further downstream. This was previously shown
to be necessary due to translation of the C-terminus from one of the internal
AUG codons (Section 3.2.1 and Zamarin et al., 2006). Mutations were
introduced by PCR-mediated site-directed mutagenesis (Section 2.4.3) and
primer sequences are listed in Table 2.9 and 2.12. The obtained plasmids
were named pHH-∆N40 and pHH-∆F2/∆N40 and were amplified in E.coli
and sequenced before further use in virus rescues.
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Mutation Forward primer Reverse primer
∆N40
A142T sv172 sv173
∆F2/∆N40
G144A sv174 sv175
G291A sv13 sv14
Table 6.1: Oligonucleotide primers used to delete N40 in A/WSN/33. Primer
Sequences are listed in Table 2.9 and 2.12 in Chapter 2.
PB1 ORF: Met40 -> Ile40
PB1-F2 ORF: Tyr9  -> Stop
                       Tyr58 -> Stop
Figure 6.2: Strategy to delete N40: A/WSN/33 segment 2 encodes three
polyproteins - the polymerase subunit PB1, PB1-F2 and an N-terminally truncated
version of PB1 called N40. Deletion viruses were engineered by deleting the start
codon of N40. (1) ∆N40: The start codon was mutated to a leucine. This mutation
did not have an effect on the PB1-F2 ORF, but changed residue 40 in PB1 to a
leucine. (2) ∆F2/∆N40: Insertion of a point mutation led to the deletion of PB1-F2
and N40. Changing the start codon of N40 into isoleucine also introduced a stop
codon into the PB1-F2 ORF at amino acid 9. Additionally, a second point mutation
was introduced to abolish the expression of the C-terminus of PB1-F2 (Zamarin
et al., 2006).
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6.2.2 Rescue of viruses deficient for N40
Viruses were rescued using the 12-plasmid rescue system as described
in Section 2.2.2 and 3.3.1. The plasmid for the expression of the vRNA
of segment 2 (pHH-PB1) was exchanged by either of the N40 deletion
plasmids pHH-∆N40 or pHH-∆F2/∆N40. Recombinant viruses were plaque
purified and following RT-PCR, the nucleotide sequence of segment 2 was
determined.
Expression of viral proteins from segment 2 was monitored by western blot
analysis. Confluent monolayers of MDCK cells were infected with the panel
of viruses at an MOI of 3 and cells were lysed 8 h later. Results of the
western blot are shown in Figure 6.3.
PB1
N40
PB1-F2
α-Tubulin
rWS
N W
T
rWS
N  Δ
AUG
rWS
N F
2-11
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N Δ
N40
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N Δ
F2/Δ
N40
MO
CK
Figure 6.3: Detection of viral protein expression in cells infected with
segment 2 deletion viruses: MDCK cells were infected with a panel of
recombinant viruses and viral protein expression was determined 8 hpi. 4 - 12%
gradient Bis-Tris gels were used to detect PB1 and N40. 16% Tricine-SDS-PAGE
was used to detect PB1-F2. Detection of α-tubulin served as an internal loading
control.
As expected, no N40 was detected in cells infected with either of the
N40 deletion viruses rWSN ∆N40 or rWSN ∆F2/ ∆N40. However, cells
infected with the WT virus or the PB1-F2 deletion viruses ∆AUG and F2-11
expressed N40, with the highest expression level noticed in cells infected
with rWSN ∆AUG viruses.
Expression of PB1-F2 was also monitored and as expected it was only
detected in cells infected with either the WT virus or rWSN∆N40, but not
in cells infected with a PB1-F2 deletion virus or the PB1-F2/N40 double
mutant virus (Figure 6.3).
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6.3 In vitro characterisation of the N40 mutant
viruses
To determine any possible effect the loss of N40 may have had on virus
replication, its plaque phenotype was analysed. Confluent monolayers of
MDCK cells were infected with the two N40 deletion viruses. Cells were
overlayed with a mixture of Avicel and DMEM supplemented with N-acetyl
trypsin. At 24 or 72 hpi, cells were fixed and stained either with crystal
violet or by immunostaining and plaque size was compared to those of WT
infected cells. As can be seen in Figure 6.4, plaques seemed slightly smaller
24 hpi, however no difference was observed in plaque size at day 3 post
infection.
rWSN WT rWSN ΔN40 rWSN ΔF2/ΔN40
Figure 6.4: Plaque
phenotype of viruses
with a N40 deletion:
Confluent monolayers of
MDCK cells were infected
with recombinant viruses.
Cells were overlayed with
1.2% Avicel-DMEM and
incubated at 37°C for 3
days (top panel) or 24
h (bottom panel). Mean
values ± SEM for ∼30
plaques/recombinant
virus (3 dpi) are plotted.
To evaluate this further, viral growth was determined under multi-step
conditions or single-step conditions. Confluent MDCK cells were infected
with low or high MOI (0.001 or 3, respectively) and supernatants were
collected at the indicated time points to measure viral growth. Beside MDCK
cells, viral growth in a multi-step cycle was also determined in A549 cells
(Figure 6.5(B)). As shown in Figure 6.5, the loss of N40 had a minor effect
on viral replication in MDCK cells; in A549 cells no difference in growth
was observed. This finding was independent of PB1-F2 expression and the
results were in line with the observed plaque phenotype.
156
CHAPTER 6 Influence on viral replication
(A)
(B)
Figure 6.5: Multi-step growth curve of viruses with a N40 deletion: Triplicate
MDCK cell (A) or A549 cell (B) monolayers were infected with the recombinant
WSN viruses WT, ∆N40 and ∆F2/∆N40 at an MOI of 0.001. Media was
supplemented with N-acetyl trypsin. Supernatants were harvested at the indicated
time points post infection and virus titres were determined by plaque assay. Mean
values ±SEM of each set of triplicates are plotted.
Wise et al. reported that viral growth in a multi-step cycle was unaffected
by the loss of N40, similar to the results seen in this study. However they
found a delay of viral growth under single cycle conditions (Wise et al.,
2009). To evaluate this for the influenza A virus strain A/WSN/33, confluent
monolayers of MDCK cells were infected with either the WT or one of the
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Figure 6.6: Single-step growth curve of viruses with a N40 deletion: (A)
Triplicate MDCK cell monolayers were infected with the recombinant WSN viruses
WT, ∆N40 and ∆F2/∆N40 at an MOI of 3. Supernatant was harvested at indicated
time points post infection and virus titres were determined by plaque assay. Mean
values ±SEM of each set of triplicates are plotted. (B) Synthesis of viral protein
was analysed by Western blot at indicated time points. 4 - 12% gradient Bis-Tris
gels were used to detect PB1, N40 and NS1. α-tubulin was used as an internal
loading control. (C) Quantification of the accumulation of NS1 and PB1.
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mutant viruses at an MOI of 3 and supernatants were harvested at the
indicated time points (Figure 6.6 (A)). Both N40 deficient viruses were
attenuated under these conditions. Following this, viral protein synthesis
was determined by western blot analysis. Although accumulation of NS1
was similar in cells infected with either virus, PB1 expression levels were
decreased at later time points in cells infected with N40 deficient viruses
compared to cells infected with the WT virus (Figure 6.6 (B and C)).
Based on the results described in Chapter 3 and the results in this Chapter,
a mixed infection assay was used to further evaluate possible effects of
N40 and PB1-F2 on viral growth. When cells were infected at a high MOI,
viruses overexpressing N40 in a PB1-F2 deficient background (∆AUG)
showed similar growth to WT viruses. On the other hand, viruses deficient
for N40 showed an attenuated phenotype. The opposite result was found
when infecting at a low MOI: ∆AUG viruses were attenuated, viruses
deficient for N40 showed a similar growth phenotype to WT virus. The
potential of the presence of high levels of N40 in combination with the
availability of PB1-F2 in the same cell was examined by infecting MDCK
cells with both viruses simultaneously at an MOI of 3. Viral infections follow
a Poisson distribution and ∼80% of cells are expected to be infected with
more than one virus particle at an MOI of 3 (Knipe et al., 2001). Cells were
also infected with either of the two viruses at an MOI of 3 or 6 and with WT
virus (MOI 6). The results are shown in Figure 6.7. As described before,
cells overexpressing N40 showed a small plaque phenotype, whereas the
plaque size of ∆N40 viruses was comparable to WT viruses. Infection of
cells with a mixture of ∆AUG and ∆N40 viruses caused a mixed plaque
phenotype, although the majority of plaques were similar to those seen for
WT and ∆N40 viruses (Figure 6.7(A)).
All viral infections gave rise to high levels of released virus and viral proteins
were detected at all time points examined (Figure 6.7(B and C)). Whereas
PB1-F2 was absent in cells infected with ∆AUG viruses and N40 was
absent in cells infected with ∆N40 viruses, PB1-F2 and N40 were detected
in cells infected with a mixture of rWSN ∆AUG and rWSN ∆N40.
Regarding viral growth, findings could be summarised as follows:
(1) Under conditions of high MOI, ∆AUG viruses grew similar or even better
then WT viruses, whereas ∆N40 viruses showed an attenuation.
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Figure 6.7: Comparison of in vitro phenotypes of WT,∆AUG,∆N40 and mixed
infections: Triplicates of MDCK cell monolayers were infected with rWSN WT,
rWSN ∆AUG, rWSN ∆N40 or a mixture of ∆AUG and ∆N40. (A) Supernatants
were harvested at 8 hpi and plaque phenotype was determined. (B) At the indicated
time points, cells were lysed and accumulation of viral proteins was determined by
western blot analysis. 4-12% gradient Bis-Tris gels were used to detect PB1, N40
and NS1. 16% Tricine-SDS-PAGE was used to detect PB1-F2. α-tubulin was used
as an internal loading control. (C) Supernatants were harvested at the indicated
time points and viral growth was measured by plaque assay. Mean values ±SEM
of each set of triplicates are plotted.
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(2) Only minor differences were observed comparing infections with MOI of
3 and MOI of 6. The differences in the percentage of infected cells for both
MOI are thought to be small, as MOI of 3 led to 95%, MOI of 6 to about 99%,
infected cells (Knipe et al., 2001).
(3) Viral growth in a mixed infection was more similar to growth seen for
∆N40 virus rather than ∆AUG virus infections.
6.4 Effect of loss of N40 on virulence in mice
Although previous reports linked the attenuated virulence in mice to the loss
of PB1-F2, it is more likely that this attenuation was caused by a loss of
PB1-F2 in combination with overexpression of N40 (Chapter 3: Section
3.3.5).
To determine the virulence of viruses deficient for N40, female BALB/c
mice were infected intranasally with rWSN ∆N40 or rWSN ∆F2/∆N40 and
compared to WT virus infections. Body weight was measured daily and
four mice per group were culled at day 4 or day 7 in order to evaluate the
viral lung titres. As can be seen in Figure 6.8(A), mice infected with rWSN
∆N40 viruses lost weight similar to WT infected mice, whereas mice infected
with rWSN ∆F2/∆N40 viruses lost weight more slowly. At day 6 pi, these
mice seemed to start gaining weight, which may be a sign for recovery.
All infected mice showed symptoms of infection such as staring coat and
increased respiratory effort. However, rWSN ∆F2/∆N40 infected mice only
started to show these symptoms after day 6, whereas WT and rWSN ∆N40
virus infected mice showed symptoms as early as 4 dpi. Viral titres in the
lungs measured at day 4 post infection were similar for all three viruses,
but differences were observed at the later time point. Lung titres of mice
infected with rWSN WT and rWSN ∆N40 viruses were reduced by ∼ 10-fold
compared to day 4 pi, however, PB1-F2/N40 double mutant viruses were
reduced by almost 1000-fold at this time point (Figure 6.8(B)). These data
correlate with the weight loss and the observed clinical signs.
At day 7 pi, lungs from two mice per group were taken for histology.
Whereas lungs of mock-infected mice (PBS) had healthy lungs, all lungs of
virus infected mice exhibited similar signs of infection. Immune cells were
found in the interstitial region and within alveoli. Bronchus walls showed
evidences of necrosis as the terminal airways contained cellular debris
(Figure 6.9).
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Figure 6.8: Virulence of the recombinant WSN viruses WT, ∆N40 and
∆F2/∆N40 in mice: Groups of 8 female BALB/c mice were infected with the
recombinant WSN viruses WT, ∆N40 and∆F2/∆N40 with 5x103 pfu. (A) Weight
loss was measured every day over a period of 7 days. Day 0 was set as 100% for
each group. (B) At day 4 and day 7, 4 mice of each group were culled and lung virus
titres were determined by plaque assay. Mean values ±SEM are plotted. Mouse
infections were done in collaberation with B. Dutia and her lab at the University of
Edinburgh.
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Figure 6.9: Histological section of lungs from BALB/c mice infected with
WT WSN, ∆N40 and ∆F2/∆N40 viruses: Mice were infected intranasally with
5x103 pfu of the panel of recombinant WSN viruses - WT, ∆N40 and ∆F2/∆N40.
PBS served as a negative control. At day 7 pi lung sections were stained with
Hematoxylin & Eosin. All virus infected mice showed markedly increased numbers
of neutrophils in the alveoli as well as necrosis of the bronchus epithelial wall. This
work was done with the help of Jill McVee, University of St Andrews.
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To exclude the possibility that the viruses have acquired mutations
that altered the expression level of PB1-F2 or N40, viral RNA of samples
obtained at day 7 pi was isolated and the nucleotide sequence of segment
2 was determined. All mutations introduced by PCR-mediated site-directed
mutagenesis were still in place (data not shown).
6.5 Effects of loss of PB1-F2 and N40 on viral
gene expression and replication
6.5.1 De novo synthesis of viral proteins
The differences in the accumulation of PB1 in cells infected with viruses
deficient for N40 observed by western blot analysis (Figure 6.6 (C)) were
further analysed. MDCK cells were infected with PB1-F2 and N40 knockout
viruses as well as the WT virus at an MOI of 3 and at the desired time points
proteins were labelled with [35S] methionine in order to determine the de
novo synthesis of viral proteins. At the same time, the efficiency of host
protein shut-off caused by influenza virus infections was monitored.
As can be seen in Figure 6.10 (A), all viruses efficiently produced viral
proteins at all time points measured. No difference was observed for the
shut-off of host cell protein synthesis. However, when quantifying protein
synthesis using a Fluorescent Image Analyzer, some differences were
noticed (Figure 6.10 (B)). Similar to the results in the western blot analysis
(Figure 6.6 (C)), less synthesis of viral polymerase subunits (3 Pol) was
observed for viruses deficient in their N40 expression. On the other hand,
an increased synthesis of the three polymerase subunits was seen in cells
infected with rWSN ∆AUG compared to WT virus infected cells. A similar
increase was noticed for the synthesis of NP in rWSN ∆AUG infected cells.
NS1 and M1 synthesis was overall equal for all viruses.
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Figure 6.10: De novo synthesis and accumulation of viral proteins: MDCK
cells were infected with the panel of viruses at an MOI of 3. Before adding
methionine-free medium supplemented with 30 Ci/ml [35S] methionine to the cells,
cells were starved for methionine using methionine-free medium for 30 min. De
novo synthesis of viral proteins, polymerase subunits (3 Pol), NP and M1/NS1, as
well as host cell shut-off were quantified.
165
CHAPTER 6 Influence on viral replication
6.5.2 Influence of segment 2 gene products on
polymerase activity
To determine whether the differences in viral protein synthesis had an
influence on viral replication, the activity of the viral polymerase was tested
in a mini-genome assay. Cells were cotransfected with plasmids expressing
PB2, PA, NP and either PB1 WT or one of the PB1-F2 and N40 mutants.
A plasmid encoding the vRNA for a virus-like Renilla luciferase was also
transfected along with a transfection control plasmid expressing firefly
luciferase under a CMV promoter. The Renilla luciferase was expressed
efficiently and its activity was normalised and values were set to 100% for
WT. This activity was compared to PB1-mutants deficient in PB1-F2 and / or
N40 expression.
Plasmid X: PB1; ΔATG; ΔN40; ΔF2/ΔN40; N40; pcDNA3.1
Pol II promoter
Pol I promoter
CMV promoter
PB2 PA NP Penilla Firefly
X
Figure 6.11: Effects of PB1-F2 and N40 on polymerase activity: Triplicates
of 293FT cells were transfected with plasmids expressing PB2, PA and NP
together with PB1 WT or one of the mutants deficient in PB1-F2 or N40. Activity
was measured using a luciferase dual reporter assay (Promega). Values were
normalised to transfection efficiency and expressed as activity compared to WT
PB1. Mean values ±SEM of three independent experiments are plotted. Asterisks
indicate significant differences (Student’s t-test : ** P < 0.05; *** P < 0.001).
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The results are shown in Figure 6.11. The loss of PB1-F2 did not change
the polymerase activity as long as N40 was still present. However, the loss
of N40 led to a decrease in polymerase activity, which was enhanced by the
loss of PB1-F2 (Student’s t-test : ∆N40 P=0.0059; ∆F2/∆N40 P<0.0001).
N40 was not able to replace PB1 in this system and only background Renilla
activity was measured, similar to the empty vector pcDNA3.1. It should
be noted that viruses knocked out for N40 have an amino acid change in
the polymerase subunit PB1 and it can not be ruled out that the reduced
polymerase activity is due to this mutation.
To evaluate the effect of PB1-F2 and N40 on these systems, plasmids
expressing either protein were added to the transfection mixture. As shown
in Figure 6.12, addition of PB1-F2, N40 or PB1-F2 and N40 to PB1, ∆AUG
or F2-11 did not alter the Renilla luciferase activity. A slight increase was
seen when N40 was added to ∆N40. Although this increase was not
significant (Student’s t-test : P=0.175), additional N40 may be counteracting
the effects of the∆N40. If N40 or PB1-F2 was supplemented to∆F2/∆N40,
only a small increase was noted. However, a significant change was
observed when PB1-F2 and N40 were present and Renilla luciferase activity
almost reached WT levels (Figure 6.12).
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Figure 6.12: Effects of PB1-F2 and N40 on polymerase activity: Triplicate
monolayers of 293FT cells were transfected with plasmids expressing PB2, PA
and NP together with PB1 WT or one of the mutants deficient in PB1-F2 or N40.
Additionally PB1-F2 and N40 were transfected as indicated. Activity was measured
using a luciferase dual reporter assay (Promega). Values were normalised to
transfection efficiency and expressed as activity compared to WT PB1. Mean
values ±SEM of three independent experiments are plotted. Asterisks indicate
significant differences (Student’s t-test : ** P < 0.05; *** P < 0.001).
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6.5.3 Effects of PB1-F2 and N40 on viral RNA
accumulation
Overall, the loss of PB1-F2 alone did not affect viral polymerase activity,
but the loss of N40 had a significant effect, which was enhanced by the
loss of PB1-F2. Although rWSN ∆N40 and rWSN ∆F2/∆N40 showed
an attenuation in viral growth in a single-step cycle, they grew normally
in a multi-step cycle and no decrease in plaque size was observed.
To understand the results seen in a mini-genome assay better and to
dissect the influence of segment 2 gene products on transcription and
replication, primer extension assays were performed. A549 cells were
infected with the different viruses and RNA was extracted at 3, 6 or 8
hpi. [γ-32P]-ATP labelled primers specific for RNA segments 1, 6 or 8
were used to monitor viral mRNA, cRNA or vRNA synthesis in a Primer
extension reaction. The synthesis of cellular 5S rRNA was used as internal
control. Primer sequences are listed in Table 2.15 and a protocol of primer
extensions is described in section 2.5.4. Products were separated on a 6%
polyacrylamide/6M urea gel and detected by autoradiography. Expression
levels of all RNA species at 8 hpi were quantified and normalised against
5S rRNA. Levels of RNA species of rWSN WT at each time point were
set to 100%. As a comparison of the relative amounts of replication and
transcription, the ratio between mRNA and cRNA (or vRNA for segment 8)
was calculated. The results of the primer extension assays for segments 1,
6 and 8 are shown in Figures 6.13, 6.14 and 6.15, respectively.
All three viral RNA species and the cellular 5S rRNA were detected in the
primer extension assay for segments 1 and 6. The levels of cRNA for
segment 8, however, were very low, possibly due to difficulties with the
available primer. Therefore, only mRNA and vRNA levels were quantified
for segment 8. Other than for segments 1 and 6, the ratio of mRNA to
vRNA was calculated for segment 8 to compare transcription to replication.
Overall, the three tested segments showed similar results and some
generalisation could be made.
(1) All viruses accumulated viral RNAs over time.
(2) Although the amounts of RNA species of the mutant viruses varied from
WT virus, the ratios between the different RNA species for one segment
remained similar.
(3) An exception was the ∆AUG virus. Accumulation of vRNA and cRNA
were remarkably increased compared to mRNA levels. This led to a shift
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towards replication in rWSN ∆AUG infected cells, as seen by the calculated
ratios mRNA:c/vRNA.
However, none of these differences resulted in a change in viral titer (Figure
6.16).
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Figure 6.13: Primer extension assay segment 1: A549 cells were infected
with the panel of viruses at an MOI of 3 and total RNA was extracted 3, 6
or 8 hpi. Accumulation of mRNA, cRNA, vRNA of segment 1 and cellular 5S
rRNA was detected by primer extension. Products were separated on a 6%
polyacrylamide/6M urea gel and detected by autoradiography. Quantification of
the accumulation of mRNA, cRNA and vRNA at 8 hpi is shown. Values were
normalised against cellular 5S rRNA and expressed as percentage ±SEM of WT
activity. Results are based on three independent experiments. Ratios of quantified
levels of mRNA and cRNA are shown. Error bars represent standard deviation of
the mean (±SEM) based on three independent experiments.
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Figure 6.14: Primer extension assay segment 6: A549 cells were infected with
the panel of viruses at an MOI of 3 and total RNA was extracted 8 hpi. Accumulation
of mRNA, cRNA, vRNA of segment 6 and cellular 5S rRNA was detected by
primer extension. Products were separated on a 6% polyacrylamide/6M urea gel
and detected by autoradiography. Quantification of the accumulation of mRNA,
cRNA and vRNA is shown. Values were normalised against cellular 5S rRNA
and expressed as percentage ±SEM of WT activity. Results are based on three
independent experiments. Ratios of quantified levels of mRNA and cRNA are
shown. Error bars represent standard deviation of the mean (±SEM) based on
three independent experiments.
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Figure 6.15: Primer extension assay segment 8: A549 cells were infected with
the panel of viruses at an MOI of 3 and total RNA was extracted 3, 6 or 8 hpi.
Accumulation of mRNA, cRNA, vRNA of NS1 and cellular 5S rRNA was detected
by primer extension. Products were separated on a 6% polyacrylamide/6M urea
gel and detected by autoradiography. Quantification of the accumulation of mRNA
and vRNA at 8 hpi is shown. Values were normalised against cellular 5S rRNA
and expressed as percentage ±SEM of WT activity. Results are based on three
independent experiments. Ratios of quantified levels of mRNA and vRNA are
shown. Error bars represent standard deviation of the mean (±SEM) based on
three independent experiments.
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Figure 6.16: Viral titres of
primer extension assay: A549
cells were infected with the
panel of viruses at an MOI
of 3. At 8 hpi, supernatants
were harvested and viral titres
were analysed by plaque assay.
Results are based on three
independent experiments.
Error bars represent standard
deviation of the mean (±SEM)
based on three independent
experiments.
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6.6 Discussion
This chapter focussed on the influence of N40 and PB1-F2 on viral
replication and transcription. Additional to the PB1-F2 mutant viruses
described in Chapter 3 two more viruses were engineered, one lacking
the N40 ORF, and the second mutant lacking PB1-F2 and N40 (rWSN
∆N40 and rWSN∆F2/∆N40). Whereas a virus overexpressing N40 showed
attenuation in vitro and in vivo, the loss of N40 did not have a great effect and
viruses had a WT plaque phenotype and replicated normally in MDCK and
A549 cells in a multi-step cycle (Figure 6.4, 6.5). However, when infecting
at a high multiplicity, the loss of N40 had some disadvantageous effect on
viral replication (Figure 6.6). Whether the loss of N40 itself or the altered
level of PB1 expression was responsible for this is not known: the decrease
in PB1 synthesis at later stages in infection was observed by western blot
analysis (Figure 6.6(C)) and when examining synthesis of viral proteins by
metabolic labelling (Figure 6.10). Opposite to the decreased levels of PB1
in N40 deficient cells, an increased level of the viral polymerase was found
in cells infected with rWSN ∆AUG viruses. However, it should be noted,
that the three viral polymerase subunits could not be quantified separately
in the metabolic labelling experiment due to their similar size. Therefore, the
observed differences could be due to changes of either of the polymerase
subunits. Additionally, the effect could also be caused by the enhanced
presence or absence of N40 itself (Figure 6.10).
Expression of PB1-F2 and N40 may be explained by leaky ribosomal
scanning, however the change in PB1 synthesis following the deletion of a
downstream start codon is more difficult to understand. Digard’s laboratory
described previously an interdependency of the expression of all three
segment 2 gene products that goes beyond leaky scanning (Wise et al.,
2009). In this regard, the expression of the C-terminus of PB1-F2 was
also suggested in previous studies (Figure 6.17(A)) (Zamarin et al., 2006).
This would require bypassing six AUG codons including three in a strong
sequence context. An observation made in western blot analysis using PB1
antibodies enhanced the discussion about an unusual expression mode for
segment 2 (Figure 6.17(B)). Shorter products were detected, which may
be degradation products of PB1. In this case it could be speculated that
the presence or absence of N40 altered the stability of PB1. A second
hypothesis would be that these products are expressed by an unknown
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mechanism from AUG codons 10 or 11. Changes of the upstream AUG
codons could alter their expression level. However, the expression level
seemed to be independent from the number of upstream AUG codons.
rWSN∆AUG, rWSN∆N40 and rWSN∆F2/∆N40 have one less AUG codon
compared to WT and F2-11 viruses, but they differ in the appearance of
these smaller products. When AUG4 was removed, more small downstream
products were observed, whereas loss of AUG5 led to a reduction in the
appearance of these downstream products.
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N40 (142-2298)
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Figure 6.17: Extended analysis of the 5’ end of segment 2 of A/WSN/33: (A) 11
AUG codons are present in the 5’ end of segment 2. AUG1 initiates translation of
PB1, AUG4 starts PB1-F2 and AUG5 N40. The short second, third and 6th ORFs
do not encode a protein. AUG codons 7-9 are in frame 2 and were previously
reported to express the C-terminus of PB1-F2 (Zamarin et al., 2006). AUG10 and
11 are within frame 1 and in a strong Kozak consensus context. Stop codons of the
corresponding ORFs are shown within the graphic (*1-11). The Kozak consensus
sequences of all AUGs are shown in different colors according to their strength. (B)
Western blot analysis of segment 2 gene products. Additionally to the described
products PB1 and N40, slightly smaller products could be found expressed from
segment 2 and detected by the PB1 antibody.
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How could such an hypothesis be explained? Ribosomes are thought
to bind to capped 5’UTRs and start their scanning process until the
first AUG is found to initiate translation (Kozak, 1999). However, many
viruses have evolved mechanisms to overcome restrictions of genome size
constraints by having polycistronic mRNAs. Expression of the individual
genes is assured by different mechanisms, such as leaky ribosomal
scanning, ribosomal shunting, use of internal ribosomal entry sites (IRES) or
translation termination-reinitiation. Segment 2 of influenza A viruses code
for up to three proteins in overlapping reading frames and the process by
which they are expressed is at least partially by leaky ribosomal scanning
(Chen et al., 2001; Wise et al., 2009). Hence, it would be unusual if AUG
codons 10 or 11 are used to initiate translation by leaky scanning, because
the ribosome would need to bypass several other AUGs, some in strong
Kozak consensus sequences. However, several complex initiation strategies
have been described for other viruses. The human papillomavirus type 16
encodes the two oncogenes E6 and E7 in one mRNA and the expression of
E7 was shown to be due to an extreme process of leaky scanning bypassing
up to 13 AUGs (Stacey et al., 2000). Another example was found for avian
reoviruses. The three overlapping ORF from segment 1 were translated
by leaky scanning and ribosomal shunting (Racine and Duncan, 2010).
Just recently, a possible mechanism for the translation of influenza A virus
segment 2 gene products was suggested (Wise et al., 2011). The short
ORFs, between the ORFs for PB1 and PB1-F2, could have a regulatory
function, with the main regulator being the short ORF2 translated from
AUG3. This ORF was shown to suppress the expression of PB1-F2, but
promote the expression of N40 by skipping AUG4 and directing ribosomes
to AUG5 (Wise et al., 2011).
The function of N40 and even PB1-F2 are still under examination and many
aspects are still unknown. One of these aspects may be a different role
in human and avian cells. Leaky scanning processes were shown to be
modulated by temperature (Liu et al., 1997). In this system, the first AUG
was preferred at high temperatures, whereas at low temperatures the third
AUG was favoured. Because humans and avian species differ in their
normal temperatures, one could speculate about different expression levels
of PB1, PB1-F2 and N40. If the amounts of the three proteins produced is
important for viral pathogenicity in a particular host system, this could be a
way of balancing the synthesis of segment 2 gene products.
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Viral proteins interact with the cellular transcription and translation
machinery as well as with cellular factors to down-regulate immune
responses or induce apoptosis. Several viral and host cell proteins have
been reported to interact with PB1. Among the viral proteins are the
polymerase subunits PB2 and PA, the nucleoprotein, PB1-F2 and it was
also suggested that PB1 interacts with itself. Cellular interaction partners
are Hsp90, Hsp70, Ebp1 and RanBP5 (Naito et al., 2007; Mayer et al.,
2007; Honda et al., 2007; Deng et al., 2006a). N40 may compete with
PB1 for binding to some or all of of these proteins and in cells infected
with rWSN ∆AUG viruses, which overexpress N40, this competition may
be disadvantageous for the virus. On the other hand, viruses deficient for
N40 also showed some growth attenuation. Not all of the above mentioned
proteins enhance viral replication. Hsp70 and Ebp1 were shown to interfere
with viral growth (Honda et al., 2007; Li et al., 2011) and N40 may help to
quench some of these effects by binding to these proteins rather than PB1.
All of these interactions may have a hierarchy in timing or importance and
the benefits of one or the other interaction remains unknown.
N40 itself could also have a function in the virus life cycle by modulating
the viral polymerase activity. Results of the mini-genome assay would
support this idea, as cells infected with plasmids deficient for N40 had a
decreased polymerase activity (Figure 6.11 and 6.12). Primer extension
assays showed a shift towards replication in cells infected with viruses
overexpressing N40. Two options can be discussed:
(1) N40 helps to modulate the polymerase function and promotes replicase
rather than transcriptase functions of PB1, or
(2) the shift is only a consequence of the increased levels of polymerase
subunits and nucleoproteins observed in the protein labelling experiment.
The shift from transcription to replication is not fully understood yet. Several
hypothesis have been suggested (Figure 6.18). Jorba et al. proposed
a model in which the RNP-bound polymerase complex is responsible for
transcription, whereas newly synthesised soluble polymerase complexes
replicate the viral genome (Figure 6.18(A)) (Jorba et al., 2009). Other
strategies suggest the involvement of small viral RNAs that derive from the
5’ end of each segment (Figure 6.18(B)) (Perez et al., 2010; Scull and Rice,
2010). To what extent N40 may be involved in these processes is not known,
but because N40 is proposed to bind several viral and host cell proteins it
may have some influence. Another model for the switch from transcription
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(A) (B)
(C)
Figure 6.18: Summary of predicted models for the switch between
transcription and replication: (A) Replication takes place by newly synthesised
polymerase complexes coloured in semi-solid colouring. Transcription is fulfilled by
the parental polymerase complex shown in solid colours. Picture taken from Jorba
et al. (2009). (B) Synthesis of viral proteins and small viral RNAs is followed by
replication. Taken from Scull and Rice (2010). (C) The stabilisation model was
described by Vreede et al. (2004). Transcription and replication take place at the
same time, but cRNA will be degraded until stabilised by newly synthesised NP and
polymerase complexes.
to replication was suggested by Vreede et al. (Figure 6.18(C)) (Vreede
et al., 2004). The authors proposed that both transcription and replication
take place at the same time in infected cells. However at early times the
replication intermediates are unstable and are likely degraded. Only later
in infection, when appropriate amounts of nucleoprotein and polymerase
178
CHAPTER 6 Influence on viral replication
subunits are present, these RNA species are stabilised and replication
occurs. This hypothesis would be in line with the increased levels of NP and
polymerase subunits in cells infected with rWSN ∆AUG viruses. Therefore,
increased levels of cRNA and vRNA detected by primer extension assays
may be due to higher degree of stabilisation of these RNA species. Support
for this is provided by findings from Olsen et al., who suggested that high
levels of viral polymerase promote replication (Olson et al., 2010).
The loss of N40 and PB1-F2 caused an attenuation to a higher degree
than the loss of N40 alone (Figures 6.8 and 6.11). Replication deficits
resulted in an intermediate phenotype of virulence in mice and virus was
cleared more effectively from the lungs of infected mice. As seen in this
Chapter and Chapter 3, the loss of either of the two proteins alone was not
disadvantageous to the virus, however the alteration of both, PB1-F2 and
N40, was. Efforts were made to restore the WT phenotype by infecting cells
with a mixture of two viruses (∆AUG and ∆N40). Ideally, cells would get
co-infected with both viruses so that PB1-F2 and high levels of N40 were
present in the same cell. However, the results were similar to those seen
for infections with rWSN ∆N40 viruses. Although infections with MOI of 3
should result in more than one virus particle in ∼ 80% of cells, an estimation
of how many cells were infected with one particle of each of the two mutant
viruses cannot be made. Alternatively, the combination of high levels of
N40 and PB1-F2 does not have any advantage for the virus. To which
degree each of the proteins plays a role remains unknown. The dynamics
of expression of PB1, PB1-F2 and N40 and their localisation within the cell
may be of some importance and may not exist in cells infected with a mix of
rWSN ∆AUG and rWSN ∆N40.
Several differences were observed comparing the phenotypes of viruses
carrying N40 deletion between the closely related strains A/WSN/33 and
A/PR/8/34. Both plaque size and polymerase activity in a mini-genome
assay varied. Although similar outcomes were expected due to the
relatedness of the two virus strains, it should be noted that even different
results for similar experiments using A/PR/8/34 were reported. For PB1-F2
deficient viruses overexpressing N40, plaques were reported to be smaller,
similar or even bigger compared to WT viruses. A different influence on
replication was also found (Wise et al., 2009; Mazur et al., 2008; McAuley
et al., 2010b). Diverse variants of A/PR/8/34 have been shown to exist in
laboratories around the world. These variants range from low virulence to
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high virulence (Grimm et al., 2007; Blazejewska et al., 2011; Heynisch et al.,
2010). If variants within one virus strain can cause different results, it may
not be surprising that differences between two virus strains were observed.
It has been suggested that a combination of changes in PB1-F2, PB2 and
NS1 contribute to viral pathogenicity (Ozawa et al., 2011). It becomes more
and more evident that influenza A viruses and their interactions with different
hosts are very complex and studying one particular mutation may only shed
light on one specific aspect.
Further studies will be necessary to define the roles of PB1-F2 and N40
in human or avian cells. A host-specific role is equally conceivable as a
complex cooperation of all three segment 2 products.
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6.7 Summary of Chapter 6
Additional to the segment 2 mutant viruses described in Chapter 3, two new
viruses were engineered lacking the N40 ORF or PB1-F2 and N40 ORFs,
respectively. A summary of the observed phenotypes is shown in Table 6.2.
Virus Mutation Protein levels Phenotype
∆N40 A142T PB1: reduced normal plaque size
PB1-F2: WT WT phenotype in vivo
N40: null Growth: attenuation (high
MOI)
∆F2/∆N40 G144A PB1: reduced normal plaque size
G291A PB1-F2: null attenuation in vivo
N40: null Growth: attenuation (high
MOI)
Table 6.2: Summary chapter 6
Viruses described in Chapter 3 and 6 were used to determine the influence
of PB1, PB1-F2 and N40 on viral transcription and replication.
(1) Loss of N40 led to reduced polymerase activity, whereas the
overexpression of N40 or the loss of PB1-F2 alone had no effect.
(2) Deletion of PB1-F2 (∆AUG) or N40 resulted in changes in the expression
level of PB1.
(3) Overexpression of N40 in a PB1-F2 deficient background caused a shift
from transcription towards replication.
Taken together, PB1-F2 and N40 are likely to play some role in the
influenza A virus life cycle, however the effects may also depend on
other viral and cellular proteins. Regulation of expression of segment 2
gene products seems to be a complex process and further studies will be
necessary to fully understand the interaction of these factors.
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7.1 Final remarks
When this project was started, the aim was to separate the PB1-F2 ORF
from the underlying PB1 ORF. The idea was to delete PB1-F2 in its original
position and insert it downstream of PB1 via three different methods.
Deletion of PB1-F2 was done using a method described by Zamarin et
al., introducing three point mutations including the removal of the start
codon (Zamarin et al., 2006). The initial attempt to insert PB1-F2 into
segment 2 did not result in a successful expression of PB1-F2. The second
attempt was the insertion of the gene downstream of NA, which was more
successful and the protein was expressed in high quantities. However,
viruses were still attenuated, which made a mutational analysis of PB1-F2
difficult. Additionally the insertion into segment 6 via a duplicated promoter
was not stable. Although not useful to study single aspects of PB1-F2 by
introducing point mutations or deletions, the strategy provides a possible
starting point for future evaluations. Antibodies against PB1-F2 were difficult
to handle and detection of PB1-F2 in Western blots often resulted in high
background. The separation of the PB1-F2 ORF from the PB1 ORF offers
the possibility to add a short peptide onto PB1-F2 (V5-tag, FLAG-tag). This
would help to detect and localise the protein within cells and may be of
use when looking for additional interaction partners of PB1-F2. The stable
insertion of PB1-F2 into segment 2 via FMDV 2A showed that influenza A
viruses are highly flexible regarding their genome length.
The discovery of a third ORF expressed from segment 2 and the related
consequences the removal of the PB1-F2 start codon had on the system
influenced the direction of research in the present study (Wise et al., 2009).
The comparison of the two PB1-F2 deletion mutants (∆AUG and F2-11)
showed that the loss of PB1-F2 was not the main factor for attenuation,
whereas the loss of PB1-F2 in combination with an increased expression
level of N40 was detrimental for the virus. Four major functions of PB1-F2
have been reported so far:
The protein was shown to induce apoptosis in a cell-dependent manner
(Chen et al., 2001). It targets the mitochondrial membrane and interacts
with two mitochondrial membrane proteins, ANT3 and VDAC1 (Zamarin
et al., 2005). Two phosphorylation sites were identified that are critical
for the mitochondrial localisation and the apoptotic function (Mitzner et al.,
2009). Like other small viral pro-apoptotic proteins, the C-terminus of
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PB1-F2 forms an amphipathic α-helix (Gibbs et al., 2003). How PB1-F2
induces apoptosis is not fully understood. One possible mechanism it that
apoptosis is induced via the PTPC (Zamarin et al., 2005). It was also
suggested that PB1-F2 oligomerises and forms a pore or ion channel in
lipid bilayers, which could cause apoptosis (Chanturiya et al., 2004; Henkel
et al., 2010). A dependency of BAK/BAX was also reported (McAuley et al.,
2010a). However, the induction of apoptosis is restricted to a few viral strains
(Chen et al., 2010; McAuley et al., 2010a).
In 2008, a second function was identified. Besides the mitochondrial
membrane, PB1-F2 localised to the cytoplasm and nucleus of infected cells
and this was connected to an interaction with the polymerase subunit PB1
(Mazur et al., 2008). An involvement of the protein in the regulation of
the viral polymerase activity was suggested, however the positive effect
was reported to be cell-type and virus-strain specific (Mazur et al., 2008;
McAuley et al., 2010b; Chen et al., 2010).
Thirdly, infections with a virus deficient for PB1-F2 were less pathogenic and
it was therefore suggested that the protein is a virulence factor (Zamarin
et al., 2006). When PB1-F2 was absent, a decrease in inflammation and in
the occurrence of secondary bacterial infections was found (McAuley et al.,
2007). Amino acid 66 may be of particular interest in this context (Conenello
et al., 2007, 2011).
Recent insights revolve mainly around the induction of IFN-β and other
cytokines. PB1-F2 was reported to delay or even suppress the level of
IFN-β in infected cells (Conenello et al., 2011; Varga et al., 2011). PB1-F2
containing 66S was reported to be more effective in antagonising the
immune response. However, when PB1-F2 was deleted by removing the
AUG in the PB1-F2 ORF, the expected increase in IFN-β expression did not
occur, but the opposite effect was found (Goffic et al., 2010; Varga et al.,
2011).
Many of these conclusions were based on findings made with viruses
deficient for PB1-F2. However, with the discovery of N40 it became
clear that the design of many of these viruses was not optimal as it
changed the expression level of N40 (Wise et al., 2009; Chen et al., 2001;
Zamarin et al., 2006). The comparison of viruses deficient for PB1-F2
but expressing different levels of N40 (Chapter 3 and 6) revealed that
the loss of PB1-F2 alone (rWSN F2-11) was not sufficient to change the
phenotype of A/WSN/33 to a great extent. The deletion of both ORFs
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(rWSN ∆F2/∆N40) had some negative effects on viral growth, polymerase
activity and pathogenicity. More dramatic effects were seen with a virus
that was knocked out for PB1-F2, but showed an increased level of N40
synthesis (rWSN ∆AUG). This virus was attenuated in growth, apoptosis
and pathogenicity in mice, and the polymerase showed a bias towards
replication in primer extension assays, suggesting a new role for N40 in
the viral life cycle. Expression of PB1-F2 in transfected cells showed that
some of the above mentioned functions can be associated to the protein
directly. PB1-F2 was shown to induce apoptosis possibly by interacting with
VDAC1 and ANT3 in the mitochondrial membrane (Zamarin et al., 2005).
It was also shown to suppress the induction of IFN-β expression via MAVS
proteins (Varga et al., 2011). MAVS proteins were reported to be involved in
IFN-β-expression following RIG-I activation and they are also important in
the regulation of apoptosis by interacting with VDAC1 (Seth et al., 2005; Xu
et al., 2005; Kawai et al., 2005; Meylan et al., 2005; Xu et al., 2010). The
assumption seems alluring that PB1-F2 influences both cellular processes
by interacting with MAVS, thereby linking and modulating the pathways.
However, the role of N40 in this system remains obscure. Viruses only
deficient for PB1-F2 show WT levels of apoptosis, but increased levels
of N40 attenuated the virus in an so far unknown manner (Chapter 3).
Additionally these viruses did not induce IFN-β expression (Varga et al.,
2011).
PB1-F2 was reported to localise to the cytoplasm and nucleus and this
was connected to an interaction with the polymerase subunit PB1 (Mazur
et al., 2008). The domain for this interaction is not known, but it is possible
that N40 retained the ability to interact with PB1-F2. The interaction with
different partners in the cytoplasm and in the mitochondrial membrane may
also be influenced by the conformation of PB1-F2, which was reported to
vary depending on the hydrophobicity of the solvent (Chevalier et al., 2010).
Also, the amino acid sequence of PB1-F2 in different virus strains could
alter the stability of the secondary structure or the binding affinity to different
interaction partners, which may explain the reported strain specificity of
PB1-F2 on virus induced apoptosis and the regulation of polymerase activity
(Chen et al., 2010; McAuley et al., 2010a).
The 5’ UTR of segment 2 was shown to be highly complex. It combines
elements that regulate the initiation of translation of PB1, PB1-F2 and N40
and it also contains segment-specific packaging signals (Wise et al., 2011).
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Some of the effects found in this study and in the studies by Wise et al.
showed that the influence of point mutations may not always be selective
but they might be highly complex and unpredictable (Wise et al., 2009,
2011). It can be speculated that influenza A viruses code for more than
12 proteins and that fragments of already identified proteins or alternative
splicing products may have some regulatory functions. The finding that
segment 2 expresses additional N-terminal truncated fragments of PB1
is as intriguing as the observation that they show a different expression
level depending on the removed upstream AUG (Figure 6.17). There
are also reports about possible 13th or 14th proteins expressed from the
influenza A virus genome. Human strains were reported to posses an
ORF in the positive-sense orientation in segment 8 encoding a hypothetical
transmembrane protein (Baez et al., 1981; Zhirnov et al., 2007). Due to the
finding of cytotoxic T cells responding to epitopes derived from this ORF,
it has been suggested that the protein is expressed (Clifford et al., 2009).
Additionally, the existence of an M2 variant with an alternative ectodomain
expressed from the second AUG of mRNA4 from segment 7 was suggested
(Wise, personal communication; 2011). Some of these proteins might be
more important in humans or in an avian host. This host specificity may be
also possible for PB1-F2 and N40. So far, studies of the effect of PB1-F2
on avian hosts are limited. Three amino acid residues were determined to
influence on viral pathogenicity in mallard ducks (residues 51, 56 and 87),
which are different to the previously detected residue 66 that influences on
the virulence in a mammalian host (Marjuki et al., 2010). Future work on
PB1-F2 and N40 will be necessary to understand the role of these protein
in different hosts and cell types and to define key residues.
7.2 Outlook
The strategy and the design of mutant viruses in order to study a protein
or only one aspect of a protein becomes more and more important. The
anticipated change of one ORF in segment 2 altered the level of a number
of proteins and the effects seen are not always predictable. Also, a single
mutation may not change the viral phenotype but the combination with other
mutations in the same or other proteins could make a difference. Examples
can be found in this work and outside. Ozawa et al. determined in a recent
study that amino acids in three proteins influence viral pathogenicity but only
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certain combinations had an effect (Ozawa et al., 2011). The amino acid
627 in PB2 is a well known residue that contributes to viral pathogenicity.
However, other sites are at least as important. The H1N1 2009 pandemic
strain does not contain the lysine residue that is thought to increase viral
replication in humans, but amino acid 591 was found to compensate for
the lack of lysine at position 627 (Yamada et al., 2010). The search for
amino acids that are involved in the degradation of cellular RNA polymerase
II showed that a combination of several amino acids is likely (Chapter 4).
As an analogy, this seems like a big orchestra and every protein acts as
one instrument with the cell as its concert hall. The piece of music played
depends on each individual instrument and changing one violin string may
change the sound of the piece of music. But it also depends on other
instruments as well as on the concert hall. Therefore, changes may not
be heard because they are covered by other instruments.
The role of the segment 2 proteins PB1-F2 and N40 seems even more
unclear. The reported functions of PB1-F2 are mainly based on studies
using the laboratory strain A/PR/8/34 and deletion viruses with an increased
level of N40. The results of the work presented here show that the induction
of apoptosis and the contribution to viral pathogenicity are not due to PB1-F2
alone, but the balance of PB1-F2, PB1 and N40. What role PB1-F2 plays
remains unknown and requires further investigation. A possible new role for
N40 was discovered. Although the mechanism is not known, high levels
of N40 resulted in a switch from transcription to replication. This could
be due to competition for viral and cellular interaction partners between
PB1 and N40. Alternatively, N40 may act on the polymerase complex to
alter the specificity for the vRNA or cRNA promoter. Additionally, viruses
overexpressing N40 were highly attenuated in vitro and in vivo, interfering
with the induction of apoptosis, viral growth and pathogenicity in mice.
Further experiments should examine the influence of N40 in different virus
strains, in mammalian and avian hosts, using similar approaches to design
knockout viruses for PB1-F2 and/or N40. High levels of N40 in a PB1-F2
deficient background were most severe, but the effects could not be clearly
addressed to overexpression of N40 alone or if the combination with the
loss of PB1-F2 is important. Therefore high levels of N40 in combination
with PB1-F2 expression may be studied to dissect the influence of each of
the proteins on the virus attenuation. Because the engineering of such a
virus is not possible, cells could be infected with a mixture of ∆AUG and
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∆N40 viruses similar to the experiment explained in Section 6.3 but using
higher MOI to increase to possibility that the majority of cells is co-infected
with one of the two viruses. Alternatively cells could be transfected with
plasmids expressing N40 or PB1-F2 following an infection with WT viruses
or ∆AUG viruses, respectively. However, it is of importance that mutations
are chosen in a careful way and that changes are studied in an authentic
genetic background avoiding the use of chimeric viruses.
More work will be necessary to fully understand these fascinating viruses
and the relationship between the virus and its host, the interaction
between viral proteins and host proteins, the influence of the host towards
pathogenesis or the importance of a possible hierarchy of events within the
host cell. Although Influenza A viruses are one of the most researched
viruses, they are still full of surprises and new exciting discoveries are
continued to be made. Without question, these new insights will also open
new questions: The more you learn, the more you realise how little you
know.
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